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Abstract
Anti-tetrahydrocannabinol (THC), anti-cocaine and anti-morphine polyclonal antibodies 
were produced. These antibodies were successfully applied to an ELISA format for the 
detection of THC, cocaine, and morphine in saliva samples.
Monoclonal antibodies against amphetamine and its derivatives were produced using 
two different conjugates, amphetamine-bovine serum albumin and methamphetamine- 
bovine serum albumin. Two successful clones were produced, and the antibodies were 
applied to an ELISA format for the detection of amphetamine, methamphetamine, and 
the other common amphetamine derivatives, such as methylenedioxyamphetamine 
(MDA) and methylenedioxymethamphetamine (MDMA). The ELISA was developed 
using saliva as the matrix. During the screening stage of the production of these 
antibodies, particular attention was given to their cross reactivity profiles. Among the 
molecules tested for cross-reactivity, were legally available medications such as 
ephedrine, as other commercially available antibodies show cross reactivity. The 
resulting monoclonal antibodies detected amphetamine and other designer derivatives, 
and showed negligible cross reactivity with the legal structurally related molecules. 
The antibodies were applied to a biosensor (BIAcore) assay for the detection of 
amphetamine and methamphetamine in saliva samples. The affinity constants for the 
antibodies were determined by ELISA and BIAcore methods. The values obtained 
were found to be similar by both methods.
A novel automated prototype device, developed by our collaborators, Envitec, was 
optimised and the anti-THC polyclonal antibody was applied to it for the screening of 
saliva samples for the presence of THC. This was a rapid, qualitative test, and it could 
be performed in less than 20 minutes. The basis of the assay was competition between 
horseradish peroxidase-labeled THC and THC present in the saliva samples, for binding 
to the anti-THC polyclonal antibodies that coated the reaction wells of the device.
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Chapter 1 
Introduction
i
1.1 Drugs o f abuse in saliva -  Background
The use of saliva as an alternative matrix for the detection of drug abuse is currently 
being investigated by analytical laboratories and international agencies. The obvious 
advantages of using saliva as a matrix is that the collection is non-invasive and does not 
intrude on the subjects privacy, is relatively easy, and can be performed under close 
supervision. From an analytical point of view, saliva is a relatively uncomplex matrix 
and does not contain some interfering substances that are found in plasma. A simple 
freeze-thaw cycle followed by centrifugation is the usual method of preparation of 
saliva before laboratory analysis (W. Lambert, Personal Communication). Another key 
advantage of using saliva as a matrix is that the presence of certain drugs and 
metabolites can be a better indication of recent drug use and current levels of 
intoxication as compared to the more traditional matrices of blood and urine (Cone, 
1993). There are some publications that examine the correlation of drug and metabolite 
concentrations and the correlation with level of intoxication, these are discussed later. 
It would appear that additional studies would need to be performed before definitive 
guidelines could be established for all drugs of abuse.
The main disadvantage of using saliva is that only low quantities of drugs and 
metabolites are found in comparison to blood and urine. This means that the analytical 
assays developed must have high sensitivity, with low limits of detection. Another 
major disadvantage is the level of contamination that can occur with drugs that are 
inhaled or smoked. This can lead to buccal and nasal contamination. Also, passive 
smoking may lead to contamination. One way to avoid this problem is to raise the cut 
off levels of detection of substances such as THC. In this way, subjects who are 
contaminated by passive smoking do not test positive. The presence of buccal 
contamination can be considered an advantage if the purpose of the test is to detect 
evidence of drug abuse at any time point after smoking.
1.1.1 Saliva as a matrix
The concentration of free drug found in saliva is dependent on the different chemical 
and physiological properties of the drugs and saliva. The lipid membrane of the thin 
layer of epithelial cells that separates the saliva from the systemic circulation, is 
responsible for determining the molecules that cross the layer into the saliva. The drugs
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can potentially be transported by active transport, diffusion through pores in the 
membrane, or by passive diffusion across a concentration gradient. It is well 
documented that the presence of drugs in saliva are achieved largely through passive 
diffusion across the lipid layer of the epithelial (acinus) cells (Haeckel & Hanecke, 
1 9 9 6 ) .  Drugs are commonly assigned an S/P ratio (saliva/plasma) to represent the 
concentration ratio found between the saliva and plasma. Ethanol is a very good 
example of a molecule with an S/P ratio of close to 1 . This is achieved through its low 
molecular mass and high lipophilicity, allowing diffusion into the saliva. It is also 
un-ionised in blood and not protein bound. These properties are the factors responsible 
for influencing the diffusion of molecules into saliva. The molecular mass and lipid 
solubility of the drug are important properties controlling passage through the 
membrane. The degree of ionisation of a drug is of importance, as described by the 
partition phenomena, and this in turn is influenced by the pH of the saliva (Mucklow et 
al., 1 9 7 8 ) .  When a molecule crosses into the saliva, the degree of accumulation is 
dependent on the pH of each side of the membrane. Once the molecule reaches 
equilibrium the concentration is influenced by the pH of the saliva as described by the 
classic Henderson-Hasselbach equation and the equation for mass balance.
pH = pKa + log [A']/[HA] Henderson-Hasselbach Equation
[A ]  = [ A  ] + [ H A ]  Mass Balance Equation
Where:
A = total concentration o f drug in both ionised and non-ionisedforms
This gives the total amount of drug in either form described by the following:
[ A ] / [ H A ]  =  1 +  1 0  (pH‘pKa)
The Saliva/Plasma (S/P) ratio can then be determined by:
S /P  [ A  saliva] [ H A  plasma]/ [ A  plasma] [ H A  saliva]
g / p  _  j  _|_ J Q  (pH sa liva-pK a) /  2 +  1 0  (PH Plasm a‘PKa)
At this point consideration must be given to drugs binding to proteins in the plasma and 
saliva. Since we have assumed that the concentration of HA must be the same in
plasma and saliva as it was this form that was transported, the equation becomes the 
following:
S/P (acidic drug) = {1 + 10 (pHsaliva'pKa) / 1 + 10 (pH plasma'pKa)} . [Fp]/[Fs]
Where:
[FpJ =free drug in plasma 
[Fs] = free drug in saliva
For basic drugs a similar equation can be deduced as the un-ionised form of the drug is 
transported across the membrane.
S/P (basic drug) = {1 + 10' (pI[saHva-pKa) / 1 + 10‘(pHplasrna-pKa)} . [Fp]/[Fs]
(Rasmussen, 1964; Haeckel & Hanecke, 1996)
The usefulness of saliva for detection of drugs has expanded far beyond the scope of 
drugs of abuse, for example, for therapeutic drug monitoring (Homing et al. 1997). 
For management of chronic treatment of patients, it is necessary to determine the 
concentration of free drug in plasma, as this is the pharmacologically active form. This 
again serves as a considerable advantage, as there is minimal protein binding of drugs in 
saliva. The noninvasive nature of collection is very convenient, in the case of children. 
Horning et al. (1977) investigated the S/P ratios of anti-epilepsy agents by measuring 
concentrations by GC-MS and immunoassay. Saliva is also used for measurement of 
hormone levels, to monitor fertility cycles, menopausal fluctuations, and other diurnal 
fluctuations (Hofman, 2001).
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1.1.2 pH  o f saliva and influence on drug concentrations
The normal pH of blood is 7.4 while the pH of saliva is around 6.4, but this can vary 
from 5.6 to 7 (Haeckel & Hanecke, 1996; Kidwell et al., 1998). For neutral, weakly 
basic and weakly acidic molecules, the change in saliva pH has little effect on the S/P 
ratio. For acidic, ionised drugs, the S/P ratio increases with an increase in pH. 
Conversely, for basic drugs the S/P ratio decreases with an increase in pH. The 
relatively small variability of the pH of saliva is also another advantage of using saliva 
as a matrix for the screening of drugs of abuse. The pH of saliva is determined by the 
secretions that originate in the plasma, through the parotid, sublingual and 
submandibular and other minor glands. The volume of saliva that is produced can vary, 
and this is another point of consideration. Low volumes are typically seen in the case of 
drug abusers and methadone users where they are dehydrated and so the collection of a 
sufficient amount of saliva maybe a problem (Drobitch & Svensson, 1992). The 
solution to this would be to stimulate saliva secretion through chewing on gum, or citric 
acid coated sweets.
However, stimulation of saliva leads to an increase in bicarbonate secretion resulting in 
an increase in pH. For non-ionic or weakly acidic and weakly basic drugs the change in 
pH will have little effect on the S/P ratio. Many drugs, however, are affected by these 
changes in salivary pH. This, therefore, must be taken into account when the samples 
are being collected and a consistent mechanism of collection should be followed. Many 
of the saliva tests for drugs of abuse are qualitative and so this argument for using 
stimulated versus unstimulated saliva becomes less important. Indeed, the very 
definition of stimulated saliva can be vague as it could be suggested that even spitting 
for the purposes of collection of a sample is stimulated. A variety of different saliva 
collection devices are commercialy available. Most of them utilise an absorbant pad 
which is placed in the mouth and after enough saliva has been absorbed it is it is 
removed and the saliva extracted through a filtration device or by mechanically forcing 
the fluid from the pad. The important factor relating to salivary pH is that it is more 
difficult to change through external means and so the concentrations of drugs present 
cannot be interfered with, for example by ingestion of certain acid or bases. This is not 
the case with urine, and experienced drug abusers can modify the pH through ingestion 
of different substances.
1.2 Other alternative biological matrices
The most commonly used biological fluid used for screening of drugs of abuse is urine. 
Blood, when available, is most commonly used for post-mortem samples for forensic 
analysis. The analysis of urine and blood for drugs of abuse is well documented, 
(Braithwaite, 1995). The ease of collection of the other fluids and the information that 
can be obtained from these samples has initiated the scientific and commercial sectors 
to investigate their worth. The cost saving implications of using oral testing as 
compared to urine testing have been presented by the commercial sector in relation to 
work place testing, (Kunsman, 2000). Substance abuse or dependence is seen in 33 -  
50% of chronic mentally ill patients indicating that drugs of abuse testing is also hugely 
important in this area (Shearer et al, 1998).
In addition to saliva, sweat and hair also provide options for matrix selection for 
analysis. Sweat was investigated recently for the detection of cocaine (Spiehler, 1996; 
Preston et al., 1999), and opiates (Fogerson, 1997; Huestis, 2000), methadone, (Skopp 
et al., 1996), and amphetamine and MBDB, (Fay el a i, 1996; Kintz, 1997). Skopp and 
Pôtsch (1999) have reviewed aspects of saliva and sweat in the realm of roadside 
testing, including the concentration and form of drugs found in sweat, and the transport 
mechanisms from the blood to the skin. The potential pathways include perspiration 
and sebum, intracellular diffusion along the cell membrane complex and transcellular 
diffusion and transport by the keratinocytes. The conclusions made by the reviewers 
suggest that the main drug form found on the skin surface is the parent form. The time 
interval between the consumption of drugs and the appearance of the drug on the skin 
surface is drug specific and there seems to be a considerable time delay of several 
hours. This would imply that the detection of drugs on the skin surface in sweat may 
not be suitable as a means of detecting current intoxication.
Hair has been investigated as an alternative matrix with particular application in 
forensic science. The analysis of hair for drugs of abuse is useful for long term 
examination, and this in itself is advantageous compared to the other matrices for 
forensic cases. It is believed that there are two pathways for the passage of drugs into 
hair; incorporation from the blood into the shaft and adsorption from sweat and other 
environmental factors. The analysis of hair is a convoluted procedure with extensive 
preparatory steps for sample extraction. Even the actual process of removing the 
complete hair is intricate as it important to get the root end as this has the highest
concentration of drugs. Another factor that has to be considered is the effect of 
bleaching, perming and other cosmetic treatments on the drug in the hair (Skopp et al., 
1997; Yegles, 2000). Nakahara, (1999), has extensively reviewed the basic aspects and 
analytical studies of hair for drugs of abuse.
The nature of many forensic cases demands the ingenuity of scientists to develop 
analytical methods for detecting drugs of abuse in many different matrices. Diverse 
matrices for the detection of drugs of abuse range for nails (Engelhart, 1998), to 
meconium, (Halstead, 1997). Wolff et al. (1999) have reviewed practical 
considerations and clinical usefulness of the different biological fluids. Table 1.1 A and 
1.1B outlines the specific issues for each matrix.
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Table 1A: Characteristics of using blood, urine and saliva as matrices for the detection 
of drugs of abuse.
Blood U rine Saliva
Collection
Procedure
• Invasive
• Requires healthcare 
professional
• Exposes professional 
to health risk
• Invasion of privacy
• Requires additional 
staff to monitor 
procedure
• Non-invasive
Sample
Preparation
• Yes, extensive • Yes • Minimal
Period & 
Level of 
Detection
• Dependent on 
metabolism of drug -
indicates recent use
• Low concentrations
• Cannot be correlated 
to plasma levels
• Indicates prior use 
over last few days and 
subsequent 
mcatabolism
• Higher concentrations 
build up
• Dependent on 
metabolism of drag -  
indicates recent use
• Can be correlated to 
plasma levels
• Low concentrations
Correlation to
current
intoxication
• Correlation can be 
made
• Correlation cannot be 
made
• Correlation can be 
made
Possible
Problems
• Small sample volume • pH can be altered and 
concentrations of 
drugs/metabolites 
affected
• Dilute concentration
• Small sample volume
• Buccal & oral 
contamination
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Table IB: Characteristics of using sweat, hair, and breath as matrices for the detection 
of drugs of abuse.
Sweat Hair Breath
Collection
Procedure
• Non-invasive • Non-invasive • Non-invasive
Sample
Preparation
• Minimal • Yes - extensive • None
Period & 
Level of 
Detection
• Dependent on 
metabolism of drug -  
indicates recent drug 
use
• Low concentrations
• Can not be correlated 
to plasma levels
• Indicates prior use 
over previous weeks
• Higher 
Concentrations
• Correlate to plasma 
levels
Correlation to
current
intoxication
• Correlation can be 
made to an extent
• Correlation can not be
made
• Correlation can be
made
Possible
Problems
• Small sample volume • Interference by 
external chemicals 
such as hair dyes and 
contaminants
• Only certain analytes 
suitable
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1.3 Legal status o f alternative biological matrices
Cone (2001), discusses the legal, workplace and treatment drug testing using alternate 
biological matrices in different countries. Illicit drug dealing and abuse continue to 
increase around the world, with implications for drug testing in the workplace, in 
treatment programs, in roadside testing for driving under the influence and in other 
forensic investigations. The analytical advances made using matrices such as saliva, 
and hair have not been appropriately addressed in the laws of a majority of countries. 
Guidelines are under development and review by various bodies across the US, Europe 
and Asia. The important points to consider in such guidelines are the collection and 
storage procedures, what drug form or metabolite is analysed, and the cut-off values 
that differentiate between positive and negative samples. The guidelines must be an 
evolving standard that are updated to take into account the advancements that are being 
made in technology and analytical techniques. Currently, there are no established 
guidelines for the detection of drugs of abuse in saliva samples, with regard to the form 
of the drug or concentrations.
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1.4 Drugs o f Abuse: metabolism, form  and concentrations found in saliva
The first step in the development of an assay for the detection of illicit drugs in saliva is 
to establish the concentration of these drugs and their metabolites in the saliva of drug 
users. The following section outlines findings from publications regarding the form of 
the drug found in saliva after intake and comparison to the form and concentration 
found in plasma and urine for each drug of interest.
1.4.1 Cocaine
N
/
CH.
Cocaine
/
H
OOCC6H5
Benzoylecgonine Ecgonine Methyl Ester
Figure 1.1: The metabolism of cocaine to benzoylecgonine and ecgonine methyl
ester.
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Cocaine is a fast acting drug with accompanying immediate mood changes after 
ingestion. The main metabolites are benzoylecgonine (BEC) and ecgonine methyl ester 
(EME), as shown in Figure 1.1, formed by the enzymatic activity of plasma 
cholinesterase, (Inaba et al., 1978). The main routes of administration of cocaine are 
intranasal, intravenous and smoking of crack cocaine, which is now the predominant 
route used. The most common method used to determine the concentration of cocaine 
and the metabolites in biological fluids is gas chromatography/mass spectrometry 
(Cone, 1995). Many studies have been conducted to obtain information regarding the 
elimination half-time of cocaine and the main metabolite, BEC. Cone et al. (1988) 
investigated the correlation between cocaine-induced behaviour and mood effects and 
cocaine concentrations in plasma and saliva as measured by GC/MS. They observed a 
significant correlation between cocaine-induced pharmacological effects and saliva and 
plasma concentrations, with an elimination half-time of 34.9 minutes in plasma and
34.7 minutes in saliva. The subjects experienced the “rush” feeling quickly after 
administration, followed by the “high” feeling, which lasted approximately 30 minutes. 
Other behavioural and physiological effects returned to baseline within one hour after 
administration. This correlation between the time period for the pharmacological 
effects and the elimination half-life is encouraging for the development of an assay to 
detect recent use or current intoxication with cocaine. They detected cocaine in the 
saliva following intravenous administration. This demonstrated that the cocaine in the 
saliva came from the blood. The concentration of the main drug found in saliva may be 
higher due to contamination of the oral and nasal cavities by the smoking and intranasal 
routes of administration.
Kato et al. (1993) investigated the cocaine and metabolite concentrations in saliva and 
their results were consistent with the elimination half-time of approximately 35 minutes 
found by Cone et al. (1988). A longer elimination half time of 7.5 hours was calculated 
for BEC by Cone & Weddington (1989). In this study the subjects, were chronic 
cocaine users, and the elimination half-time of cocaine in saliva ranged from 21.6 to
110.4 hours. Cocaine could be detected in saliva for up to ten days post administration. 
The presence of cocaine in saliva after such a long period of use suggests that chronic 
use and high exposure leads to a build up of the lipophilic cocaine in tissue, and this is 
slowly released back into the circulation and excreted. Jufer et al. (2000) investigated 
the elimination of cocaine and metabolites following repeated oral administration to
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chronic cocaine users. Two phases of elimination of cocaine and metabolites were 
observed. An initial elimination phase that gave results similar to previous 
investigations was observed with mean cocaine elimination half-times in plasma, saliva 
and urine were 1.5, 1.2, and 4.1 hours, respectively. The urinary elimination half-time 
for the second phase was 19 hours. This suggests the accumulation of cocaine in the 
body after chronic use resulting in a longer elimination phase.
Cone et al. (1993) found that after cocaine administration by three different routes, 
intravenous, smoking and intranasal, cocaine was the major compound found in saliva. 
BEC and EME were present in minor amounts and the concentrations of these peaked 
later, corresponding to longer elimination half-times.
Schramm et al. (1993) looked at the levels of cocaine and benzoylecgonine in saliva, 
serum and urine. They found cocaine concentrations were 4.9 times higher in saliva 
than in serum, and benzoylecgonine levels were 2.5 times higher in serum. Thompson 
et al. (1987), found significant correlation between the plasma and saliva levels in one 
patient who received doses of cocaine. The S/P ratio varied from 2.96 to 0.5 over time. 
Cone et al. (1994), found S/P ratios of about 3.0 for cocaine, and, as found previously, 
the levels of benzoylecgonine in saliva were lower than in plasma.
Cone et al. (1997) investigated the concentrations of cocaine, BEC and EME in saliva 
by GC/MS and immunoassay. Subjects were administered different doses of cocaine by 
the intravenous, smoked and intranasal routes of administration. They found that BEC 
and EME concentrations were consistently lower in saliva compared to the cocaine 
concentration. The concentrations were only comparable with cocaine when the 
cocaine levels had fallen to below 100ng/ml. Cocaine appeared in saliva 0.08 hours 
after administration. The peak concentrations for the various doses and routes of 
administration were 258-1303 ng/ml. However, the levels decreased rapidly and 
reached the limit of detection by 12 hours after administration. BEC and EME levels 
could be detected 0.08 hour and 1 hour, respectively, after cocaine administration. The 
peak concentrations were detected 0.17 to 4 hours after administration and were 
consistently lower than cocaine concentrations (less than 100 ng/ml).
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In conclusion, these results indicate that BEC could be used as the analyte in an 
immunoassay to detect recent cocaine use because of its longer detection period 
compared to cocaine. For the purposes of development of the immunoassay, the 
detection of cocaine is sufficient given the similarity in structure and likelihood that an 
antibody raised against BEC would also recognise cocaine and vice versa.
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1.4.2 Tetrahydrocannabinol
Figure 1.2: Structure of tetrahydrocannabinol (THC), the active constituent of
marijuana (cannabis).
The pharmacological active constituent of cannabis is delta-9-tetrahydrocannabinol 
(THC), as shown in Figure 1.2. The main route of administration of cannabis, (also 
known as marihuana), is by smoking however it may also be taken orally. THC is 
metabolised to an active metabolite, ll-hydroxy-delta-9-THC, which is then 
metabolised to ll-nor-9-carboxy-delta-9-THC, (THC-COOH). This carboxy
metabolite, as the glucuronide conjugate, is the most common metabolite detected in 
the screening of urine (Cone, 1993).
Lemberger etal. (1970) investigated the metabolism of delta-9-THC in humans after IV 
administration. They found THC had an elimination half-life, (ti/2), of 56 hours in 
plasma. The time period of behavioural effects of cannabis in humans is well 
documented, the peak effects occur 15 minutes after administration. These affects are 
diminished between 30 minutes and 1 hour post intake and are generally absent after 3 
hours. When the time period for the behavioural effects of cannabis is compared with 
the half-life of THC in plasma it would seem reasonable to assume that the detection of 
THC in plasma could be an indicator of current or recent use, within a couple of days, 
of cannabis.
For the purposes of this project it was important to review data regarding the correlation 
of the plasma levels of THC to the saliva levels. Gross et al. (1985) found that the 
salivary THC concentration did indicate positive results in the blood but the two 
concentrations did not correlate well, a much higher concentration being found in 
saliva. Based on the dissociation constants for the compounds and the Henderson-
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Hasselbach equation the calculated saliva/plasma ratio should be around 0.1. One 
reason for the high concentrations of THC and the metabolite ll-hydroxy-delta-9-THC 
in saliva is that due to the smoking route of administration the nasal and oral cavities 
become contaminated with the THC. It is now generally accepted that the presence of 
THC in saliva is as a result of contamination and has not been passed from the plasma. 
Menkes et al. (1991) found that subjective intoxication and elevated heart rate were 
significantly correlated with the salivary THC concentration. Maseda et al. (1986), 
found that THC could be detected in saliva by capillary GC, with an lower limit of 
detection of lng/ml, for at least four hours after smoking.
Schramm et al. (1992) presented preliminary results of HPLC analysis on a urine and 
saliva sample collected simultaneously from a subject who had smoked cannabis. 
THC-COOH was the main metabolite found in the urine sample. The saliva sample 
contained THC-COOH, THC, cannabidol, and 11 -hydroxy-delta-9-THC. However, 
information concerning the time frame for when the samples were collected after 
administration of the drug were missing from this study as was information regarding 
the subject's prior history of cannabis use. If the subject was a chronic user of 
marihuana this would have implications regarding the build up of metabolites in the 
urine and saliva. Kintz et al. (2000), investigated the presence of cannabis in saliva and 
sweat from drivers involved in road traffic accidents. Of the 22 subjects who tested 
positive for THC-COOH in urine, 14 and 16 of these tested positive for THC in saliva 
and sweat, respectively. Urine is the ideal matrix from an analytical viewpoint for the 
testing of cannabis use, as the cannabinoids can be detected for longer in urine (Cone 
1993). However, from the viewpoint of testing for recent use and current intoxication, 
saliva is the most appropriate method. It would seem more appropriate to screen for 
THC in saliva, as opposed to THC-COOH in urine, as it is considered the only form of 
the drug found in saliva, and is as a result of contamination and not passed from the 
plasma.
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1.4.3 Amphetamines
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Figure 1.3: Structures of amphtamine, methamphetamine and the ‘designer’ 
amphetamine derivatives.
In the 1970's, amphetamines were commonly used for the treatment of obesity because 
of their anorexic effects. The use of amphetamines for this indication was dramatically
include mood elevation, increased blood pressure, increased energy and alertness and 
decreased appetite. Amphetamines are available in the d- and the 1- isomeric forms and 
also in the racemic mixture form. (Cone, 1993). The common routes of administration 
of amphetamines are oral and intravenous. Methamphetamine, also called by its street 
name ‘ice’, and other substituted derivatives are commonly administered by oral, 
intravenous or smoking routes. The most commonly abused substituted derivative of 
amphetamines are 3,4-methylenedioxymethamphetamine, (MDMA) also called by its 
street name, “ecstasy”, 3,4-methylenedioxyamphetamine, (MDA), and 3,4- 
methylenedioxyethylamphetamine, (MDEA). These drugs are abused to a huge extent 
particularly at "rave" parties where the pharmacological effects of increased energy and 
alertness are exploited. Other amphetamine derivatives such as ephedrine, 
pseudoephedrine and phenylpropanolamine are used in medicinal allergy and cold 
formulations (Cone, 1993). This is an important consideration when developing a
decreased because of the associated abuse. The psychological effects of amphetamines
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detection system for amphetamine abuse. The cross reactivity of the immunoassay with 
these common cold medications must be investigated, as false positive results could 
have significant legal and financial implications. An example of such a case currently 
in the news involves the British Olympic medalist skier who tested positive for 
methamphetamine. He claimed that it was a result of using the ‘over the counter’ Vicks 
inhaler, available in the US, that contains 1-methamphetamine.
Meth amph etamin e Amphetamine
Deamination, p-hydroxylation and conjugation 
Figure 1.4: Metabolism of methamphetamine and amphetamine. (Braithwaite et al.,
1995)
Beckett & Rowland (1965), examined the clinical effects and excretion of the d- and the 
1- isomers of amphetamine, d-amphetamine was found to be the more potent isomer 
with regard to clinical effects, such as, central nervous stimulation and dryness of the 
mouth. These clinical effects were not seen when the 1-isomer was administered. They 
found that the excretion of amphetamines is highly dependent on the pH of the urine. 
Under normal urinary pH conditions, up to 40% of amphetamine is eliminated 
unchanged in the urine. The amphetamine can be detected in the urine 20 minutes after 
the dose is administered (Braithwaite, 1995). Amphetamine is metabolized by the 
hydroxylation of the phenolic ring to p-hydroxyamphetamine and by deamination to 
phenol acetone which is oxidised to benzoic acid (Figure 1.4). Methamphetamine is
Phenylpropanolamine
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metabolized to amphetamine. When the urine is acidic, renal excretion is the major 
pathway of elimination of amphetamines from the body. Wan et al. (1978) found that 
the elimination of the amphetamines was dependent on the urinary pH. The salivary pH 
in the subjects they tested remained constant even under conditions used to induce 
alkaline and acidic urinary conditions. These findings indicate that saliva would be a 
more suitable matrix for detection of amphetamine use as the levels of amphetamine 
measured in urine are too highly dependant on the urinary pH to give reliable results. 
Experienced drug abusers can manipulate this property by taking large quantities of 
sodium bicarbonate concurrently with the dose of amphetamines. This results in basic 
urinary conditions and so the amphetamines are metabolised in the plasma rather than 
being excreted, in the original form, via the renal route. This prolongs the clinical 
effects of the drug and also reduces the excretion of amphetamines into the urine, hence 
reducing the likelihood of detection in urine (Braithwaite 1995).
The relationship between the plasma and saliva concentrations of a drug can be 
predicted on the acidity/basicity of the drug as discussed above. Amphetamines have a 
S/P ratio greater than 1.0, due to their pKa greater than 5.5, (Haeckel and Hanecke,
1996). This theoretical greater concentration of amphetamines in saliva compared to 
plasma is another advantage of using saliva for detection. Wan et al. (1978), 
investigated the kinetics and salivary excretion of the d- and 1- isomers. They found 
that the major difference between the isomers is in the elimination half-time. The d- 
isomer has a more rapid half-time than the 1- isomer. The d- isomer is rapidly 
metabolised under basic urine conditions when metabolism rather than renal excretion 
is the major route of elimination. The authors proposed that the stereoselectivity of the 
deamination process, which is more complicated for the d- isomer, is the basis of the 
stereoselective metabolism. The difference in the half-time between the isomers is 
decreased when renal excretion is the major route of elimination and this would occur 
under acidic urine pH conditions.
Kintz & Samyn (1999) reviewed the determination of designer amphetamines in saliva, 
sweat and hair. In saliva, it was found that the parent drug is detected in higher 
concentration compared to its metabolites. An investigation into the excretion of 
MBDB and BDB in saliva and sweat also supported these results by finding that MBDB 
was present in higher concentrations than its metabolite, BDB, (Kintz, 1997). The only 
other publication examining the concentration and form of MDMA found after 
administration is by Navarro et al. (2001 A). They measured the concentration of
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MDMA, and its metabolites, MDA and 4-hydroxy-3-methoxymetamphetamine, 
(HMMA), in saliva and plasma after administration of lOOmg of MDMA. MDMA was 
the major form found, at concentrations between 1728 and 6510 ng/ml in the saliva, 
with the peak concentration occurring at 1.5 hours after administration. The 
saliva/plasma ratio was 32.3 -  1.2. The reports from a different study of users, showed 
that the subjective psychological feelings mirrored the profile of the salivary 
concentrations, with subjective feelings reaching a peak at 1.5 hours. Another 
interesting parameter measured in the study was salivary pH. The pH decreased by 0.6 
units at 1.5 hours after administration, probably related to the accumulation of the drug 
in the saliva. There is a lack of publications regarding the concentrations of 
amphetamines found in saliva. The concentrations reported, in the limited number of 
publications are in the nanogram/ml to microgram/ml range. However, it could be 
presumed, given the previous discussions, that it is an appropriate matrix for its 
detection.
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Ephedrine Methamphetamine
Figure 1.5: Structure of ephedrine, found in ‘over the counter’ flu and cold remedies 
and structure of methamphetamine. (Braithwaite et a l, 1995)
1.4.4 Opioids
Opioids are used for the relief of severe pain in the clinical setting. The effects include 
analgesic, drowsiness, mental clouding, decreased gastrointestinal motility, nausea, and 
vomiting and respiratory depression. Heroin is the probably the best known of the 
opiates due to its addictive characteristic. Heroin abuse remains a serious problem in 
many cities. Heroin abuse and addiction arises from the psychological effects.
Heroin 6-Monacetyl Morphine Morphine
Mainly - conjugation with glucuronic acid mainly at 3-position 
Small amounts - conjugation with glucuronic acid at 6-position
- déméthylation to normorphine
- méthylation to codeine
Figure 1.5: The metabolism of heroin and morphine.
Heroin is the diacetyl derivative of morphine, it is more lipid soluble and gets into the 
central nervous system faster than morphine. Directly after heroin administration, the 
user describes a "rush" feeling. Heroin is rapidly metabolised to 6-acetyl morphine, 
which is the active metabolite and responsible for the clinical effects. The nature of the 
reported initial rush is not clear as it may be the anticipation experienced by the abuser 
rather than the actual clinical effect. (Palfai and Jankiewicz, 1997).
Opioids are rapidly absorbed from the gastrointestinal tract but do undergo significant 
first pass elimination on passage through the liver. Morphine is metabolised mainly by 
conjugation with glucuronic acid at the 3- or 6- position. Codeine is a less potent
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analgesic than morphine or heroin. It is metabolised in the liver to morphine by 3-0- 
demethylation and to norcodeine by N-demethylation. (Braithwaite et al, 1995). 
Boerner et al. (1975) summarised the experimental results regarding the metabolism of 
heroin and morphine. Very low concentrations of heroin and 6-acetyl morphine, 0.13% 
and 1.3%, respectively, were recovered in the urine of heroin users. The major 
metabolite recovered is morphine-3-glucuronide. Trace amounts of free morphine, 
morphine-6-glucuronide, morphine-3-etheral sulphate, free normorphine, normorphine 
conjugates, free norcodeine and codeine were recovered.
Heroin abusers generally administer the drug by the intravenous, subcutaneous, 
intramuscular, intranasal, and smoking routes, and also by heating the powder and 
inhaling the vapours. Jenkins et al. (1995) measured the heroin, 6-acetyl morphine and 
morphine concentrations in blood and saliva samples from subjects after they had been 
administered heroin by the smoking and intravenous routes. The samples were 
collected over a 24 hour period and analysed by gas chromatography/mass 
spectrometry. The limit of detection of the assay was 1 ng/ml. The results showed 
significantly higher concentrations of heroin, morphine and 6-acetyl morphine in 
salivary samples following administration by the smoking route. This is obviously due 
to contamination of the nasal cavities with the drugs by the smoking route. The 
concentration of morphine in the blood declined more slowly than heroin or 6-acetyl 
morphine and it was detected for up to 2 hours after smoking and up to 12 hours after 
intravenous administration. Following heroin administration via the smoking route, the 
peak concentration of morphine in saliva ranged from 6 to 142 ng/ml. Morphine 
salivary concentrations were less than 16 ng/ml after administration by the intravenous 
route.
Wang et al. (1994) analysed saliva from subjects who had received 12 mg of heroin by 
the intranasal route of administration. The analysis was performed by solid phase 
extraction and gas chromatography/mass spectrometry. They found that heroin and 6- 
acetyl morphine concentrations reached their peak 10 minutes after administration, 
being 307.8 ng/ml and 58.7 ng/ml, respectively, and then decreased over a period of one 
hour. Morphine concentrations peaked at one hour after administration, 
(25.4 ng/ml), and declined to 1 ng/ml, the limit of detection of the assay, by 3 hours. 
Cone (1990), found that morphine shows increasing concentrations in saliva, plasma 
and urine in that order. The presence of opiates, (dihydrocodeine, dihydromorphine, 
codeine, morphine, 6-monoacetylmorphine) in saliva and urine, was investigated by
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GC-MS in subjects participating in a drug withdrawal program. The correlation of the 
results of the saliva samples with urine results was over 90%, concluding that saliva 
may be adequate for the detection of the opiates, (Speckl et al., 1999).
The rapid metabolism of heroin to 6-acetyl morphine and its subsequent metabolism to 
morphine with a longer elimination half-life would lead to the conclusion that it is 
appropriate to focus on morphine as the analyte in an immunoassay to detect recent 
heroin or morphine use. The main concern in relation to analysing saliva samples for 
recent heroin or morphine use is of the quantitative nature given the results presented by 
investigators (Cone, 1993) in which low concentrations were detected. However, other 
studies have shown that the concentration of morphine found after a short time of 
administration can be as high as 20fig/ml, (Chapter 6; Leute et al., 1972). Thus, the 
concentrations of morphine and indeed heroin and 6-acetyl morphine detected in saliva 
samples of opioid users needs to be considered when determining the cut off 
concentration and limit of sensitivity in an immunoassay.
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1.5 Levels o f detection o f assays and cut o ff levels
Currently, there are no established cut off levels for drugs of abuse in saliva samples. 
For the purposes of the Standards, Measurements and Testing (SMT) project, 
discussions were held between the following; School of Biotechnology, Dublin City 
University; Department of Toxicology, University of Ghent, Belgium; Envitec Gmbh, 
Germany, and Nunc, Denmark; to establish suitable cut off levels for THC, cocaine, 
morphine and amphetamines in saliva samples. The current international guidelines 
recognised by the Substance Abuse and Mental Health Service Administration 
(SAMHSA), National Institute of Drugs of Abuse (NIDA), and World Health 
Organisation (WHO), for cut off levels in urine and plasma were considered and 
extrapolations made to the salivary concentration. The cut off level for THC was raised 
as compared to the plasma level due to high degree of contamination and also the 
possibility of positive samples by passive smoking and ingestion of cannabis containing 
(hemp) products .
The following were established as guidelines for our assay development, (Table 1.2).
Table 1.2: Cut o ff concentrations o f drugs fo r  the SMT project.
Saliva 
Cut-Off Level 
(ng/ml)
Urine 
Cut-Off Level 
(ng/ml)
Plasma 
Cut-Off Level 
(ng/ml)
THC 200 50
(THC-COOH)
2
Cocaine 50 300
(BEC)
50
Morphine 20 300 20
Amphetamines 50 1000 50
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1.6 Methods o f Detection o f Drugs o f Abuse
The methods for analysis of drugs of abuse include thin-layer chromatography (TLC), 
gas chromatography coupled with mass spectroscopy (GC-MS), high performance 
liquid chromatography (HPLC) and capillary electrophoresis (CE). GC-MS is the gold 
standard test for the confirmation of the presence of drugs of abuse in biological 
samples (Braithwaite, 1995). This test would only be performed on samples that had 
previously being screened using a more rapid method for example immunoassay, TLC. 
The extensive preparation of the samples required in order to run these chromatographic 
tests is well documented (Braithwaite, 1995). Modified solvent extractions and solid 
phase extraction techniques are used and commercial kits are available for these 
purposes.
The current chromatographic methods used for drugs of abuse are concisely reported on 
by Braithwaite et al. (1995). The focus of the following section will be the 
immunological methods, biosensors and commercial tests available.
1.6.1 Immunoassays
Immunoassays are widely used for the detection of drugs of abuse. They can be 
developed to be highly specific, sensitive, relatively rapid and usually require little or 
no preparative clean up steps for the test matrix. The following are types of 
immunoassays that are used for detection of drugs of abuse: enzyme-linked
immunosorbant assay (ELISA), enzyme-multiplied immunoassay techniques (EMIT), 
fluorescence polarisation immunoassays (FPIA) and up-converting phosphor 
technology (Braithwaite, 1995; Niedbala, 2001). Immunoassays can be divided into 
two types, heterogenous and homogenous. In heterogenous assays, the antigen antibody 
mixtures are separated from the free antigen or antibody by a solid support, such as an 
immobilised conjugate. In homogenous assays, there is no such separation. There are 
many more sub-divisions and types of immunoassays. The basis of all enzyme 
immunoassays is the binding of the antibody to the antigen of interest. This binding is 
detected using an enzyme, with the enzyme acting on a substrate producing a coloured 
product which is subsequently measured. Two broad classifications of heterogenous 
immunoassay are competitive, and non-competitive, e.g. sandwich ELISA.
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1.6.1.1 Competitive Immunoassay
In a competitive immunoassay, one species is immobilised onto the ELISA plate, a 
mixture of a second and third species are added. Competition is created through two of 
the species binding to the antibody. An example of a competitive ELISA is shown in 
Figure 1.8. Antigen is immobilised, and a mixture of antibody and free antigen are 
added. The amount of free antibody available to bind to the immobilised antigen is 
inversely proportional to the amount of free antigen in the solution. The subsequent 
substrate colour change is inversely proportional to the antigen in the solution. An 
example of a variation of the competitive assay is the inhibition assay. This is the 
immobilisation of antigen, followed by the addition of a sample of antigen free in 
solution, followed by addition of antibody. During the incubation period, competition 
occurs between the immobilised antigen and the antigen free in solution for binding by 
the antibody. This step is then followed by incubation with anti-species antibody 
that is enzyme-labelled. The resulting change in substrate colour in the final step is 
inversely proportional to the amount of free antigen in the test solution. The difference 
between the inhibition assay and the competitive assay is subtle. In the inhibition assay, 
the antigen and antibody are not equilibrated before each are added to the antigen- 
coated wells.
1.6.1.2 Non-Competitive Immunoassay
In a sandwich ELISA, (Figure 1.7), two different antibodies, reactive with different 
epitopes of the antigen are required. One antibody is immobilised to the solid phase, 
and the antigen is then added. This is followed by the addition of another antibody that 
is specific for a different epitope of the antigen.
One of the most common rapid assays available currently are the dip-stick or test strip 
immunoassays. These involve antibodies being coated on surfaces such as nitrocellulose 
strips. Test strip assays usually employ a sandwich or competitive immunoassay format 
and lateral flow of the applied sample facilitates accumulation at a region pre-coated 
with antigen, (Figure 1.9). An example of a format used is the One-Step Rapid Opiates 
Test, (Craig Medical, USA), for detection of opiates in urine. The urine sample is 
applied to the chromatographic strip and reacts with labeled antibody-dye conjugate. 
They laterally flow along the strip and any unbound antibody-dye conjugate binds to 
immobilised antigen conjugate in the test zone of the strip. This produces a specific
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colour line in the result window of the strip, which indicates a negative result. On the 
other hand, if the urine contains opiates, at a concetration above the cut-off level, the 
antibody-dye conjugate binds to the free drug in the urine and forms an antigen- 
antibody-dye complex. This complex competes with the immobilised antigen conjugate 
in the test zone, preventing the development of a coloured line. A positive control is 
built in by incorporating a non-specific sandwich dye conjugate reaction.
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%
Figure 1.7: Schematic diagram of a non-competitive sandwich ELISA. Two
antibodies of different antigenic specificty are used, one of which is labelled with an 
enzyme. The unlabelled antibody is used to coat the wells. Antigen in solution binds to 
this antibody. The enzyme-labelled antibody is then added and will bind to the antigen. 
Substrate is added and the absorbance measured. The intensity of the response is 
directly proportional to the concentration of antigen that was in the test solution.
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(i) Negative Result
(ii) Positive Result
(iii) Invalid Result
Test Line Control Line Absent
Figure 1.9: Diagram of example of lateral flow 'dip stick'-type immunoassay for 
the detection of drugs in a urine sample. The development of the two lines, a test 
line and a control line, indicates a negative test for the targeted drug (i). The 
development of the control line and absence of the test line indicates a positive 
result (ii). The absence of a control line in the window indicates an invalid result 
regardless of the test line result (iii).
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Figure 1.8: Schematic diagram of a competitive ELISA. Antigen is immobilised on the 
wells. A mixture of the sample containing antigen, and a constant amount of antibody 
are added. Competition occurs between the immobilised antigen and the free antigen 
for binding to the antibody. Labelled secondary antibody is added, that recognises the 
bound antibody. Substrate is added and the absorbance measured. The intensity of the 
response is inversely proportional to the concentration of antigen that was in the test 
solution.
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1.6.2 Enzyme-Multiplied Immunoassay Technique
EMIT is an homogenous competitive assay. The antigen is labelled with an enzyme 
and mixed with the sample antigen free in solution and antibodies. Competitive binding 
takes place, and the binding of the enzyme-labelled antigen, sterically hinders the active 
site of the enzyme thereby preventing enzyme activity. When unlabelled free antigen is 
added, it competes with the labelled antigen for binding to the antibody. The greater the 
level of antigen added, the greater the level of unbound enzyme-labelled antigen 
resulting in greater enzyme activity. Behring Diagnostics Inc supply a number of EMIT 
kits for the detection of cannabinoids, opiates, cocaine and amphetamine.
1.6.3 Fluorescence Polarisation Immunoassay
FPIA is a homogenous competitive assay in which a known amount of antigen or drug 
analog is labelled with fluorescein and mixed with sample antigen and antibody in free 
solution. The labelled and sample antigen compete for binding to the antibodies and 
detection is by means of a vertically polarised detector. The detection is based on the 
difference in the rotation speeds of the free and bound fluorescein-antigen. The free 
fluorescein-antigen rotates at higher speeds and results in emission of light in a different 
plane to the incident light, so it will not be detected. The bound fluorescein is not free 
to rotate and so the emitted light is almost in the same plane as the incident light and so 
it is picked up. A major advantage of the FPIA is that it is homogenous and there is no 
need for the immobilisation step.
1.6.4 Detection o f  analytes by immunoassay using up-converting phosphor 
technology.
Up-converting phosphor technology is based on lanthanide-containing, ceramic 
particles that can absorb infrared light and emit visible light. The important distinction 
between fluorescence and phosphorescent is that biological matrices do not up-convert 
and so there is no background sample autofluorescence. Niedbala et al. (2001 A) have 
developed lateral flow immunoassay strips for the detection of drugs of abuse using this 
up-converting phosphor technology, (UPT). The assay strips are designed like a lateral
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flow test that uses colloidal gold or latex particles. The up-converting phosphor 
particles, about 400nm in diameter, are covalently conjugated to the antibodies using 
EDC/NHS chemistry. The basis of the test is that in the competitive format used, the 
UPT-antibody-drug complex will not bind to the test line, immobilised drug-protein 
conjugate, in the presence of drug in the sample. If the drug is not present in the 
sample, the UPT-antibody binds to the immobilised drug-protein on the test line giving 
a signal. This response at the test line is inversely proportional to the amount of drug in 
the sample.
1.6.5 Agglutination
Agglutination assays are common, and easy to perform. The basis of the assay is the 
specific mixture of antibody and antigen and visible aggregation of particles. They are 
homogenous, as they do not require the separation of free and antibody-bound fractions 
of the analyte. A variation of the agglutination assays include haemagglutination and 
haemagglutination-inhibition. In the case of haemagglutination the antigen-antibody 
interaction is mediated using red blood cells pre-coated with the antigen of interest. The 
addition of test sample containing antibodies results in a visual agglutination, 
(Fitzpatrick et al, 2000). Latex agglutination is similar to haemagglutination assay, in 
this case the antigen or antibody is coated to latex beads. An example of one popular 
commercially available agglutination test for drugs of abuse in urine, is the Ontrak® 
kits, by Roche Diagnostics.
1.6.6 Biosensors
One description of a biosensor is as follows: a sensing device that incorporates a
biological entity as a fundamental part of the sensing process (Diamond, 1998). 
Biosensors have been applied to the field of detection of drugs of abuse, e.g., Ogert et 
al. (1992), developed a continuous flow immunosensor for the detection of cocaine 
based on a fluorescence assay. The immunosensor is based on the displacement of the 
fluorophore-labeled cocaine from immobilised antibody. It consists of a sepharose 
microcolumn with immobilised anti-cocaine antibodies. A buffer flows into the column 
and exits to an on-line fluorimeter. The immunosensor depends on the immobilised 
antibodies for specific recognition of cocaine and its closely related metabolites. The
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displacement of fluorophore-labelled benzoylecgonine from the immobilised antibodies 
by samples containing cocaine produces the fluorescent signal. The limit of detection 
of cocaine was 5ng/ml.
Devine et al. (1995) developed a fibre optic biosensor for the detection of cocaine. 
Anti-benzoylecgonine monoclonal antibodies were immobilised onto quartz fibres and a 
flow fluorometer was used to detect changes in the fluorescence. A BEC-fluorescein 
conjugate was produced, and it bound to the immobilised antibody. The cocaine in the 
test sample competed for binding to the antibody in a concentration-dependant manner, 
and so reduced the initial rate or steady state fluorescence. The regenerable nature of 
this assay and that described by Ogert et al. (1992), is key to its success. The detection 
limit for cocaine in this assay was 5ng/ml and for benzoylecgonine was 30ng/ml. Yu et 
al. (1996) presented results from a similar flow immunosensor for the detection of 
benzoylecgonine in urine samples, giving a 97% correlation with results from samples 
analysed by GC-MS.
Another variation on the theme of fluoroimmunoassay-based biosensors is described by 
O’Connell et al., (1999). They evaluated a fluoroimmunoassay using microbeads 
instead of quartz fibers as a solid support, and the commercial system KinExA™ 
(Kinetic Exclusion assay) for the bead handling flow fluorometer system. A quantity of 
beads are coated with antibody and are introduced into a capillary flow cell and retained 
on a screen. Free benzoylecgonine in the test solution competes with fluorescein- 
benzoylecgonine conjugate for binding to the screen, and so the bead-bound 
fluorescence is reduced in the competitive format. The system monitors the binding of 
the fluorescent conjugate to the fiber in real-time and so it is also designed to measure 
association and dissociation rate constants of antigen-antibody complexes, similar to 
surface plasmon resonance technology.
Analyte 2000 (Research International, Woodinville, WA USA) is a fibre optic 
biosensor that has been applied to the analysis of cocaine and its metabolites in human 
urine using a competitive fluorescence immunoassay, (Nath et al., 1999). In this case, 
the binding of anti-benzoylecgonine monoclonal antibody to casein-benzoylecgonine 
antigen-coated optical fibres was inhibited by the presence of cocaine. The bound 
antibody, which is inversely correlated to the cocaine concentration in the sample, is 
measured by the fluorescence produced by the subsequent binding of cyanine dye- 
tagged anti-mouse antibody. The use of evanescent excitation of fluorescence in fibre
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optic biosensors ensures that only fluorophore bound to the surface of the fibre optic is 
detected, and so the sensor does not detect any sample constituents or unbound 
fluorophores. The minimum level of detection in this assay was 0.75ng/ml. The 
Analyte 2000 is composed of four single-fibre optics and so can perform the analysis of 
four drugs in the one sample. Currently, the main disadvantages with the systems is the 
lack of automation and the labour intensive preparation of the fibres. These problems 
however, are likely to be addressed and improved upon as further applications are 
developed. For all of the types of immunoassays described it must be reiterated, that 
their performance in terms of sensitivity and specificity are fundamentally associated 
with the quality of the antibodies that are used.
As mentioned previously, the detection of drugs by chromatographic methods requires 
an extraction step, as opposed to immunoassays that usually do not require a sample 
pretreatment step. There has been considerable research into amperometric and 
piezoelectric immunosensors (Cassidy, 1998), however, they do not seem to have found 
a place yet in the routine analytical laboratory.
Surface plasmon resonance-based biosensors are very successful analytical tools and are 
being used increasingly in research and anlytical labs. They are discussed in Chapter 5, 
in detail.
A novel, non-immunological-based biosensor using frog melanphores to detect opioids 
has been developed by Karlsson et al. (2002). This sensor harnessed the ability of 
lower vertebrates such as fish and frogs to change colour. In response to specific 
stimulii, chromaphores change colour by redistributing their pigment granules within 
the cell. Melanophores which are a particular type of chromophore that contains brown 
melanin pigment granules, were transfected with human opiod receptor 3 and cultured 
and used for opiate detection. In the presence of opiods, the pigment granules 
aggregated in a dose-dependant response in the melanophores. This technique of 
transfection of melanophores with different receptors may create an alternative 
biosensor for other substances. An example of another novel non-immunological-based 
assay is the bioluminescent assay for heroin and morphine that uses heroin esterase and 
morphine dehydrogenase linked to bacterial luciferase (Holt, 1996).
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1.7 Commercial Tests
The ROSITA project, funded by the European Commission, produced comprehensive 
papers on roadside drug testing in Europe. Work packages on different aspects of the 
project include:
• Drugs and medicines that are suspected to have a detrimental impact on road user 
performance, (Maes et al, 1999, www.rosita.org).
• Inventory of state-of-the-art roadside drug testing equipment, (Samyn et al., 1999).
• Operational, user and legal requirements across EU member states for roadside drug 
testing equipment, (Moller et al., 1999, www.rosita.org).
• Evaluation of different roadside drug tests, (Verstraete & Puddu, 2000, 
www.rosita.org).
• General conclusions and recommendations, (Verstraete & Puddu, 2000).
These informative documents can be accessed on the Rosita website at www.rosita.org. 
There are numerous commercial kits available for the screening of urine for drugs of 
abuse. However, because of the different form and concentrations of the drugs found in 
saliva, they are not ideally suited to saliva screening, and are not marketed for such an 
application. Three devices are commercially available for the purposes of roadside drug 
testing in saliva samples. These are Drugwipe (Securetec GmbH, Germany), Oral 
Screen (Avitar Technologies Inc, USA), and Rapiscan, (Cozart Biosciences Ltd., UK). 
The advantages and disadvantages of each are detailed in the above reports. Drugwipe 
is used for the detection of drugs on surfaces. Different tastes are available for the 
detection of opiates, cocaine, cannabis and amphetamines. The test is a lateral flow 
memebrane immunoassay, that consists of a wiping section and the chromatographic 
reaction cartridge. The substances captured on the wiping device are applied to the 
strip. The addition of water allows the progression of the immunnoassay, (Securetec, 
Germany). Drugwipe, as reported by the Rosita project, is available for the detection of 
recent use of cocaine, amphetamine, and designer amphetamines. They found that it 
was unreliable for detection of cannabis and some false negative results with regard to 
the detection of opiates. The Drugwipe for opiates is supposed to give a positive test 
with 5ng/ml of heroin, morphine or codeine. Kintz (1998), found an unacceptable 
number of false negative results in a study in which volunteers were administered 
codeine and subsequently tested using Drugwipe and saliva samples were also analysed
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by GC-MS. Part of the problem contributing to the false negatives may have been the 
inadequate sample collection or too low a cut-off mark for the analyte. An advantage of 
this test is that it does not involve saliva collection, instead, the tongue is wiped with a 
device. This test has also been marketed for drug detection in sweat samples. Navarro 
et al. (200IB) investigated the concentration of MDMA, in saliva with Drugwipe in a 
controlled study where recreational users were administered MDMA in a double-blind, 
cross-over, placebo clinical trial. Saliva samples were collected in addition to the ‘on­
site’ procedure and these samples were retested in the lab using Drugwipe and also 
tested using GC-MS. At 1.5 and 4 hours after administration, all eight subjects gave a 
positive result. The cut-off level determined by comparison to the GC-MS results was 
650ng/ml.
OralScreen is available for the detection of opiates, cocaine and cannabis, 
(www.avitarinc.com). The ORALscreen System contains an oral fluid collection device, 
and a test device containing a lateral flow membrane immunoassay. The main 
disadvantage documented by the ROSITA project with this device, was the difficulties 
with the saliva collection procedure. Many of the testers were in direct contact with the 
saliva during the procedure. Barrett et al. (2001) of Avitar conducted a study 
comparing the ORALscreen test for THC, cocaine, opiates and methamphetamine in 
oral fluid with a laboratory-based urine screen that involved EMIT testing for THC, 
cocaine metabolite, and opiates and by CEDI A® (Microgenics, USA) testing for 
amphetamine and methamphetamine. CEDIA testing is a commercial immunoassay 
that can be run on automated clinical chemical analyzers. The urine samples that tested 
positive by these screening tests were then analysed by GC-MS confirmation assays. 
The results show very good correlation for detection of cocaine and opiates for 2.5 and 
3 days after use, respectively. THC was detected by the ORALscreen on the day of use 
and one day following use. There was good correlation between the urine and oral fluid 
testing for methamphetamine. However the number of days following use was not 
determined.
Rapiscan, produced by Cozart Bioscience, is probably the most advanced roadside 
testing device as it incorporates a digital read-out of the results. It has been tested in a 
major trial by UK authorities. The test consists of three components, a test swab, for 
saliva collection, a disposable cartridge, and an instrument which displays the results. 
The sample is placed in the cartridge in the hand held device and the immunochemical
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reactions take place, giving results after five minutes, (www.cozart.co.uk). This test 
detects cannabinoids, ecstasy, cocaine, opiates and benzodiazepines in a saliva sample 
(Cozart Biosciences, 1999). The Rosita researchers described the device as 
‘problematic’ during the course of their field test. The problems included insufficient 
saliva collected, the test taking too long, and being too cumbersome. An advantage, 
however, was the availability of the remainder of saliva that could be used for 
laboratory confirmation. A recent paper by Jehanli et al. (2001), of Cozart 
Biosciences, examined the results of a trials that involved testing saliva samples from 
43 volunteers after consumption of codeine and cannabis. The results from the 
Rapiscan device was compared with results obtained from immunoassays and GC/MS. 
They found that positive opiates results were obtained for up to nine hours after 
ingestion of the codeine, however, the cut-level for the cannabis test was too high at 
lOng/ml THC, to detect marijuana use for more than a few hours after ingestion.
In the USA Intercept developed by OraSure Technologies, Inc, (Bethlehem, PA) is a 
test kit in which the saliva is collected and then shipped to the designated lab for 
analysis in an immunoassay format, (www.Orasure.com). Niedbala et al. (2001B & C) 
have presented the results of the saliva analysis and corresponding urine analysis. 
Using immunoassay cut-off values of lOng/ml and 2000ng/ml for positive opiate 
presence in saliva and urine, respectively, it was found that the correlation was 93.6%. 
In the corresponding test for marijuana, they found that the time course of the 
concentration of THC in oral fluid is similar to that described for THC in plasma. This 
is remarkable as the presence of THC in saliva is believed to be as a consequence of 
impregnation, rather than diffusion of the THC from the plasma. Concentration of THC 
in the oral fluid declined in a multi-phasic nature that suggests the presence of fast and 
slow releases of sequestered THC in the oral cavity. The concentrations of the THC 
detected in the oral fluid were higher in the first six hours after smoking and the 
concentration in urine increased and exceeded the urine concentration after about 16 
hours.
Immunological tests for drugs of abuse in urine are based on the following techniques: 
enzyme multiplied immunoassay technique (EMIT) such as EMIT® d.a.u.™ (Syva, 
UK), agglutination, such as Ontrak®, (Roche Diagnostics), fluorescence polarisation 
immunoassay, TDx® (Abbott Diagnostics) and radioimmunoassay, Abuscreen® 
(Roche Diagnostics). There are many different tests available for urine testing and 
these are also documented in the ROSITA reports. These urine screening tests are in
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widespread use in analytical labs in institutions, hospitals, and clinics and are of an 
overall good standard. The limitations of the urine tests are that they can only be used 
for detection of drug metabolites in urine. The form of ding metabolites found in urine 
can differ significantly from the drug form found in saliva. Another significant 
limitation is that the cut off level of these tests (Table 1.2) is generally greater than the 
cut off level that would be acceptable for saliva testing. This therefore limits the use of 
these tests to urine screening for drugs of abuse.
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1.8 Summary o f Introduction
Assays for the detection of drugs of abuse range in complexity from immunoassays to 
more complicated analytical methods such as gas chromatography/mass spectroscopy 
(GC/MS). The development of immunoassays for the detection of illicit drug use that 
could be used in roadside testing would mean that screening could be performed in the 
same manner as current alcohol testing and the confirmatory test would be by GC/MS. 
Currently, the most popular biological media for quantitative measurement of illicit 
drugs is plasma and urine. However, saliva is now becoming common because of the 
obvious advantage of the non-invasive nature of collection and the correlation between 
psychological impairment and the level of detection of the illicit drugs and metabolites. 
In the development of the rapid roadside tests, the following considerations should be 
taken into account. The test must be:
• rapid
• specific and sensitive, with positive results correlating to the legal cut off level as 
determined by authorities such as the National Institute of Drugs of Abuse (N1DA)
• degree of cross reactivity with drug metabolites and other common legal substance 
needs to be established
• ‘user-friendly’ as it will be performed by non-lab personnel
The international scientific and legal communities must also begin to create guidelines 
for the establishment of such tests in order that all the essential qualities can be 
incorporated by research and development groups.
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1.9 Aims o f Thesis
There is a huge demand in the scientific and security communities to establish rapid, 
robust, specific, sensitive assays for the detection of drugs of abuse in saliva samples. 
The aim of this project is the development of novel assays for the detection of drugs of 
abuse in saliva.
Chapter 3 describes the process of producing morphine and cocaine protein conjugates 
for the immunisation procedures. The drug-protein conjugates were used for the 
production of polyclonal antibodies to morphine and cocaine. THC-BSA was also used 
for the production of anti-THC polyclonal antibodies. The purified antibodies were 
then applied to an ELISA format for the detection of morphine, cocaine and THC.
Chapter 4 describes the production, purification and characterisation of the anti­
amphetamine and anti-methamphetamine monoclonal antibodies. Successful clones of 
each antibody were produced and the antibodies were applied to an ELISA for the 
detection of amphetamine, methamphetamine, and the other common designer 
derivatives, MDA, MDMA, MDEA, MBDB. The ELISA was also established using 
saliva samples as the matrix. Particular attention was given to the cross reactivity 
studies of these antibodies during the cloning procedure, as many other legal 
‘amphetamine like’ molecules, such as, ephedrine have shown cross reactivity with 
assays reported in the literature.
Chapter 5 expands the characterisation and application of the anti-amphetamine and 
anti-methamphetamine monoclonal antibodies using biosensor technology (BIAcore). 
Affinity constant measurements were determined using two different techniques, the 
classic ELISA based Friguet method and the solution-phase BIAcore assay. The 
antibodies were also applied for the development of a BIAcore-based inhibition assay 
for the detection of amphetamine and methamphetamine in saliva samples.
Chapter 6 describes the results of a pilot clinical study that was conducted to investigate 
the application of the antibodies produced for the detection of drugs of abuse. A 
number of different assays were used for the analysis of THC, and morphine. A
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prototype of the Envilec device was used, and a rapid test for THC using the anti-THC 
polyclonal antibody was developed. BIAcore assays were also investigated for the 
detection of morphine in saliva samples. Real saliva sample samples were collected 
from drug users and analysed in the different formats. Specific issues relating to the 
stability of drugs in biological samples and the collection and storage of real saliva 
samples are also discussed.
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Chapter 2 
Materials and Methods
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2.1 Materials
All chemicals and materials were obtained from Sigma Chemical Co. (Tallaght, Dublin 
24). The exceptions are listed in Table 2.1.
Table 2.T. Chemicals that were obtained from companies other than Sigma-Aldrich.
Non-Essential Amino Acids Gibco BRL
Fetal Calf Serum Gibco BRL
Sodium Pyruvate Gibco BRL
Briclone (Bioresearch Ireland) Archport
Hydrochloric Acid (HC1) (Riedel de Haen) Riedel de Haen
Acetic Acid Riedel de Haen
Tween 20 Riedel de Haen
PBS Tablets Oxoid
THC-BSA Fitzgerald Industries
Morphine-BSA Fitzgerald Industries
BEC-BSA Fitzgerald Industries
BEC-BgG Fitzgerald Industries
Amphetamine-BSA Fitzgerald Industries
Methamphetamine-B S A Fitzgerald Industries
THC-HRP Fitzgerald Industries
Cocaine McFarland Smith
Morphine McFarland Smith
CM-Dextran Fluka Chemicals
Bicinchoninic Acid Assay Kit Pierce and Warriner
All licences necessary for importing and possessing illicit drugs were obtained.
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Full Addresses of Suppliers
Archport, Dublin City University Campus, Dublin 9.
Fitzgerald Industries, 34 Junction Square Drive, Concord, MA 01742, USA. 
Fluka Chemicals, Gillingham, Dorset, UK,
Gibco BRL, RenfewRd., Paisley, PA4 9RF, Scotland.
McFarland Smith, Wheatfield Road, Edinburgh, EH11 2QA, Scotland. 
Oxoid, Basingstoke, Hampshire, RG24 8PW, UK.
Pierce and Warriner, Chester, UK.
Riedel de Haen, Wunstorfer Strabe, D-3106, Seelze, Hanover, Germany. 
Sigma Aldrich, Tallaght, Dublin 24.
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Table 2.2\ Equipment used and the supplier.
2.2 Equipment
Equipment Supplier
BIAcore 3000 BIAcore AB
3015 pH Meter Jenway Ltd.
Titertek Multiscan Plate Reader Medical Supply Company
Millipore Filtration Device Medical Supply Company
Heraeus Labofuge 6000 Heraeus Instruments
Biofuge A Microcentrifuge Heraeus Instruments
Ultrafiltration Cell Amicon
Heraeus C02 Incubator EG 115IR Heraeus Instruments
Holten 2448K Laminar Flow Unit Holten Laminar A/S
Nikon Diaphot Inverted Microscope Nikon
UV 160A Spectrophotometer Shimadzu
RM6 Lauda Waterbath AGB Scientific
SB1 Blood Tube Rotator Medical Supply Company
Atto dual minislab system AE-6450 Atto
Full Addresses of Suppliers
AGB Scientific, Dublin Industrial Estate, Glasnevin, Dublin 9.
Amicon Inc., Beverely, MA 01915,
Atto, Bunhyo-Kui, Tokyo 113, Japan.
BIAcore AB, Uppsala, Sweden.
Holten Laminar A/S, Gydevang 17, DK 3450 Allerod, Denmark.
Heraeus Instruments Inc., 111-a Corporate Boulevard, South Plainfield, NJ 07080. 
Jenway Ltd., Gransmore Green, Felsted Dunmow, Essex, CM6 3LB, UK.
Medical Supply Company, Damastown, Mulhuddart, Dublin 15.
Nikon Corp., 2-3 Marunouchi 3-Chrome, Chiyoda-Ku, Tokyo, Japan.
Shimadzu Corp., 1 Nishinokyo-Kuwabaracho, Nakagyo-ku, Kyoto 604, Japan.
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2.3 Consumables
Table 2.3\ Consumables used and the suppliers.
Consumable Source
BIAcore sensor chips BIAcore
Plastic labware, e.g., eppendorfs, 
centrifuge tubes, pipettes, pipette tips
Sarstedt
Maxisorb 96 well plates Nunc
Tissue culture plasticware Nunc
Ultrafiltration filters Amicon
Saliva Collection Device Trinity Biotech
Full Addresses of Suppliers 
Amicon, Beverely, MA 01915.
BIAcore AB, Uppsala, Sweden.
Nunc, Kamstrup DK, Roskilde, Denmark.
Trinity Biotech, Southern Cross Business Park, Bray, Co. Wicklow. 
Sarstedt, Sinnottstown Lane, Drinagh, Co. Wexford.
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2.4 Standard Solutions
Phosphate Buffered Saline (PBS)
One PBS tablet was dissolved in lOOmls deionised water per the manufacturers 
instructions. The final solution contains lOmM phosphate buffer with 0.14 M NaCl, pH 
7.2-7.4.
PBS/Tween
PBS containing 0.05% (v/v) Tween-20 
Hepes Buffered Saline (HBS)
50 mMNaCl, 10 mM Hepes, 3.4 mM EDTA, and 0.05% (v/v) Tween-20. The pH was 
adjusted to pH 7.4 with 2M NaOH. The solution was filtered through a 0.2p.m filter and 
degassed.
2.4.1 Cell culture media 
DM KM
DMEM (Dulbecco’s modification of Eagle’s medium) supplemented with 2mM L- 
glutamine, 25(ig/ml gentamicin and 10% (v/v) fetal calf serum.
HAT
DMEM (as above) supplemented with non-essential amino acids, ImM sodium 
pyruvate, lOOuM hypoxanthine, 400nM aminopterin, and 16uM thymidine.
HT prepared as for HAT without aminopterin.
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2.4.2 SDS PA GE Solutions
Stock Solutions
• 30% (w/v) acrylamide containing 0.8% (w/v) bis-acrylamide
• 1.5 M Tris-HCl, pH 8 .8, containing 0.4% (w/v) SDS
• 0.5 M Tris-HCl, pH 6 .8, containing 0.4% (w/v) SDS
• 10 % (w/v) ammonium persulphate
Table 2.4: Volumes of stock solutions required for resolving and stacking gels for
SDS-PAGE.
Solution Resolving Gel 
(10% (w/v) Acrylamide)
Stacking Gel 
(3% (w/v) Acrylamide)
Distilled H20 14.0 ml 5.625 ml
30% (w/v) Acrylamide 10.5 ml 1.875 ml
1.5 M Tris pH 8.8 6.3 ml -
0.5 M Tris pH 6.8 - 0.9 ml
10% (w/v) SDS 0.18 ml 0.075 ml
TEMED 0.03 ml 0.075 ml
Ammonium Persulphate 0.15 ml 0.04 ml
Electrophoresis Buffer
25 mM Tris (pH 8.8), 192 mM glycine, and 0.1% (w/v) SDS.
Sample Loading Buffer
60 mM Tris (pH 6 .8), 25% (v/v) glycerol, 2% (w/v) SDS, 14.4 mM 2-mercaptoethanol, 
and 0 .1 % (w/v) bromophenol blue.
Coomassie Blue Stain
Coomassie blue stain was prepared containing 0.2% (w/v) coomassie blue R250 in 
30:10:60 (v/v/v) (methanol:acetic acid:water).
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Destain Solution
Destain was made up with methanol:acetic acid:water in a 10:7:53 (v/v/v) ratio.
2.5 Production o f  drug-protein conjugates
2.5.1 Conjugation o f  morphine-3-glucuronide to protein
Morphine-3-glucuronide (25mgs) was dissolved in 0.5mls 0.15M HC1 and the solution 
made up to 2.5mls in 0.05M phosphate buffer, pH 7.8. Solid NHS was added to the 
morphine-3-glucuronide to give a final molarity of 0 .1M. EDC was dissolved in 
1.25mls H2O and added to the mixture to give a final molarity of 0.4M. The solution 
was mixed for 10 minutes with stirring. Protein (OVA, BSA, or BTG) (30mgs) was 
dissolved in 2.5mls 0.05M phosphate buffer, pH 7.8. This was added to the mixture and 
stirred for 1-2 hours at room temperature. The mixture was dialysed extensively against 
PBS at 4°C overnight.
2.5.2 Conjugation o f  cocaine to protein
A solution of cocaine was prepared in phosphate buffered solution as the phosphate ions 
could serve as a catalyst for the hydrolysis reaction, (Das Gupta, 1982). A 5mg/ml 
solution in PBS was prepared and stored at room temperature for one week to allow the 
conversion of cocaine to BEC. NHS was added to 1 ml of the solution to give a final 
molarity of 0.1M. EDC was dissolved in 0.25mls H2O and when added to the mixture 
gave a final molarity of 0.4M The solution was mixed for 10 minutes at room 
temperature. lOmgs of protein (OVA, BSA or BTG) was dissolved in 0.5mls 0.05M 
phosphate buffer, pH 7.8. This was added to the mixture and stirred for 1-2 hours at 
room temperature. The mixture was dialysed extensively against PBS at 4°C overnight.
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2.5.3 Commercial conjugates
Morphine-bovine serum albumin (morphine-BSA) conjugate was obtained from 
Fitzgerald Industries International, MA, USA. The morphine was conjugated to the 
BSA at the -3 position. The molar ratio of morphine to BSA of the conjugate was 
123:1.
Benzoylecgonine-bovine serum albumin (BEC-BSA) was obtained from Fitzgerald 
Industries International, M A USA. The molar ratio of BEC to BSA of the conjugate 
was 60:1.
Tetrahydrocannabinol-bovine thyroglobulin (THC-BTG) was obtained from Fitzgerald 
Industries International, MA, USA. The THC was conjugated through the delta-8 
position.
2.6 Immunisations fo r  polyclonal and monoclonal antibody production
The following protocols are employed for the production of polyclonal and monoclonal 
antibodies. Three rabbits were immunised with THC-BTG, BEC-BSA and morphine- 
BSA. Two groups of mice (4 in each group) were immunised with amphetamine-BSA 
and methamphetamine-BSA. Care of animals was in accordance with DCU guidelines. 
All appropriate licenses were obtained and adhered to for work involving animals.
2.6.1 Immunisation Protocol fo r  the production o f  Monoclonal Antibodies
Animals Used
6 week old Balb/c female mice 
Day 1:
Mice were immunized by sub-cutaneous injection with an emulsion (250ul) 
consisting of a 1 mg/ml solution of hapten - protein conjugate mixed 1 : 1 with 
Freund’s Complete Adjuvant 
Day 21:
Re-immunized intraperitoneally
Note: Freund’s Incomplete Adjuvant is used instead of Freund's Adjuvant.
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Day 28:
A blood sample was collected (by least invasive method -  tail bleed) and the 
antibody titre determined by ELISA against the respective antigen.
Day 52:
The mouse was boosted intraperitoneally using Freund’s Incomplete Adjuvant. 
Antiserum Recovery:
Animal was re-immunised and serum titred, when possible, until an acceptable 
titre was obtained and a schedule of immunisations of approximately six 
months or greater is completed.
Five days after the last immunisation, the animal was sacrificed and the blood 
and the spleen removed.
2.6.2 Immunisation Protocol fo r the production o f Polyclonal Antibodies
Animals Used
Adult New Zealand white female rabbits 
Day 1:
Rabbit immunised by sub-cutaneous injection with an emulsion (1ml) 
consisting of a 1 mg/ml solution of hapten - protein conjugate mixed 1 : 1 with 
Freund’s Complete Adjuvant.
Day 14:
Rabbit re-immunised as before.
Note: Freund’s Incomplete Adjuvant was used instead of Freund’s Complete 
Adjuvant.
Day 28:
5ml blood sample removed from ear vein and the antibody titre determined 
against the respective antigen.
Day 35:
Rabbits re-immunised as before.
Note: Freund’s Incomplete Adjuvant was used instead of Freund’s Complete 
Adjuvant.
Day 42:
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A blood sample was collected, as before, and antibody titre determined against 
the respective antigen.
Antiserum recovery:
The animal was re- immunised and serum titred when possible, until an acceptable titre 
(>1/500,000) was obtained and a schedule of approximately six months was completed. 
At this point the animal was sacrificed and the blood recovered by cardiac puncture.
2.6.3 Preparation o f  rabbit serum
For estimation of titre, the blood collected was allowed to clot for 2 hours at room 
temperature. It was stored overnight at 4°C to allow the clot to tighten and then 
centrifuged at 4,000 rpm for 20 minutes. The supernatant was removed and stored at -
20°C.
2.6.4 Preparation o f  mouse serum
The procedure was as above with the exception of the centrifuge step; for mouse serum 
because of the small volume, it was centrifuged at 13,000 rpm for 20 minutes.
2.7 Production o f  monoclonal antibodies
All cell cultures were grown in an incubator with 5% CO2, at 37°C. Cell counts were 
performed using a Neubauer Counting Chamber. The viability of cells was determined 
by mixing the cells at a 5:1 ratio with 0.4% (w/v) Trypan Blue Solution. Dead cells 
stained blue and viable cells remained white. The cells were visualised with a phase 
contrast microscope. The count was performed within five minutes of mixing with the 
Tryptan Blue.
2.7.1 Cell lines
Sp2/0 (ATCC CRL 1581) cell line was cultured in DMEM. The cells were subcultured 
using a split ratio of 1:2 when the cells had grown to approximately 75% confluency.
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2.7.2 Immunisation Schedule
The mice were immunised as per the schedule detailed in Section 2.6.1. Five days 
before the fusion the mouse was re-immunised by an intraperitoneal injection of 
0.25mls of 500|j,g/ml of drug-protein conjugate mixed 1:1 with Freund’s Incomplete 
Adjuvant.
2.7.3 Fusion 
Sp2/0
Sp2/0 cells were grown for at least two weeks prior to the fusion. The cells were grown 
in T-75 flasks and on the day before the fusion they were subcultured at a split ratio of 
1:2 as they should be in the logarithmic phase of growth for the fusion. On the day of 
the fusion, the cells were centrifuged at 2000  rpm for 10  minutes and resuspended in 
5mls of DMEM lacking FCS. They were counted, as described above, and stored until 
needed.
Splenocytes
The immunised mouse was sacrificed and the spleen removed. The splenocytes were 
harvested by injecting DMEM slowly into the spleen and repeating this procedure until 
the spleen capsule is relatively clear. The splenocytes are then injected into a universal 
centrifuge tube and a cell viability count performed separately. The cells were 
centrifuged at 2000 rpm for 10 minutes and resuspended in 5mls of DMEM lacking 
FCS.
The splenocytes and Sp2/0 cells were mixed to give a cell ratio of 10 splenocytes per 
Sp2/0 cell. This cell mixture was pelleted and washed four times with 5mls of DMEM 
lacking FCS.
All of the supernatant from the final wash was removed except for 50-100fil, and the 
cells were resuspended by tapping. The suspension was placed in an ice/water bath and
1.5 mis of 50% (v/v) PEG was added to it over a one minute period, while the 
suspension was swirled. The swirling was continued for a further 90 seconds. The 
centrifuge tube was removed from the water bath and placed in the palm of the hand. 
DMEM was pre-warmed to 37°C and 20mls was added to the suspension over a five
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minute period, with constant slow swirling. The suspension was placed in a 37°C water 
bath for 15 mins.
The mixture was centrifuged at 2000 rpm for 10 minutes and the cells resuspended at a 
cell density of 1.2 x 106 cells/ml in HAT supplemented with 5% (v/v) Briclone. The 
suspension was plated in 96 well cell culture plates at 0.1ml per well. The plates were 
incubated for 7 days. On day 7, 50|il of HAT supplemented with 5% (v/v) Briclone 
was added to each well. On day 8, 50fil of medium was removed and fresh medium 
was added. This medium was then screened for antigen reactivity. Wells were fed as 
required.
2.7.4 Screening o f  hybridoma supernatants
Supernatants from the wells were screened for antigen reactivity using a conventional 
ELISA format as described for the polyclonal antibody assays (Section 2.9). Positive 
wells were scaled up to 48 well plates with 0.5mls medium. Wells subsequently found 
to be positive were scaled up in 24, 12, and 6 well plates and finally in T-25 and T-75
flasks.
2.7.5 Storage o f  cell lines
Cells were flushed off the surface of the tissue culture flasks using a pasteur pipette. 
The media was centrifuged at 2000 rpm for 10 minutes. The resulting pellet was 
resuspended in 2 mis of FCS and 2 mis of 10% (v/v) of DMSO in FCS. The mixture of 
4mls was divided into four 1 ml cryovials. The freezing process was performed 
gradually over a 2.5 hours time period using a freezing tray, in the vapour phase of 
liquid nitrogen. The vials were then immersed in the liquid nitrogen and stored long­
term.
2.7.6 Mycoplasma screening
Mycoplasma testing was performed through the services of the National Cell and Tissue 
Culture Centre, Dublin City University. Cells were provided to them that had been 
grown in antibiotic free medium for three sub-culturing processes.
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2.8 Purification and Characterisation o f  antibodies
2.8.1 Purification o f  polyclonal rabbit serum
The rabbits were immunised as per the schedule detailed in Section 2.6. Fourteen days 
pre-sacrifice, the rabbits were reimmunised by an intraperitoneal injection of 1 .0ml of 
500|i,g/ml of drug-protein conjugate mixed 1:1 with Freund’s Incomplete Adjuvant. For 
the production of anti-THC antibodies, THC-BTG was used as the immunogen and 
THC-BSA was used as the screening conjugate. BEC-BSA was the immunogen and 
BEC-BgG was used as the screening conjugate for the production of anti-cocaine 
antibodies. Morphine-BSA was used as the immunogen and morphine-3-glucuronide- 
OVA was the screening conjugate for the production of the anti-morphine antibodies.
2.8.1.1 Ammonium sulphate precipitation
A cold saturated ammonium sulphate solution was prepared and a volume added to an 
equal volume of serum by dropwise addition, with constant stirring on ice. The mixture 
was stirred on ice for one hour and then centrifuged at 3000 rpm for 20 minutes. The 
supernatant was discarded and the pellet washed twice in lOmls of 45% (v/v) 
ammonium sulphate. The final pellet was dissolved in 5ml of PBS and dialysed 
overnight at 4°C against 5 litres PBS (pH 7.3, 0.15M NaCl).
2.8.2 Monoclonal Antibody Purification
2.8.2.1 Concentration o f  tissue culture supernatant
The hybridoma cell line was grown for one to two weeks. The cell culture supernatant 
was collected, and sodium azide was added at a concentration of 0.025% (w/v), final 
concentration. The supernatant was stored at 4°C. 50ml of supernatant was 
concentrated to 5 ml on a stirred ultracentrigfugation apparatus with a 76mm diaflo 
ultrafilter membrane, with a molecular weight cut-off of 100 Kdaltons. The concentrate 
was stored at 4 °C.
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2.8.3 Protein G Affinity Column
A protein G column was prepared by adding 1 ml of protein G immobilised on 
Sepharose 4B Fast Slow into a 5 ml syringe. The column was equilibrated with 20ml 
PBS. The dialysate from the ammonium sulphate precipitation, in the case of 
polyclonal antibody purification, and concentrated supernatant, in the case of 
monoclonal antibody purification, was added to the column. 1ml of PBS was added to 
the eluate and it was reapplied to the column. The eluate was collected and 4ml PBS 
added and the mixture reapplied again. The collected eluate was applied to the column 
again. The column was washed with 25ml PBS. The bound immunoglobulin was then 
eluted by addition of 0.1M glycine/HCl, pH 2.5, to the column. The glycine was 
equilibrated in the column for about 15 minutes. lOOul of Tris/HCl, pH 8.7 was added 
to eppendorf collection tubes and the absorbance of the eluate was monitored in each at 
280nm. The fractions containing protein were pooled and dialysed overnight at 4°C 
against 5 litres of PBS with two changes of buffer.
2.8.4 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed to assess the purity of the purified antibody fractions from the Protein G 
purification step. The solutions used are outlined in Section 2.4.2. Samples were 
prepared in sample buffer (4:1, sample :buffer ratio), and boiled for 5 minutes before 
being loaded onto gels. The gels were run at 50 mA, using an ATTO verical minigel 
electrophoresis system, until the blue dye of the sample buffer had reached the bottom 
of the gel. The gels were subsequently stained for 30 minutes using Coomassie Blue 
staining solution. The gels were destained by overnight incubation in destaining 
solution.
2.8.5 Determination o f  Protein Concentration - BCA
A Bicinchoninic Acid assay kit (BCA Kit, Pierce & Warriner, UK) was used for the 
determination of protein content. Standard protein solutions were prepared in PBS 
using either BSA or immunoglobulin. 10 pi of the solution was mixed with 190 pi of
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BCA kit working solution in a 96 well plate. The plate was incubated at 37 °C for 30 
minutes. The absorbance was read at 562 nm on the Titretek plate reader. A standard 
curve of the protein standards was plotted and the concentration of the unknown 
solutions was determined.
2.9 Immunoassays
2.9.1 Estimation o f  rabbit antibody titre
Levels of antibody in serum from immunised rabbits were measured using ELISA. One 
series of wells were coated with 10 0  [0.1 of the drug-protein conjugate (in the case of the 
serum from the rabbit immunised with THC, 1 fig/ml of THC-BTG or THC-BSA was 
used; for the serum from the rabbit immunised with BEC, 10 |_ig/ml BEC-BSA or BEC- 
BgG was used; for the serum from the rabbit immunised with morphine-BSA 10 M-g/ml 
morphine-3-glucuronide-OVA was used) and a second series of wells were coated with 
the protein alone (BTG, BSA or OVA) at a concentration of 1 |ig/ml and incubated for 
90 minutes at 37°C. The plates were washed five times in PBS/Tween and were 
blocked by adding 200 fil of PBS/Tween containing 2% (w/v) milk powder and 
incubated again for 90 minutes at 37°C. The serum was diluted in PBS/Tween and 
PBS/Tween containing 0.1% (w/v) protein (BTG in the case of the THC-BTG 
immunised rabbit, BSA in the case of the BEC-BSA and morphine-BSA immunised 
rabbits), from 1/200 to 1/51,200. The plates were incubated for 90 minutes at 37°C. 
The plates were washed five times with PBS/Tween. 100 (j.1 of commercial goat anti­
rabbit lgG antibody, labeled with horseradish peroxidase at a dilution of 1/5,000 in 
PBS/Tween, was then added to the wells. The plate was incubated for 90 minutes at 
37°C. The plates were washed five times with PBS/Tween. The substrate for 
horseradish peroxidase, OPD, was then added. The plates were incubated for 30 
minutes in the dark at room temperature. The absorbance was read at 450 nm using a 
microtitre plate reader.
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2.9.2 Estimation o f mouse antibody titre
Levels of antibody in serum from immunised mice were measured using the above 
procedure with the following exception: the secondary antibody used was 
HRP-labelled rabbit anti-mouse IgG used at a dilution of 1/2000.
2.9.3 Non-Competitive Enzyme-linked Immunosorbent Assay fo r  determination o f  
antibody litre and optimal concentration o f  protein conjugates
Microtitre plates were coated with a range of drug-protein concentrations by adding 100 
pi of drug-protein conjugate dissolved in PBS (pH 7.3, 0.15M NaCl) to each well. The 
plates were incubated for 60 minutes at 37°C. The plates were emptied and washed five 
times with PBS/Tween (0.05% (v/v) Tween 20). The wells were blocked by addition of 
100 pi PBS containing 2% (w/v) milk powder and incubated for 60 minutes at 37°C. 
The plates were emptied and washed five times with PBS/Tween as before. Serial 
dilutions of antibody in PBS (100 pi) were added into the wells of each conjugate 
concentration on the plate. The plates were incubated for 60 minutes at 37°C. The plates 
were washed five times with PBS/Tween as before. Enzyme-conjugated IgG (anti­
rabbit in the case of polyclonals, and anti-mouse in the case of monoclonal antibodies) 
were diluted in PBS/Tween containing 2% (w/v) milk powder (100 pi) was added to the 
wells and incubated for 60 minutes at 37°C. The plates were washed five times with 
PBS/Tween and 100 pi of substrate (OPD in case of HRP Conjugate, and p-NPP in case 
of AP conjugate) was added to each well. The plate was covered with foil and left at 
room temperature for 30 minutes for the colour to develop. The absorbance was 
measured on a microtitre plate reader at 450nm.
2.9.4 Competitive Enzyme-linked Immunosorbent Assay
Microtitre plates were coated by adding 100 pi of drug-protein conjugate dissolved in 
PBS (pH 7.3, 0.15M NaCl) to each well. The plates were incubated for 60 minutes at 
37°C. The plates were emptied and washed five times with PBS/Tween (0.05% (v/v) 
Tween 20). The wells were blocked by addition of 100 pi PBS containing 2% (w/v) 
milk powder and incubated for 60 minutes at 37°C. The plates were emptied and 
washed five times with PBS/Tween as before. Drug standard, 50 pi, containing from
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0.38 ng/ml to 100,000 ng/ml and mouse anti-drug antibody, 50 pi, (diluted in 
PBS/Tween containing 2% (w/v) milk powder) were added into each well. The plates 
were incubated for 60 minutes at 37°C. The plates were washed five times with 
PBS/Tween as before. Horseradish-peroxidase conjugated IgG was diluted 1/2000 in 
PBS/Tween containing 2% (w/v) milk powder and 100 fj.1 was added to the wells and 
incubated for 60 minutes at 37°C. The plates were washed five times with PBS/Tween 
and 100 pi of substrate (0.4 mg/ml o-phenylenediamine (OPD), in phosphate citrate 
buffer, pH 5, and 0.4 mg/ml of urea hydrogen peroxide) was added to each well. The 
plate was covered with foil and left at room temperature for 30 minutes for the colour to 
develop. The absorbance was measured at 450 nm on a microtitre plate reader. A 
schematic representation of the ELISA procedure used is shown in Figure 2.1.
2.9.5 Isotyping o f  monoclonal antibodies
ELISA plates were coated and blocked with the appropriate drug-protein conjugate and 
milk protein, respectively, for 60 minutes, as described in Section 2.9.3. The 
monoclonal antibody was added and incubated for 60 minutes. After washing, alkaline 
phosphatase-labelled goat anti-mouse immunoglobulins were added to the wells and the 
ELISA developed using para-nitrophenyl phosphate (p-Npp) provided in table form and 
dissolved in the required volume of deionised H20, as described by the supplier’s 
instructions. The absorbance of the reactive wells indicates the monoclonal antibody 
isotype.
2.9.6 Affinity analysis ELISA -  Friguet method
Twelve hours before the Friguet assay was performed, a series of antibody-antigen 
mixtures were incubated in eppendorf tubes, to reach equilibrium. The solutions 
contained a constant, nominal, dilution of antibody, refered to as ‘1 ’, and varying 
concentrations of antigen. In another set of eppendorfs, serial dilutions of the nominal 
concentration of antibody were prepared. These were used to construct the standard 
curve of nominal antibody concentration versus absorbance at 450nm. Twelve hours 
later, the ELISA was performed on these solutions, as per Section 2.9.3. Absorbance 
readings at 450nm of the antigen:antibody mixtures were related to the nominal 
concentration values by reference to the standard curve of nominal concentration versus
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absorbance at 450nm. The fraction of total antibody bound by the antigen (v) was 
calculated for each antigenrantibody mixture. The dissociation constant for the 
antigen:antibody interaction was defined by the slope of the plot of 1/v versus 1 /[A], 
(see Section 5.1.5).
2.9.7 Determination o f immunoglobulin concentrations by affinity capture ELISA
Commercial goat anti-mouse immunoglobulin at a concentration of 10 (J.g/ml was used 
to coat the wells of a microtitre plate, and it was subsequently blocked with PBS 
containing 2% (w/v) milk powder as described in Section 2.9.3. Dilutions of mouse 
IgG of known concentration were prepared in PBS. Dilutions of the purified antibody 
were also prepared in PBS. 100 (ill of the solutions (standards and unknowns) were 
added to the wells and the ELISA developed as described in Section 2.9.3. A standard 
curve of absorbance at 450nm versus mouse IgG concentration was used for the 
determination of the mouse IgG concentration in the purified antibody solutions.
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2.10 BIAcore Studies
The CM5 sensor chip was used for all experiments, with the exception of the use of the 
FI chip which is described in Chapter 6 , for the optimisation of the BIAcore assay for 
the detection of morphine in saliva samples.
2.10.1 Preconcentration studies
An initial preconcentration step was carried out to determine the optimum pH for the 
immobilisation of the drug-protein conjugate. Proteins at pH values below their 
isoelectric point, pi, have a positive charge and will be electrostatically attracted to the 
negatively charged carboxy groups on the dextran matrix. The pi value of a protein is 
often changed by conjugation to a drug so the optimum pH is determined by the 
preconcetration study. Drug-protein was dissolved at a concentration of 50 |ig/ml in 10 
mM sodium acetate buffer, at a range of pH values between 3.8-5.0. These were passed 
sequentially over an underivatised chip surface and the pH giving the highest mass 
change in terms of response units (RU) was used for subsequent drug-protein 
immobilisation procedures.
2.10.2. Immobilisation o f drug-protein conjugates
The carboxymethylated dextran was activated, by injecting 35 |ul of a solution 
containing 0.05 M NHS and 0.2 M EDC over the chip surfacc at a flow rate of 5 (il/min. 
35 (il of a solution of drug-protein in 10 mM acetate buffer, at the appropriate pH, was 
passed over the surface at a flow rate of 5 |J,l/min. Unreacted NHS groups were 
‘capped’ (Section 4.2.2.), by passing 35 jil of a 1 M ethanolamine (pH 8.5) solution 
over the surface at a flow rate of 5 |il/min.
2.10.3. Regeneration Studies
The stability of the immobilised drug-protein conjugates surface, was assessed by 
passing a known concentration of antibody over the chip surface and the surface was
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regenerated with mild acid/base solution as detailed in the results sections. The cycle 
of binding and regeneration was performed for approximately 50-100 cycles, and the 
binding signal measured to assess the stability of the immobilised surface for assay 
development.
2.10.4. Non-Specific binding Studies
Purified monoclonal and polyclonal antibody solutions at the appropriate dilution were 
passed over the dextran matrix and the appropriate immobilised protein surface. Non­
specific binding to either dextran or immobilised protein surface was eliminated by the 
addition of either dextran or protein, or in some cases both, to the antibody solution.
2.10.5. Competitive Assays
Drug solutions was prepared at a series of concentrations ranging from 0.03 -  25,000 
ng/ml by serial dilution, using Hepes Buffered Saline (HBS) as diluent. Antibody at a 
constant dilution was added to the various antigen concentrations. The antibody:antigen 
mixture was allowed to equilibrate for 15 minutes. The equilibrium mixtures were 
passed in random order over the chip surface at 5 iitl/min for 4 minutes, and the chip 
surface regenerated between cycles by pulses of the appropriate regeneration solution. 
The amount of bound antibody was measured in terms of response units (RU). The 
response units were divided by the response measured for the antibodyrantigen mixture 
containing zero antigen to give normalised binding responses. A plot of antigen 
concentration (ng/ml) versus normalised binding responses could then be used to 
construct the calibration plot using BIAevaluation 3.1 software.
2.10.6. Solution Affinity Analysis using BlAcore
Drug-protein conjugates were immobilised using the conventional EDC/NHS coupling 
chemistry. Serial dilutions of the monoclonal antibodies of known concentration 
(molarity) were passed over the immobilised surface, and a calibration curve was 
constructed of mass bound measured in terms of response units, versus antibody 
concentration. A known concentration of antibody was then incubated with varying
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concentrations of free drug (molarity) and allowed to reach equilibrium overnight. The 
equilibrium samples were passed over the immobilised surface and the binding response 
calculated. The response values measured were used to calculate the amount of free 
antibody in the equilibrium mixtures, from the calibration curve. A graph was then 
plotted of drug concentration versus free antibody concentration. The solution phase 
interaction models in BIAevaluation 3.1 software, was used to determine the overall 
affinity constant, (see Section 5.1.6).
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2.11 Collection o f saliva samples
Saliva samples were collected using the saliva collection device from Trinity Biotech. 
The absorbant pad was removed and placed in the mouth for a couple of minutes. It 
was removed and placed into the plastic ‘filter-like’ component. A second part was 
screwed into this container and the saliva collected in an universal tube, through the 
pressure of the second part squeezing the saliva from the pad, see Figure 2.1.
2.12 Development o f Envitec Device Assay fo r  detection o f  THC
2.12.1 Background to Envitec Device
DCU collaborated with Envitec-Wismar GmbH on the European Commission 
Standards, Measurement and Testing Project, entitled, ‘On-site measurement of drugs 
of abuse in a saliva sample’. The aim of the project was to develop a new solid-phase 
format for the rapid detection of drugs of abuse in a saliva samples. Envitec developed 
an automatic device that could be used for this purpose. To achieve a safe and easy to 
use assay, the critical steps of the laboratory procedures for completing an 
immunoassay have to be simplified and the incubation steps shortened in time.
DCU obtained a prototype of the Envitec device and worked on the development of an 
assay for detection of THC in saliva samples, using the anti-THC polyclonal antibody 
that was produced and characterised as described in 
Chapter 3.
65
Figurre 2.1: Saliva sample were collected using a saliva collection device (Trinity 
Biotech, Dublin). The absorbant pad was removed and placed in the mouth for a 
couple of minutes. It was removed and placed into the plastic filter like component. 
A second part was screwed into this container and the saliva collected in an universal 
tube, through the pressure of the second part squeezing the saliva from the pad. The 
sample collected was diluted 1:1 with PBS and the sample applied to the Envice 
device for the detection of THC.
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Figure 2.2: Envitec prototype device for rapid analysis of drugs of abuse in saliva 
samples.
The well positions are shown in Figure 2.3, and the schedule of the final assay is 
described below.
2.12.2 Envitec Assay
Well Preparation
1. Nunc prototype wells were coated with 300pl/ml of 1/500 dilution of lmg/ml Sigma 
goat anti-rabbit immunoglobulin in PBS, pH 7.4, overnight at 4°C.
2. Wells were washed four times with PBS.
3. Wells were coated with 250|il/ml of 1/100 dilution of anti-THC polyclonal antibody
for 4 hours at room temperature on orbital shaker.
4. Wells were washed four times with PBS.
5. Wells were blocked with 300p,ls of 2% (v/v) milk protein in PBS, 30 minutes at 37
°C.
6 . Wells were washed four times with PBS containing 0.05% (v/v) Tween.
Assay
• Saliva sample was diluted 1:1 with PBS and added to well 1 of the device.
• A 1/500 dilution of THC-HRP in PBS was prepared and added to well 2 of the 
device
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Automated Assay Schedule
• 100|uil of the saliva sample was transferred to wells containing 10()|il THC-HRP.
• The mixture was transferred to the reaction wells.
• The mixture was incubated for 4 minutes.
• The mixture was sent to waste compartment and reaction wells were washed three 
limes with Tris Buffer.
• TMB was transferred to reaction wells and the first optical measurement recorded.
• The wells were incubatcd with TMB for five minutes.
• A second optical measurement recorded.
• The results were displayed.
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wells.
Well 1: Saliva sample mixed 1:1 with PBS (minimum 500(j,l needed)
Well 2: TMB Substrate (1ml)
Well 3: Waste well
Wells 4-8: lOOfils THC-HRP (Saliva sample is transferred to these wells for mixing 
with THC-HRP)
Wells 9-13: Reaction wells (coated with anti-THC antibody, after incubation step with 
sample and THC-HRP mixture, the TMB is transferred here and the transmission read
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Chapter 3
Production and Characterisation o f Polyclonal Antibodies to 
Tetrahydrocannabinol, Cocaine and Morphine
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3.1 Introduction
3.1.1 The Immune System
The immune system is composed of two levels, the innate and the acquired systems. 
The innate system acts as the body’s first line of defence against pathogens. Basic 
mechanisms of the innate response include physical barriers such as skin and mucous 
membranes and internal mechanisms include phagocytosis, and inflammation. 
Phagocytosis involves the internalisation and destruction of foreign matter by cells of 
the mononuclear phagoctye system. Natural killer cells are lymphocytes that can 
recognise the Class I Major Histocompatability Complex (MHC) molecules on a cell 
surface. Cells with reduced MHC molecule expression such as cells that are virally 
infected, or cancerous cells, are susceptible to attack by the natural killer cells. In 
addition to killing cells, NK cells can also secrete cytokines such as anti-viral cytokine 
IFN-y and the inflammatory cytokine TNF-a. The important differentiation between 
the innate system and the acquired system is the non-specific nature of the innate 
response. The acquired immune system is further divided into humoral immunity and 
cell-mediated immunity. The defining characteristics of the acquired immune system 
are:
• Specificity
• Inducibility
• Diversity
• Memory
• Distinguish self from non-self
• Downregulation (Elgert, 1996)
The principle components of the humoral immune system are the B lymphocytes and 
their products, the antigen-specific antibodies. Cell mediated immunity protects against 
intracellular pathogens and release immune system messengers such as cytokines (Th 
cells) and kill target cells, (Tc cells).
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3.1.2 The Lymphoid System
Lymphoid organs are composed of lymphocytes at different stages of development. 
They are classified as primary or secondary lymphoid organs. Primary lymphoid 
organs are the sites where immune cells, lymphocytes, can mature into functional 
effector cells. Generally, T cells are responsible for cell mediated immunity, and B 
cells are responsible for the humoral response, although it is critical that there is 
interaction between T cells and B cells for antibody production. In humans, the primary 
lymphoid organs are the bone marrow and thymus. B cells are produced and mature in 
the bone marrow. The precursors of T cells, produced also in the bone marrow transfer 
to and mature in the thymus. The secondary lymphoid organs include the spleen, lymph 
nodes, and mucosal-associated lymphoid tissue, (MALT), and it is at these sites that the 
lymphocytes can interact with antigens and undergo differentiation. The lymph nodes 
primarily respond to antigens in the tissue that they serve. The spleen acts as a filter for 
the circulatory system. The MALT system organises antibodies at major entry points of 
antigen entry (Roitt, 1994; Kimball, 2002).
3.1.3 Antibody production and the Humoral immune system
The specificity, diversity and memory are the key characteristics of the acquired 
immune response. As described below haptens less than 5Kda in size are usually 
unable to illicit an immune response. Adjuvants are oil/water emulsions with microbial 
components, e.g., heat killed Mycobacterium tuberculosis, in Freund’s complete 
Adjuvant. They are used to increase the immunogenicity of the substance, by localising 
the injection in the emulsion, and the microbial components cause an increase in the 
initial response involving the macrophages. The primary response of the body to a 
foreign agent primes the immune system for subsequent immunisations.
B cell receptors bind antigens and engulf them by endocytosis. The antigen is digested 
into fragments and they are displayed at the cell surface in conjunction with a class II 
MHC molecule. Helper T cells (Th cells) specific for this structure bind the B cell and 
secrete lymphokines that stimulate the B cell to develop into a clone of cells with 
identical antibodies and differentiate into plasma cells that secrete these antibodies.
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There are two kinds of TH cells: TH1 cells that participate in cell mediated immunity and 
Th 2  cells that are essential for antibody-mediated immunity.
When the precursors to TH cells are presented with an antigen, by an antigen presenting 
cell, they proliferate and become activated. Depending on the origin of the APC, the TH 
cell will develop into TH 1 or Th 2  cells.
Th 1 cells are produced when the APC presents antigen to the Tcell receptor for antigen 
in combination with the activation by EL-12. The Th 1 cells then secrete tumor-necrosis 
factor-beta (TNF-(3 ) and interferon-gamma (IFN-y )
These stimulate phagocytosis by macrophages and recruit other lymphocytes to the site 
producing inflammation.
Th 2 cells are produced when another type of APC present antigen to the T cell's 
receptor for antigen.
The major lymphokines secreted by Th 2 cells are IL-4, IL-5, IL-10 and IL-13.
Interleukin 4 (IL-4): Stimulates class-switching in B cells and promotes synthesis of 
IgE antibodies. It also acts as a positive-feedback device promoting more TH cells to 
enter the Th 2 pathway. It also inhibits expression of the IL-12 receptor thus inhibiting 
cells from entering the Thl path.
Interleukin 5 (IL-5): Attracts and activates eosinophils
Interleukin 10 (IL-10): Inhibits IL-12 production by APCs. This inhibits cells from 
entering the Th 1 pathway.
Interleukin 13 (IL-13): Promotes the synthesis of IgE antibodies.
The foreign material is engulfed by macrophages and displayed on antigen presenting 
cells in conjunction with the Class II MHC receptor. These are presented and bind to 
Th cells and initiate a series of immune responses leading to T cell proliferation and 
release of interleukin-1 (IL-1). This results in subsequent release of IL-2. The 
activated Tc cells respond directly in the cell-medicated immune response by acting as 
cytotoxic cells. The antigen also binds specifically to the B lymphocytes, and after the 
activation and presentation of the antigen to Th cells, the B lymphocytes convert to 
plasma cells through the critical interaction of Th cells and IL-4 and IL-5. The plasma
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cells secrete the specific antibodies. Some of the cells remain as memory B cells that 
are ready in case of future exposure to the specific antigen (Kimball, 2002).
3.1.4 A ntibody Diversity
The range of antigens that are presented to lymphocytes is huge and so the immune 
system must be capable of responding through its ability to reorganise the DNA 
material responsible for the production of immunoglobulins. The human genome has 
the DNA information to encode for all the immunoglobulins, however they are not 
organised into genes, but rather the genes are assembled from different sections of 
DNA.
For the antibody chains the gene segments are composed of variable (V) segments. 
Each of these encodes most of the N-terminal of the antibody, including the first two 
(but not the third) hypervariable region. The diversity (D) gene segments encode part of 
the third hypervariable region. The joining (J) gene segments encodes the remainder of 
the V region including the remainder of the hypervariable region. The constant (C) 
regions encode the remaining constant region of the antibody.
Four mechanisms contribute to this antibody diversity. The obvious processes to 
contribute to this diversity, are the many different V, D, and J germline gene sequences, 
and secondly the combinatorial recombination of these gene segments and chain 
association (Figure 3.1). The different combinations of V and J segments combining 
for constant light chains and V, D, and J segments joining for heavy chains, and then 
subsequent random association of the different light and heavy chains leads to a large 
diverse range of immunoglobulins. Another process contributing to the diversity is 
junctional diversity. This happens when there is imprecise DNA rearrangement 
involved in the joining of V with J, D with J, or V with D. Another contributor to 
junctional diversity is the insertion of random nucleotide regions between V, or J and D 
DNA segments in heavy chain genes. Finally the other contributory factor of overall 
antibody diversity is somatic mutation. The mutants created as the B cells divide allow 
for the selection by antigen of antibodies that provide better binding (Elgert, 1996).
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Figure 3.1: Recombinational arrangement of the DNA encoding variable, (V), diversity, 
(D), junction, (J) and constant (C ) regions of an immunoglobulin heavy chain and the 
subsequent transcription to messenger RNA and translation into the heavy chain.
3.1.5 Antibody Structure
The structural characterisation of antibodies began in the 1930s with work performed by 
Tiselius & Kabat. They did electrophoretic studies on non-immunised and post­
immunisation rabbit serum, and found that there was an increase in the gamma-globulin 
fraction following immunisation. This led to one characterisation of them as gamma­
globulin. The chemical structure was further investigated by Porter, Edelman, and 
Nisonoff in the 1950s and 60s, (Elgert, 1996). Porter digested the immunoglobulin with 
the proteolytic enzyme, papain, to cleave the peptide bonds, producing three fragments, 
two antigen binding Fab fragments and a non-antigen-binding Fc fragment. Edelman 
disrupted the disulphide bonds with dithiothrietol, iodoacetamide, and a denaturing 
agent, producing the two heavy chains and two light chains. Nisonoff used pepsin to 
hydrolyse the antibody at different sites to the papain and this hydrolysis resulted in one
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large fragment called F(ab/, that could bind antibody, and other smaller fragments. It 
could be further reduced to yield two Fab-like fragments called Fab .
The basic structure of an antibody is shown in Figure 3.2. The heavy and light chains 
are made up of repeated domains, each about 110 amino acids in length. The heavy 
chains have one variable region and three constant domains. The light chain has one 
variable domain and one constant domain. The variability of the antigen binding site is 
located in the complementarity-determining regions (CDRs), sub-divided into CDR1, 
CDR2, and CDR3. The variable regions of the chains are responsible for the antigen 
recognition and the constant regions are central to the biological effector functions. 
Binding to antigen is also facilitated by the flexible movement of the two Fab portions, 
which can change angle of between 60 to 180 degrees.
Immunoglobulins are divided into five groups based on their isotype. Isotypic 
determinants distinguish C-region sites on a heavy chain. The five groups are IgG, IgA, 
IgM, IgD and IgE. Subdivisions of these classes exist also. Antigenic determinants on 
light chains distinguish them as either k  or X. Different isotypes have different 
functions. IgG is the major immunoglobulin in the blood and is primarily induced by 
antigens. IgA is dimeric and is usually found in body fluids such as saliva and tears, 
and acts to guard these areas of the body. IgM is a pentamer and is the activator of 
complement. IgD is found on the surface on B cells where it is thought to be involved 
in regulation of B cell activity. IgE is found in hypersensitivity allergic reactions (Roitt, 
1994; Kimball, 2002).
Table 3.1: Classification and characteristics of immunoglobulins.
Class Hchain L chain Characteristic
IgG gamma kappa or lambda
Most common antibody seen, transferred across 
placenta
IgM mu kappa or lambda
Pentamer antibody, appears in primary response after 
immunization
IgA alpha kappa or lambda
Dimer antibody, found in secretions such as saliva,
tears
IgD delta kappa or lambda Uncertain function
IgE epsilon kappa or lambda
Involved in allergic reactions by binding to mast cells 
and sensitizing them
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CDR
Regions
Figure 3.2: Structure of the immunoglobulin molecule. The antibody is composed of 
two light chains and two heavy chains. The variable regions are located at the amino 
acid terminal end of the molecule. The light chain is composed of one variable region 
and one constant region. The heavy chains are composed of one variable region and 
three constant regions. The hinge region allows flexibility in the molecule for antigen 
binding. The antigen binding sites are specific and are represented by the 
complementarity-determining regions (CDR) regions. The heavy and light chains are 
connected via disulphide bonds, and there are disulphide bridges at the hinge region 
also between the two heavy chains. Disulphide bonds are also present in the constant 
and variable regions.
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3.1.6 Drug protein conjugation
Haptens are small chemical compounds, less than 5 KDa in size. They must be 
conjugated to a large carrier protein to be rendered immunogenic. To elicit an immune 
response the drugs examined in this study need to be conjugated to protein. The use of 
a drug-protein conjugate as an immunogen results in antisera containing a mixture of 
antibodies specific for the drug, protein and linking region between the drug and 
protein.
In the design of the conjugate, several factors need to be considered. The reactive 
groups and the positions on the drug provide a starting point for the design. The drugs 
under study were coupled through a carboxyl group to the amine groups on the proteins. 
This proceeded through EDC/NHS coupling chemistry. For the application of 
polyclonal antibodies in an ELISA format it is necessary to use conjugates differing 
from the immunogens with regard to the protein used and if possible the linkage 
between the drug and hapten. Bovine thyroglobulin, bovine serum albumin and keyhole 
limpet haemocyanin are proteins that could be used for the production of hapten-protein 
conjugates. For the purposes of screening a more soluble protein such as bovine serum 
albumin is suitable for the ELISA format, as it is water soluble. Dextran has a low 
immunogenicty, (P. Dillion, Personal Communication) and when conjugated to a hapten 
can be used as a screening conjugate for the identification of hybridomas specific for 
the drug of interest. The likelihood of the antibodies produced recognising the dextran 
part of the conjugate is small therefore eliminating the occurrence of positives that do 
not recognise the free drug. This is true of many ‘polymer-type’ substances, in that they 
do not make good immunogens (Hermanson, 1996). Ethylenediamine can be used as a 
linker between the drug and protein.
The procedures for the conjugation of a drug to a protein are well documented, 
(Hermanson, 1996). The usual method involves linking the drug to a carrier protein via 
a peptide bond. To perform this conjugation the drug must have suitable carboxyl or 
primary amino groups. If they are not present, the drug must first be derivatised to 
synthetically produce a derivative that contains those groups. The choice of 
derivatisation site on the hapten is of utmost importance in the design of an immunogen. 
Care must be taken not to derivatise those groups that distinguish a molecule from its 
relatives. The hapten should be linked to the carrier protein according to Landsteiner's
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principle which states that ‘antibody specificity is directed primarily at the portion of 
the hapten furthest removed from the functional group that is used to link the hapten to 
the carrier protein’ (Erlanger, 1980). Exposed sites act as antigenic determinants and are 
available to circulating lymphocytes, so antibodies to these are produced in numbers. 
The ideal epitope density per molecule is in the range 8-25 haptens per protein. This 
ratio seems to affect only the time taken for a suitable immune response to be generated. 
As little as two haptens per protein can generate a response but it will be delayed, 
(Erlanger, 1980).
By preparing a conjugate that has a structure common to the parent drug and it’s 
metabolites, antibodies with a general specificity for a drug and its metabolites will be 
produced. Fasciglone et al. (1996), reported that the immunogenicity of a conjugate is 
related to the hydrophobicity of the carrier. They concluded that hydrophobic haptens 
hide inside carrier proteins by interactions with the hydrophobic segments, resulting in 
no immunogenic response. It would, therefore, follow that for the generation of an 
immunogenic response against a hydrophobic hapten, it would be advisable to use a 
hydrophilic carrier protein.
Ethylenediamine can be as a means of introducing a linker into the drug-protein 
conjugate. The ethylenediamine initially cationises the ovalbumin The carboxylate 
groups of the protein are modified by the ethylendiamine by the formation of amide 
bonds with an alkyl spacer containing a terminal primary amine group. This blocking 
of the carboxyl groups on the protein and the addition of terminal primary amines raises 
the pi value. The highly positive charge of the cationised protein has been shown to 
significantly increase its immunogenicity. (Hermanson, 1996) When haptens are 
coupled through the cationised protein amine residues, the charge still remains high and 
produces a greater immune response. The positive charge assists in its binding to the 
antigen presenting cells and gets processed at an increased rate.
The production of antibodies to the main metabolite of heroin, morphine, provides a 
challenge regarding antibody production, due to its closeness in structure to the legal 
medication codeine. Findlay et al. (1981) investigated the relationships between 
immunogen structures and the resulting antibodies in the area of opioids. They found 
that conjugates of codeine-6-hemisuccinate, ethylmorphine-6-hemisuccinate or 
oxycodone-6-carboxymethyloxime had greater recognition of structural changes around 
the piperidine ring nitrogen atom and the 14-position. N-carboxypropylnormorphine- 
BSA, N-carboxypropylnorcodeine-BSA and norcodeine-BSA elicited antibodies that
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recognised changes in the 14-substituent. Codeine conjugated through the 8 position 
elicited antibodies similar to those elicited by N-carboxypropylnorcodeine-BSA. 
Salamone et al. (1998) reported the use of a non-cannabinoid immunogen used to 
generate antibodies with broad cross reactivity to the cannabinoid metabolites. They 
derivatised a benzpyran structure to elicit antibodies that were directed towards the 
conserved epitopes of cannabinoid metabolites. These antibodies showed two to three 
times higher cross reactivity with the cannabinoids than traditional phenolie-linked or 9- 
position-linked immunogens.
The design of a immunogen can be assessed by molecular modeling studies, however, 
the success of the immunogen can only be measured by the resulting titre of the 
antiserum produced.
Figure 3.3: The carbodiimide method for conjugating haptens and proteins through 
their carboxyl and amine groups, respectively. The process is mediated by EDC and 
NHS.
8 0
In the following results section, the production of morphine-protein and cocaine-protein 
conjugations are outlined. The immunisations and resulting titres of rabbit serum are 
presented. The purification process of the antibodies and the subsequent 
characterisation of the anti-THC, anti-morphine and anti-cocaine polyclonal antibodies 
are described. These antibodies were applied to an ELISA format and an assay 
developed and optimised for the detection of THC, morphine and cocaine.
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3.2 Results
3.2.1 Drug protein conjugate production
The following schemes outline the process for the conjugation of cocaine and morphine 
to proteins, through EDC/NHS chemistry. Commercial conjugates of THC were 
obtained for the purposes of this project as there was difficulties encountered sourcing 
sufficient quantities of these drugs.
3.2.1.1 EDC/sulfo-NHS coupling chemistry
EDC (l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride)/NHS((N- 
hydroxysulfosuccinimde) coupling chemistry is used to conjugate the drug and protein. 
The scheme used is outlined in Figure 3.3 (Hermanson, 1996). EDC reacts with the 
carboxylic group to form an active o-acylisourea ester intermediate. To stabilize the 
intermediate, sulfo-NHS is added and a stable sulfo-NHS ester intermediate is formed. 
The sulfo-NHS esters are hydrophilic active groups that react rapidly with the amines 
on the protein.
3.2.1.2 Conjugation o f  morphine to protein
Morphine contains the following groups
• Tertiary amino group
• Phenolic group (crucial to analgesic activity)
• Alcohol group
• Aromatic ring (Receptor sites in the brain)
• Ether bridge
• Double bond
Heroin is a powerful analgesic with twice the effects of morphine. Heroin differs from 
morphine in two areas. The 3-OH (Phenolic OH group) has become acetylated and the 6 
alcohol has also been acetylated. Morphine has three polar groups (phenol, alcohol and 
an amine) whereas analogues have either lost the polar alcohol group or have masked it 
by an alkyl or acyl group. Heroin has two polar groups. The brain barrier is fatty, and
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the significance of the polar groups becomes clear, the more polar morphine molecule is 
prevented from entering the brain, whereas the less polar heroin can enter easily.
For the purposes of generating a morphine-protein conjugate, morphine-3-glucuronide 
was used as the starting material. The glucuronide group provides an ideal reactive 
group for conjugation through EDC/NHS chemistry, as described later. It also provides 
an excellent linker region for the purposes of screening for antibodies specific for 
morphine and not the area between the morphine and BSA. The utilisation of the 
conjugate in the ELISA format was validated by performing an ELISA using the 
morphine-3-glucuronide-OVA as the coating conjugate and the commercial morphine 
antibody as the primary antibody.
An ELISA was performed to assess the success of the above conjugation. The 
morphine-3-glucuronide-thyroglobulin was used as the coating conjugate and 
commercial anti-morphine monoclonal antibody was used as the primary antibody. The 
ELISA was performed as described in Section 2.9. The results can be seen in Figure
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M-3-G-Thy 1 ug/ml X  Thy 10Oug/ml
Log Commercial anti-Morphine Monoclonal Antibody Dilution Factor
Figure 3.4: ELISA to confirm the conjugation of morphine to thyroglobulin. ELISA 
plates were coated with different concentrations of ‘lab-produced’ morphine- 
thyroglobulin conjugate. Commercial anti-morphine monoclonal antibody was used 
in the ELISA. The response to the thyroglobulin part of the conjugate was also 
measured by coating another series of wells with throglobulin alone. The response to 
the ‘lab-produced’ conjugate was positive, indicating a successful conjugation.
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3.2.1.3 Conjugation o f cocaine to protein
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Cocaine Benzoylecgonine (BEC)
Cocaine and the main metabolite, BEC, are shown above. The original design for the 
conjugate was to use cocaine as the hapten and to derivatise the -CO2CH3, to create a 
linker and reactive carboxylic group for EDC/NHS coupling. The availability of the 
-COOH group on the BEC allows direct conjugation through EDC/NHS chemistry. 
Due to the time involved in obtaining import licenses for the BEC and the supply of 
cocaine available in the lab, an attempt was made to convert the cocaine to BEC. 
Cocaine is used topically as a local anesthetic and work has been carried out to 
determine the stability of an aqueous solution over time and over a range of pH, (Das 
Gupta, 1982). Other researchers have suggested that the levels of BEC found in blood 
and urine may not be an actual metabolite of cocaine but instead are the result of non- 
enzymatic hydrolysis and so this would lead to errors in measurements of both 
substances, (Fletcher & Hancock, 1981). The conditions under which the hydrolysis 
occurs optimally are at alkaline pH. It was with this in mind that an attempt was made 
to convert the cocaine available in the lab to BEC.
An ELISA was developed, as described in Section 2.9, to determine the degree of 
conjugation. The 'lab-produced' conjugate coated the wells at concentrations of 5mg/ml, 
500(.ig/ml and 50jj.g/ml and the commercial BEC monoclonal antibody was used at 
dilutions of l/100k, l/200k, and l/400k. Dilutions of the monoclonal antibody were 
made with and without BSA in the diluent. Controls included rows coated with the 
commercial BEC-BSA conjugate that had been used in previous competitive ELIS As 
and BSA alone. The ELISA results (see Figure 3.5) showed that the conjugation 
procedure used was successful using the protocol described above.
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Figure 3.5: ELISA to confirm the conjugation of cocaine to bovine serum albumin 
(BSA). ELISA plates were coated with different concentrations of ‘lab-produced’ 
BEC-BSA conjugate and commercial BEC-BSA conjugate. Commercial anti-BEC 
monoclonal antibody was used in the ELISA. The response to the BSA part of the 
conjugate was also measured by coating another series of wells with BSA alone. The 
response to the ‘lab-produced’ conjugate was positive, indicating a successful 
conjugation.
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3.2.2 Determination o f rabbit antibody titres
Rabbits were immunised with the following drug-protein conjugates for the production 
of polyclonal antibodies. For the production of anti-THC antibodies, the immunogen 
used was THC-BTG, (Fitzgerald Industries). For the production of anti-BEC 
antibodies, the initial immunogen used was BEC-BSA, (Fitzgerald Industries) and later 
immunisations were prepared with the BEC-BSA that was produced as described in 
Section 2.5.2. The immunogen used to induce anti-morphine antibodies was initially 
morphine-BSA, (Fitzgerald Industries), and following the initial boosts, morphine-3- 
glucuronide-BSA was used.
Figure 3.6 show the antibody titre from a rabbit immunised with THC-BTG. The serum 
was diluted in PBS/Tween containing 0.1% (w/v) BSA to remove non-specific 
interactions with the protein part of the conjugate. It was also titred against BSA, with 
and without BSA in the diluent. This was to detect any immune response to the protein 
part of the conjugate, and to ensure that 0 .1 % (w/v) was sufficient to remove the non­
specific interactions. Although there was a response to the protein, it could be 
eliminated by the addition of the protein to the diluent. As can seen from Figure 3 .6, a 
very good response was obtained, the rabbit immunised with THC-BTG had a final titre 
of approximately 1/6  million.
Figures 3.7 and Figure 3.8 show the antibody titre from a rabbit immunised with BEC- 
BSA. The serum was diluted in PBS/Tween containing 0.1% (w/v) BSA to remove non­
specific interactions with the protein part of the conjugate. It was also tested against 
BSA, with and without BSA in the diluent. This was designed to detect any immune 
response to the protein part of the conjugate, and to ensure that 0.1% (w/v) of BSA was 
sufficient to remove non-specific interactions. The response was greater to the protein 
carrier than it was to the drug, as can be seen from the figures. Figure 3.7 shows the 
final titre that was obtained and screened using BEC-BgG as the screening conjugate. 
The rabbit immunised with BEC-BSA had a disappointing final titre of approximately 
1/50,000. It was decided to discontinue the immunisation schedule at that point as all 
titres had shown a much greater response to the BSA protein carrier than to the BEC 
drug hapten.
Figures 3.9 show the antibody titre from a rabbit immunised with morphine-BSA. It 
was screened against the morphine-3-glucuronide-ovalbumin conjugate. The rabbit 
immunised with morphine-BSA had a final titre of 1/400,000.
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A final titre from the rabbit serum should be preferably in the region of 1/500,000. 
Experience by our research group and others have shown that a prolonged immunisation 
schedule of about six months is preferable (Danilova, 1994). This leads to greater 
affinity of the antibodies.
♦  THC-BSA, BSA in diluent -  ■  BSA, BSA in diluent BSA, No BSA in diluent
Log Serum Dilution Factor
Figure 3.6: Titre of serum from rabbit immunised with THC-BTG
(tetrahydrocannabinol-bovine thyroglobulin). BSA was incorporated into the diluent 
buffer to eliminate the binding interaction between the antibody and the protein 
carrier. The serum was also titered against BSA, with and without BSA in the diluent. 
This showed that the response to the protein could be eliminated by incorporating the 
protein into the diluent.
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Log Serum Dilution Factor
Figure 3.7: Titre of serum from rabbit immunised with BEC-BSA (benzoylecgonine- 
bovine serum albumin). BSA was incorporated into the diluent buffer to eliminate the 
binding interaction between the antibody and the protein carrier. The serum was also 
titered against BSA, with and without BSA in the diluent. This showed that the 
response to the BSA could be eliminated by incorporating the BSA into the diluent.
Log Serum Dilution Factor
Figure 3.8: Titre of serum from rabbit (2A) immunised with BEC-BSA
(benzoylecgonine-bovine serum albumin) and screened against BEC-BgG.
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Figure 3.9: Titre of serum from rabbit immunised with morphine-BSA and screened 
against morphine-3-glucuronide-ovalbumin.
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3.2.3 Purification and characterisation o f polyclonal antibodies
The anti-THC, anti-BEC and anti-morphine polyclonal antibodies were purified by 
applying the dialysate from the ammonium sulphate precipitation to a Protein G 
immobilised Sepharose 3B column. The polyclonal antibodies were eluted from the 
column with 0.1M glycine, pH 2, as described in Section 2.8.3. The fractions collected 
were neutralised with 2M Tris, pH 8 .6 . The fractions were then read 
spectrophotometrically at 280 nm to determine the protein content. The fractions 
containing protein were pooled and dialysed in PBS overnight at 4°C with two of 
changes of PBS.
The purified antibodies were run on an SDS-PAGE to determine purity, as shown in 
Figure 3.10 and 3.11.
Lane 1: anti-amphetamine MAb 
Lane 2:anti-amphetamine MAb 
Lane 3:anti-BEC PAb 
Lane 4: anti-BEC Pab 
Lane 5 Markers
a 2-Macroglobulin human plasma, 180KDa 
P-Galactosidase (E. coli), 116KDa 
Fructose-6-phosphatase (Chicken), 84KDa 
Pyruvate kinase (Chicken), 54KDa 
Fumerase (Porcine), 48.5KDa 
Lactic Dehydrogenase (Rabbit), 36.5KDa 
Triosephosphate isomerase (Rabbit), 26.6KDa
Figure 3.10: Characterisation by SDS-PAGE gel of the anti-BEC polyclonal
antibody. Two bands can be seen, the top one at 50KDa representing the heavy chain 
and the lower band at 25KDa representing the light chains.
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9
1 & 7:Molecuiar weight markers
Heavy Chain
L ig h t C h a in
Morphine antiserum 
Supernatant from first SAS cut wash 
Supernatant from second SAS cut wash 
Purified anti-morphine polyclonal antibody 
Purified anti-THC polyclonal antibody
Figure 3.11: Characterisation by SDS-PAGE gel of the anti-morphine and anti-THC 
polyclonal antibody. Two bands can be seen, the top one at 50KDa representing the 
heavy chain and the lower band at 25KDa representing the light chains.
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3.2.4 Development o f ELISAs fo r  the detection o f THC, morphine and cocaine 
using the polyclonal antibodies
3.2.4.1 Anti-THCpolyclonal antibody
For the development of an ELISA for the detection of THC, the optimal coating 
concentration of THC-BSA and the optimal antibody dilution was determined by an 
indirect checkerboard ELISA. The results can be seen in Figure 3.12, the conjugate 
coating concentration ranged from 1 p-g/ml to 10 (ig/ml. The coating concentrations 
gave similar sensitivities and due to the expenses and availability of the conjugate, 
1 pg /ml was chosen as the concentrations for ELISAs. The optimal antibody dilution 
was approximately 1/5000, as this gave an absorbance in the 0.5 range and this is 
considered to be the sensitive region of the curve. However, for the purposes of 
optimisation of the assay with regard to sensitivities and cut off levels, the competitive 
assay was performed using a 1/10000 dilution of the polyclonal antibody and a less 
dilute secondary antibody dilution of 1/2000. Figure 3.6, the titre of the serum from this 
rabbit showed that at this concentration the response to the BSA carrier protein was 
negligible.
Figure 3.15 shows the relationship between the absorbance at 450nm and the 
concentration of free THC as determined by the competitive ELISA format. The range 
of detection of the assay was found to be between 24 and 50000 ng/ml. The intra-assay 
variation was determined from three replicates in an assay while the inter-assay 
variation was determined over five days of performing the assay. The intra-assay and 
inter-assay coefficients of variation are listed in Table 3.2 and 3.3.
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— • — 10ug/ml THC-BSA coated — 5ug/ml  THC-BSA coated 1ug/ml THC-BSA coated
Log anti-THC Antibody Dilution Factor
Figure 3.12: Indirect checkerboard ELISA for the determination of optimal
concentration of coating conjugate, THC-BSA, and optimal determination of anti-THC 
polyclonal antibody. THC-BSA was coated at 1, 5, and 10pg/ml. Doubling dilutions of 
the polyclonal antibody from 1/200 to 1/52,428,800 were carried out.
1 ug/ml BEC-BgG coated —■— 5ug/ml BEC-BgG coated 10ug/ml BEC-BgG coated
Log anti-BEC Antibody Dilution Factor
Figure 3.13: Indirect checkerboard ELISA for the determination of optimal
concentration of coating conjugate, BEC-BgG, and optimal determination of anti-BEC 
polyclonal antibody. BEC-BgG was coated at 1, 5, and lOfxg/ml. Doubling dilutions of 
the polyclonal antibody from 1/200 to 1/52,428,800 were carried out.
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10ug/ml Morphine-3-Gluc-OVA coated
1.00E+00 1.00E+01 1.00E+02 1.00E+03 1.00E+04 1.00E+05 1.00E+06 1.00E+07 1.00E+08
Log anti-morphine Antibody Dilution Factor
Figure 3.14: Indirect checkerboard ELISA for the determination of optimal
concentration of coating conjugate, morphine-3-glucuronide-OVA, and optimal 
determination of anti-morphine polyclonal antibody. Morphine-3-glucuronide-0VA 
was coated at 1, 5, and 10fig/ml. Doubling dilutions of the polyclonal antibody from 
1/200 to 1/52,428,800 were carried out.
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Figure 3.15: Inter-day curve for the detection of THC using the anti-THC polyclonal 
antibody on a THC-BSA immobilised surface. The data was correlated to a four- 
parameter model fit and the plot constructed using BIAevaluation 3.1 software. Each 
point on the graph is the average of five results obtained on five different days from a 
set of three replicates. Each value was normalised for that intra-assay by dividing the 
RU obtained by the RU for the positive control that only contained antibody and no 
morphine. The coefficient of variation, back-calculated amphetamine concentration and 
the percentage recovery for intra-day and inter-day assays are shown in Table 3.2 and 
3.3. The range of detection of the assay is 24.4 -  50000ng/ml.
Table 3.2: Intra-assay variation (degree of precision) for the detection of THC in the
ELISA using the anti-THC polyclonal antibody. The results presented are the mean of
three replicates.
Actual THC Cone 
(ng/ml)
Back-Calculated 
THC Cone (ng/ml)
CV
%
Recovery
%
24.4 25.1 2.97% 102.75%
48.8 38.0 5.98% 77.83%
97.7 132.8 4.44% 136.03%
195.3 180.4 3.17% 92.35%
390.6 361.1 0.87% 92.44%
781.2 670.2 2.57% 85.78%
1562.5 1661.3 5.00% 106.32%
3125.0 4330.2 3.75% 138.57%
6250.0 5830.5 4.62% 93.29%
12500.0 9510.8 6.30% 76.09%
25000.0 20316.6 3.12% 81.27%
50000.0 73771.0 1.42% 147.54%
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Table 3.3: Inter-assay variation (degree of accuracy and reproducibility) for the
detection of THC in the ELISA using the anti-THC polyclonal antibody. The results 
presented are the mean values obtained from five intra-day assays, each assay had three 
replicates. The range of detection of the assay is 24.4 -  50000.0 ng/ml.
Actual THC Cone 
(ng/ml)
Back-Calculated 
THC Cone (ng/ml)
CV
%
Recovery
%
24.4 22.3 9.34% 91.46%
48.8 51.9 8.06% 106.27%
97.7 114.0 6.53% 116.71%
195.3 164.8 7.55% 84.37%
390.6 318.9 8.96% 81.64%
781.25 902.6 5.54% 115.54%
1562.5 1897.6 4.10% 121.45%
3125.0 3193.9 5.25% 1 0 2 .2 1 %
6250.0 5764.3 4.11% 92.23%
12500.0 11013.2 2.71% 88 .1 1 %
25000.0 20677.2 3.63% 82.71%
50000.0 61160.4 2.46% 122.32%
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3.2.4.2 Anti-cocaine polyclonal antibody
The optimal coating concentration of BEC-BgG and the optimal antibody dilution was 
determined by an indirect checkerboard ELISA. The results can be seen in Figure 3.12, 
the conjugate coating concentration ranged from 1 |ig /ml to 10 pig /ml. The coating 
concentrations gave similar sensitivities and due to the expenses and availability of the 
conjugate, 5 (j,g /ml was chosen as the concentrations for ELISAs. The optimal 
antibody dilution was 1/1000, as this gave an absorbance in the 0.5 range. However, in 
order to develop the competitive assay to detect free cocaine it was necessary to use a 
dilution of antibody at 1/500. The relationship between the absorbance at 450 nm and 
the concentration of cocaine is shown in Figure 3.16. This shows that a satisfactory 
competitive ELISA can be used with an antibody dilution of 1/500. The range of 
detection of the assay was between 6.1 to 25000 ng/ml. The intra-assay variation was 
determined from three replicates in an assay while the inter-assay variation was 
determined over five days of performing the assay. The intra-assay and inter-assay 
coefficients of variation are listed in Table 3.4 and 3.5.
Another series of experiments were devised to look at an assay format using the 
immunogen, BEC-BSA, as the coating conjugate with and without BSA in the diluent. 
Figure 3.7 shows that the response to the BSA-coated plate was greater that that to the 
BEC-BSA-coated plate, although this could be relieved by incorporating 1% (w/v) BSA 
into the diluent. Prior titres performed on the serum from animals immunised with this 
BEC-BSA conjugate also showed greater binding to the BSA. This means that there 
was a greater immune response towards the BSA part rather than the hapten. When a 
competitive assay format was investigated using the BEC-BSA as the coating 
conjugate, it was found that competition did not occur between the conjugate and the 
free cocaine.
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Figure 3.16: Inter-day curve for the detection of morphine using the anti-BEC 
polyclonal antibody on an BEC-BgG (benzoylecgonine-bovine gamma globulin) 
immobilised surface. The data was correlated to a four-parameter model fit and the 
plot constructed using BIAevaluation 3.1 software. Each point on the graph is the 
average of five results obtained on five different days from a set of three replicates. 
Each value was normalised for that intra-assay by dividing the RU obtained by the 
RU for the positive control that only contained antibody and no morphine. The 
coefficient of variation, back-calculated amphetamine concentration and the 
percentage recovery are shown in Table 3.4 and 3.5. The range of detection of the 
assay is 6.1 -  25000ng/ml.
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Table 3.4: Intra-assay variation (degree of precision) for the detection of cocaine in the
ELISA using the anti-BEC polyclonal antibody. The results presented are the mean
values of three replicates.
Actual Cocaine 
Cone (ng/ml)
Back-Calculated 
Cocaine Cone 
(ng/ml)
CV
%
Recovery
%
6 .10 7.97 5.02% 130.69%
12 .2 0 9.70 1.35% 79.50%
24.41 22.85 1.44% 93.62%
48.83 52.47 2.82% 107.45%
97.65 91.64 5.82% 93.85%
195.31 219.05 1.99% 112.16%
390.62 417.69 0.84% 106.93%
781.25 543.01 0.45% 69.51%
1562.50 1755.70 2.44% 112.36%
3125.00 5632.17 0 .00% 180.23%
6250.00 7442.83 1.72% 119.09%
12500.00 7928.00 4.36% 63.42%
25000.00 18029.05 4.42% 72.12%
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Table 3.5: Inter-assay variation (degree of accuracy and reproducibility) for the
detection of cocaine in the ELISA using the anti-BEC polyclonal antibody. The results 
presented are the mean values obtained from five intra-day assays, each assay had three 
replicates.
Actual Cocaine 
Cone (ng/ml)
Back-Calculated 
Cocaine Cone 
(ng/ml)
% CV % Recovery
6 .10 7.31 6.39% 119.85%
12 .2 0 11.69 6.29% 95.84%
24.41 21.36 9.71% 87.48%
48.83 53.34 12.84% 109.24%
97.65 92.95 13.01% 95.18%
195.31 202.95 10.48% 103.91%
390.62 393.24 1 0 .0 1 % 100.67%
781.25 709.07 5.88% 90.76%
1562.50 1704.25 7.30% 109.07%
3125.00 3647.00 10.60% 116.70%
6250.00 5803.12 13.28% 92.85%
12500.00 9060.86 16.26% 72.49%
25000.00 33737.83 13.94% 134.95%
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3.2.4.3 Anti-morphine polyclonal antibody
The optimal coating concentration of morphine-3-gluc-OVA and the optimal antibody 
dilution was determined by an indirect checkerboard ELISA. The results can be seen in 
Figure 3.13, the conjugate coating concentration ranged from 1 [ig/ml to 10 (ig/ml. The 
coating concentrations gave similar sensitivities and 1 (ig/ml was chosen as the 
concentrations for ELISAs. The optimal antibody dilution was approximately 1/3200. 
However, for the purposes of optimisation of the assay with regard to sensitivities and 
cut off levels, the competitive assay was performed using a 1/1500 dilution of the 
polyclonal antibody.
Figure 3.17 shows the relationship between the absorbance at 450nm and the 
concentration of free morphine as determined by the competitive ELISA format using 
the antibody dilutions listed above. The range of detection of the assay was found to be 
between 0.38 and 6250 ng/ml morphine. The intra-assay variation was determined from 
three replicates in an assay while the inter-assay variation was determined over five 
days of performing the assay. The intra-assay and inter-assay coefficients of variation 
are listed in Table 3.6 and 3.7, and show the assay to be reproducible and accurate, as 
determined by the acceptable percentage recoveries and coefficient of variations.
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Figure 3.17: Inter-day curve for the detection of morphine using the anti-morphine 
polyclonal antibody on an morphine-3-glucuronide-OVA immobilised surface. The 
data was correlated to a four-parameter model fit and the plot constructed using 
BIAevaluation 3.1 software. Each point on the graph is the average of three results 
obtained on three different days from a set of three replicates. Each value was 
normalised for that intra-assay by dividing the RU obtained by the RU for the positive 
control that only contained antibody and no morphine. The coefficient of variation, 
back-calculated amphetamine concentration and the percentage recovery are shown in 
Table 3.6 and 3.7. The range of detection of the assay is 0.38 -  6250ng/ml.
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Table 3.6: Intra-assay variation (degree of precision) for the detection of morphine in
the ELISA using the anti-morphine polyclonal antibody. The results are obtained from
three replicates.
Actual Morphine 
Cone (ng/ml)
Back-Calculated 
Morphine Cone 
(ng/ml)
CV
%
Recovery
%
0.38 0.23 1.63% 60.00%
0.76 1.0 2 3.96% 133.82%
1.52 2.42 2.30% 159.47%
3.05 2.66 1.51% 87.28%
6 .10 5.90 0 .00% 96.64%
12 .2 0 11.62 1.39% 95.26%
24.41 22.55 0.83% 92.39%
48.83 57.16 3.66% 117.06%
97.65 96.22 0 .00% 98.54%
195.31 176.62 0.55% 90.43%
390.62 364.64 1.81% 93.35%
781.25 894.13 1.40% 114.45%
1562.50 2056.40 0.97% 131.61%
3125.00 3390.73 2.05% 108.50%
6250.00 3744.29 2.76% 59.91%
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Table 3.7: Inter-assay variation (degree of accuracy and reproducibility) for the
detection of morphine in the ELISA using the anti-morphine polyclonal antibody. The 
range of detection of the assay is 0.38 -  6250.0 ng/ml. The results presented are the 
mean values obtained from five intra-day assays, each assay had three replicates.
Actual Morphine 
Cone (ng/ml)
Back-Calculated 
Morphine Cone 
(ng/ml)
CV
%
Recovery
%
0.38 0.35 6.19% 91.05%
0.76 1 .0 2 5.82% 134.74%
1.52 1.99 5.32% 131.05%
3.05 3.60 4.74% 118.00%
6 .10 6.87 5.17% 112.54%
12 .2 0 12.24 5.44% 100.30%
24.41 21.93 5.31% 89.85%
48.83 51.99 10.77% 106.46%
97.65 90.61 7.81% 92.79%
195.31 184.08 9.04% 94.25%
390.62 406.15 8.91% 103.98%
781.25 961.24 8.85% 123.04%
1562.50 1820.32 8.56% 116.50%
3125.00 3033.26 9.62% 97.06%
6250.00 3740.58 9.82% 59.85%
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3.2.4.4 Cross reactivity studies: Anti-morphine polyclonal antibody
The cross reactivity of the anti-morphine polyclonal antibody was determined against 
morphine-3-glucuronide, 6-MAM, norcodeine and codeine. The degree of cross 
reactivity was determined as per the competitive ELISA described in Section 2.9.4. The 
standards were obtained from a stock solution of lmg/ml standard in ethanol. The 
degree of cross reactivity was determined as the concentration of cross reactant that 
gives a response of 50% or one-half of the observed maximum binding, (EC50 -  Cross 
Reactant) expressed a percentage of the specific analyte concentration that gives a 50% 
response, (EC50 -  Specific Analyte).
% Cross Reactivity = Concentration of Analyte ( E C 50  -  SA) X 100% 
Concentration of Cross Reactant ( E C 50 -  CR)
The degree of cross reactivity of the anti-morphine antibody is expressed in Table 3 .8.
Table 3.8: Cross reactivity of anti-morphine polyclonal antibody.
Drug % Cross Reactivity Range of Detection 
(ng/ml)
Morphine-3-glucuronide 10 0% 97.7-6250.0
6-monoacetylmorphine
(6-MAM)
30.39% 48.8 -1562.5
Norcodeine 0.78% 195.3-12500
Codeine 10 0% 390.1
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The conjugation of morphine and cocaine to proteins for the production of drug-protein 
conjugates was described. The resulting immunogens were used to induce antiserum in 
rabbits to the drugs of interest. Three different rabbits were induced with THC-BtG, 
morphine-BSA and BEC-BSA. Once a suitable titre was achieved, the animals were 
sacrificed and the serum collected and the polyclonal antibodies, anti-THC, anti-BEC 
and anti-morphine were purified and characterised. The antibodies were applied to an 
ELISA format for the detection of THC, cocaine and morphine.
A competitive ELISA was developed for the detection of THC with the anti-THC 
polyclonal antibody, and a 4-parameter fit was applied to the data. This antibody 
showed a range of detection between 24.4 to 50,000 ng/ml THC. The assay showed 
very good precision as determined by the intra-assay coefficients of variation (0.87% to 
5.98%), and very good reproducibility as determined by the inter-assay coefficients of 
variations (2.46 -  9.34%). The degree of accuracy was also determined by a calculation 
of the percentage recovery. As described by Findlay, 2000, this is a concept that 
expresses the closeness of agreement between a measured test result and its theoretical 
true value. The percentage recoveries for the inter-assay were very good, between 
81.64% and 122.32%. Overall, the anti-THC polyclonal antibody competitive ELISA 
for the detection of THC was a very good, accurate, reproducible assay.
The competitive assay for the detection of cocaine had a range of detection of 6.1 to 
25,000ng/ml. The assay showed very good precision as determined by the intra-assay 
coefficients of variation (0% to 5.02%), and good reproducibility as determined by the 
inter-assay coefficients of variations (5.88% -  16.26%). The high %CV of 16.26% was 
obtained for the value of 12500 ng/ml THC. This larger CV value could have been a 
result of the fact that it is at the high end of the range of detection, and so there is more 
variability. The degree of accuracy was also determined by a calculation of the 
percentage recovery. The percentage recoveries for the inter-assay were very good, 
between 72.49% and 134.95%. These two outer ranges were obtained for the high 
cocaine concentrations of 12500 and 25000 ng/ml. All other CVs were within an 
acceptable range of 92.85% to 119.85%. Overall, the anti-BEC polyclonal antibody 
competitive ELISA for the detection of cocaine is a very good, accurate, reproducible 
assay. One interesting point found with this antibody is that it is only competitive in an
3.3 Discussion
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ELISA format when the BEC-BgG was used as the coating conjugate. The use of BEC - 
BSA as the conjugate resulted in an ELISA that did not detect free drug. This would 
imply that the orientation of the BEC in the BEC-BSA conjugate is such that the BEC is 
not sufficiently exposed for recognition by the antibodies. Whereas in the case of the 
BEC-BgG conjugate, the orientation of the BEC on the conjugate allows for it to be 
recognised by the anti-BEC antibodies.
A competitive ELISA was developed for the detection of morphine, the main metabolite 
of heroin, with the anti-morphine polyclonal antibody, and a 4-parameter fit was applied 
to this data, also. This antibody showed a range of detection between 0.38 to 6250.0 
ng/ml morphine. The assay showed very good precision as determined by the intra­
assay coefficients of variation (0% to 3.96%), and very good reproducibility as 
determined by the inter-assay coefficients of variations (5.17% -  10.77%). The 
percentage recoveries for the inter-assay were very good, between 89.85% and 
123.04%. The percent recovery for the highest standard concentration of the range, 
6250ng/ml, was 59.85%, which is considered to be outside of an accurate assay. This is 
probably due to the characteristic inaccuracies that are inherent in the asymptotes of 
such a model fit. Overall, the anti-morphine polyclonal antibody competitive ELISA 
for the detection of morphine was a very good, accurate, reproducible assay. The 
degree of cross reactivity of the assay with morphine-3-glucuronide, 6-MAM, 
norcodeine, and codeine was also examined. The degree of cross reactivity was 100% 
for the main metabolite found in urine, morphine-3-glucuronide, and for the medication, 
codeine. This was to be expected as the point of conjugation of the morphine to the 
protein, through the glucuronide group was the -3 position. It is at this position that 
codeine is distinguished from morphine, by the presence of an acetyl group. There is a 
30.4% cross reactivity between 6-MAM, which again is expected as the 6-MAM 
molecule differs from the morphine molecule only at the 3-position, by the presence of 
a -C 2H3O2 group. The degree of cross reactivity to norcodeine, a minor metabolite, was 
also examined and showed a 0.78% cross reactivity.
The characterisation and application of the anti-THC and anti-morphine polyclonal 
antibodies is continued in Chapter 6 . The ELISAs described above were applied to 
saliva samples spiked with THC and morphine. Real samples were analysed using 
these assays. The antibodies were also applied to the BIAcore and competitive assays
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were established for the detection of the drugs. Chapter 6 also describes the application
of the anti-THC antibody to the Envitec Device for the development of a novel rapid
assay.
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Chapter 4
Production and Characterisation o f Anti-Amphetamine 
and Anti-Methamphetamine Monoclonal Antibodies
u i
4.1 Introduction
4.1.1 Monoclonal Antibodies -  Background
The 1984 Nobel Prize in Physiology and Medicine was awarded to Georges Kohler and 
Cesar Milstein for their pioneering work to produce an immortalised monoclonal 
antibody producing cell (Kohler & Milstein, 1975). Their work revolutionised antibody 
production and the associated areas where the antibodies can be applied. Monoclonal 
antibodies are antibodies of a single idiotype produced by immortalised B cells. 
Normal B cells are the end products of a differentiation pathway and cannot be 
maintained in culture. Myeloma cells are immortal, but the antibodies produced are of 
unknown specificity. Kohler and Milstein harnessed the pertinent qualities of each of 
the cells, and fused the B cells producing antibody of desired specificity with the 
myeloma cells. The result is a hybrid-mye\-oma, called a hybridoma.
Interestingly, at the time of publication of the original work, the National Research 
Development Council, the organisation through which the Medical Research Council 
scientists could commercially exploit their work, wrote ‘It is certainly difficult for us to 
identify any immediate practical application which could be pursued as a commercial 
venture’ (Austin, 1989).
4.1.2 Production o f monoclonal antibodies
The production of monoclonal antibodies begins with immunisation of mice by either 
in-vivo or in-vitro immunisations. In-vivo immunisations are carried out at regular time 
intervals, usually at least 4-6 weeks apart for several months. The success of the 
immunisations can be monitored by taking samples of serum and following the titre of 
the antibodies produced. There are publications detailing shorter immunisation periods 
by more frequent immunisations, (Wring et al., 1999). Normally, for the isolation of 
spleenocytes, a longer time-scale is more beneficial, with regard to the affinity of the 
antibodies produced. It is also possible to produce an hybridoma from other lymphoid 
tissue such as lymph nodes.
The fusion between the spleenocytes and the myeloma cells e.g., Sp2/0-Agl4, is usually 
achieved through the use of polyethylene glycol, which causes a change in membrane
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permeability. The original method for fusion was inactivated Sendai virus, which 
induces intercellular fusion in activated cells. However, the receptors for the Sendai 
virus fusion protein are needed and since some cells lack these proteins the fusion agent 
used now is PEG. Electroporation is another method that is used to promote fusion, 
though to a lesser extent (McCullough and Spier, 1990).
The fusion process is a relatively random process and the fused hybridoma cells must be 
selected from the unfused B cells and myeloma cells. The selection process used by 
Kohler and Milstein is accomplished by culturing the hybridoma cells in hypoxanthine- 
aminopterin-thymidine medium (HAT). Aminopterin blocks the de novo biosynthesis 
of the purines and pyrimidines that are required for DNA synthesis. When this pathway 
is blocked the cells can use the salvage pathway using the exogenous hypoxanthine and 
thymidine, however they need the enzymes hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT) and thymidine kinase (TK) to do this (Figure 4.1). The myeloma 
cells chosen for a fusion deliberately lack the hypoxanthine-guanine phosphoribosyl 
transferase enzyme (HGPRT'). So, in the HAT medium the uniused myeloma cells die, 
as do any myeloma cells fused to other myeloma cells. The spleenocytes possess the 
HGPRT enzyme, however they have a limited time in culture and will eventually die 
after about 2  weeks. The myeloma cells that fused with spleenocytes now possess the 
HGPRT enzyme and can grow in the HAT medium.
The hydridoma cells are grown in HAT medium for about two weeks. This ensures that 
all hybridomas that revert to a myeloma phenotype are eliminated. The media is then 
changed to HT media for at least another seven feedings and sub-cultures at which time 
any traces of aminopterin should have been eliminated (McCullough and Spier, 1990). 
The process for producing a monoclonal antibody is outlined in Figure 4.2 and 
described in detail in Chapter 2.
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Figure 4.1: In the presence of aminopterin, the de novo biosynthesis of purine and 
pyrimidines is blocked. Hypoxantihne and thymidine are needed for the salvage 
pathway, as are the enzymes HGPRT and thymidine kinase. Cells lacking these 
enzymes will die in HAT medium because they are incapable of producing the nucleic 
acids. It is through this process that fused myeloma cells are selected. The myeloma 
cells are HGPRT' and so only those fused with the HGPRT+-B cells survive in the 
HAT medium.
114
Spleen
Extracted
1
Approx 
Ixl06-lxl08 
spleenocytes 
per typical 
spleen
1
ego □
Fusion performed 
by addition of PEG 
at specific time intervals
1
o 0 0 o 0 0 0 0 0 0 o 0
0 o 0 0 o 0 0 o o o 0 0
o 0 o o 0 o 0 0 o 0 o 0
o o o 0 0 o 0 o 0 0 0 0
0 0 o o 0 0 0 0 0 0 o 0
0 o 0 0 0 o 0 o o o 0 0
o 0 o 0 0 o 0 0 0 0 0 0
! 00 o o o o o 0 o 0 0 0
Fusion Ratio of 
10 Spleenocytes to 1 SP2 Cell
Fused hybridoma cells, incubated for 
7 days in HAT medium
1
Screening performed for specific hybridomas and first cloning 
step performed ¡sr^
After at least three rounds 
of cloning specific 
monoclonal antibody is 
produced and 
characterised
Figure 4.2: Principle of monoclonal antibody production.
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An alternative to in vivo immunisation is in vitro immunisation of cultured spleenocytes 
(Borrebaeck, 1988). This procedure has several advantages over in vivo immunisations:
• It follows a reduced immunisation schedule leading to less time needed prior to 
fusion.
• It uses smaller amounts of the antigen of interest. This is particularly important as 
many substances are in extremely short supply due to expense or purification 
methods.
• It allows the production of antibodies to weakly immunogenic agents, to self- 
antigens and to toxic agents that cannot be immunised in vivo.
• It avoids the ethical arguments associated with in vivo immunisation (Borrebaeck, 
1988).
The main disadvantage however, is that the primary immunological response is 
obtained, which means that IgM antibodies are produced rather than IgG antibodies that 
are usually produced by the in vivo immunisation method. This means that the 
antibodies produced have a greater chance of being polyreactive, (Bouvet and Dighiero, 
2000). McMahon and O’Kennedy (2001) looked at a panel of nine hybridomas, 
secreting IgM anti-goat IgG, that had been produced from splenocytes that had been 
immunised in vitro with the goat IgG. The affinity constants of the antibodies against 
six antigens were examined and the specific anti-IgG activities of the hybridoma 
supernatant and corresponding affinity purified IgM fraction were determined. Nine 
antibodies were tested, eight were found to be polyreactive. The degree of 
polyreactivity may be underestimated by screening techniques such as ELISA as 
discussed in the next section.
4.1.3 Screening fo r  antibodies o f interest
The successful fusion of the myeloma cells and spleenocytes produces a range of 
hybridomas that secrete antibodies. The splenocytes are a heterogenous group of cells 
and so a different antibody is produced by each hybridoma. The mice used for the 
fusion would have been immunised for up to several months and kept in the laboratory 
animal facility and so would have been exposed to somewhat different environmental 
and endogenous factors along with the immunogen. This exposure means the immune
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system is responding to other immunogens. There is also the issue that not all 
hybridomas will produce any antibody at all. The hybridoma cell when formed is 
tetraploid, because it is formed from two diploid cells. As the cells grow and divide, the 
extra chromosomes are lost. This means that some cells die, some stop producing the 
antibody and other successful ones go on to produce the antibody of interest. All of 
these factors mean that the screening procedure for the selection of hybridomas is of the 
utmost importance. The screening step is also the most time-consuming stage of 
hybridoma production and has to be performed alongside the continued cultures of the 
hybridomas. When the specific hybridoma cells are identified the cloning procedures 
must begin in order to isolate the single hybridoma that is secreting the required 
antibody. Screening must continue during this step as the hybridomas can be unstable 
and stop growing during the cloning or can continue to grow but cease to secrete 
antibody. The importance of screening in the production of antibodies to small haptens, 
such as drugs of abuse, is frequently discussed (Chappey et al., 1992; Danilova, 1994). 
It is important to screen for antibodies that are reactive against the free hapten rather 
than the linker region between the hapten and protein or the protein. The common 
formats used for screening are ELISA, Western blots, and ELIspots. Danilova (1994) 
outlines the three main criteria that should be followed for the screening for antibodies 
against small haptens. They are as follows:
• The hapten-protein conjugate used as the immobilised conjugate in the ELISA 
format for screening should use a different protein compared to the hapten-protein 
used as the immunogen.
• Different methods of chemistry should be used to link the hapten and protein in the 
conjugates used for immunisations and screening.
• If possible, a different reactive group should be used for the conjugation of the 
screening conjugate.
Delcros et al. (1995) investigated the reactivity of an anti-spermine monoclonal 
antibody towards three different polyamines either free or covalently bound through 
EDC or glutaraldehyde to a solid surface by using equilibrium dialysis and ELISA. 
They found that the affinity of the antibody for putrescrine, spermidine and spermine 
depends on whether it is free or bound. The reactivity of the antibody differs according 
to the nature of the link to the solid phase. This should be considered when the 
screening method uses immobilised antigen in the ELISA format. If this approach is
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being used, an inhibition ELISA should be performed to determine the reactivity of the 
antibody to the free antigen.
Chappey et al. (1992) discusses the issue of controlled monoclonal polyspecificty 
towards haptens with the same core chemical skeleton, for example metabolites, versus 
uncontrolled polyspecificity involving the cross reactivity of monoclonal antibodies 
with compounds different from the native hapten. They propose that the solution to this 
problem is to produce a large number of monoclonal antibodies and then subsequent 
selection of the antibody with the appropriate specificity. McMahon and O’Kennedy 
(2001), suggest that the degree of polyreactivity from in vitro immunisation-based 
hybridomas can be determined to a greater extent by using an ELTspot method whereby 
washed cells could be resuspended in PBS. The binding of the antibodies to the culture 
components such as proteins, lipids, sugars, would be eliminated and a more accurate 
determination of the polyreactivity determined.
4.1.4 Cloning techniques
Immediately after the first round of screening the cells should be examined and the 
positive clones scaled up from 96 well plates, containing 0.1 ml medium to 48 well 
plates, containing 0.2mls medium. The cells are subsequently scaled up to 6 well 
plates, containing 1.6mls medium, and supernatants should be screened, ideally with 
each scale up. The cells should be cloned as early as possible, to ensure that a given 
culture contains only one cell type (Hurrell, 1983). If the cloning is not carried out at an 
early stage there is the likelihood that cells not producing specific antibody will increase 
and overgrow the specific clone of interest.
The main methods used for cloning cells are reviewed by McCullough and Spier (1990) 
and are as follows:
• Cloning by limiting dilution
• Cloning by isolation of colony by microscope and micromanipulation
• Cloning in semi-solid medium
• Cloning using a fluorescence-activated cell sorter
The easiest technique to master is probably cloning by limiting dilution. This method is 
based on diluting the cells and growing them at very low densities, starting at 
5 cells/well to 1 cell/well. The main problem associated with seeding at 1 cell/well is
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that the hybridomas have a tendency to die at such a low seeding density. This is why it 
is advisable to reseed several plates at a range of different densities. After the screening 
process, the positive wells are examined and only the cells that look to be of a single 
colony are expanded and re-cloned. This procedure is repeated for at least three cloning 
cycles. The cycle involves screening at each stage of growth, including a competitive 
screen for the antigen of interest, subsequent scale up of positives and the cloning out 
process is repeated again.
Monoclonal antibody production from hybridomas is a specialised technique that takes 
time to master. Like any specialist, the carer of a hybridoma gets to know the 
characteristics of the hybridoma, including the times suitable for screening, the growth 
stage suitable for cloning, the appropriate colour of the media and how indictitive it is 
of growth and the general appearance of a clone and its stability.
4.1.5 Scale up process fo r production
The application of a monoclonal antibody determines the quantities of antibody that 
need to be produced. Small amounts of less than O.lgram are needed for most research 
purposes. Diagnostic kit reagents usually require medium scale quantities from 0.1 to 
l.Ogram. Larger amounts, over lgram are used for routine diagnostic and therapeutic 
procedures. The production of large amounts of the antibody can be achieved through 
two means: in vivo, by intraperitoneal injection of a mouse to create ascites or, by in 
vitro tissue culture. The in vivo method was very common and has many advantages. 
The main advantage being that it is a method familiar to many labs, is relatively easy, 
and high concentrations of antibody can be produced. However, the major disadvantage 
is the use of mice and the associated ethical dilemma and veterinary considerations. In 
vitro tissue culture is the method that is being encouraged and is the primary method to 
be attempted before a licence to produce ascites is approved by the regulatory bodies. 
The general thinking is that in vitro methods can often provide an adequate means of 
generating most of the monoclonal antibodies needed by research. It is the 
responsibility of the researcher to be able to justify using mouse ascites as a method. 
Due to ethical and scientific pressure, the Committee on Methods of Producing 
Monoclonal Antibodies, Institute for Laboratory Animal Research, National Research 
Council (USA) conducted a study on the production of monoclonal antibodies. They 
issued a very comprehensive report that details their findings. In their executive
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summary they issued the following recommendations (Committee on Methods of 
Producing Monoclonal Antibodies, 1999):
Recommendation 1: There is a need for the scientific community to avoid or minimise 
pain and suffering by animals. Therefore, over the next several years, as tissue-culture 
systems are further developed, tissue culture methods for the production of monoclonal 
antibodies should be adopted as the routine method unless there is a clear reason why 
they cannot be used or why their use would represent an unreasonable barrier to 
obtaining the product at a cost consistent with the realities of funding of biomedical 
research programs in government, academia, and industry. This could be accomplished 
by establishing tissue culture production facilities in institutions.
Recommendation 2: The mouse ascites method of producing antibodies should not be
banned, because there is and will continue to be scientific necessity for this method.
Recommendation 3: When the mouse ascites method for producing monoclonal
antibody is used, every reasonable effort should be made to minimize pain or distress, 
including frequent observation, limiting the number of taps, and prompt euthanasia if 
signs of distress appear.
Recommendation 4: Monoclonal antibody now being commercially produced by the 
mouse ascites method should continue to be so produced, but industry should continue 
to move toward the use of tissue culture methods.
The following section will concentrate on the in vitro methods for monoclonal antibody 
production.
4.1.5.1 Batch tissue culture method
This is the simplest method for producing batches of antibody. The current range of 
media and specially formulated hybridoma additives, e.g. BRIclone, Bio Research 
Ireland, Dublin City University, support the growth of hybridomas without the need for 
feeder cells. Fetal calf serum can sometimes be blamed for contamination, to avoid this 
the hybridomas can be adapted to grow in 1% FCS or in FCS-free media, (Federspiel, 
1991). Due to the large volumes of medium involved in batch production, spinner 
flasks and roller bottles are used to increase the concentration of dissolved oxygen in 
the media. This increases cell viability and growth and so leads to an increase in 
antibody production (Reuveny, 1986). Another addition to the market is the gas 
permeable bag, i-MAB (Diagnostic Chemical Ltd., Canada), this allows for greater 
exchange of gases. The normal procedure is then for the cells to be grown for 
approximately 10 days and then the supernatant concentrated and purified for use. The 
disadvantage of this is that the overall quantity of antibody produced is quite low.
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Semipermeable membrane-based devices can allow cells to grow at high densities. The 
basis of the technique is the separation of the cells and monoclonal antibody produced 
from a larger compartment that contains the media. Supplements can be added to the 
media to enhance the growth of the cells. The waste products diffuse across into the 
larger volume to equilibrium. This method can produce antibody concentrations 
comparable to those produced by the in vivo mouse ascites method. Two commercial 
systems are the mini-PERM (Unisyn Technologies, MA. USA), and the CELLine 
(Integra Bioscience, MD, USA).
Hollow fibre bioreactors are a variation of the semipermeable membrane system, and 
consist of three parts, the hollow fibre cartridge, a gas permeable tubing through which 
the media is oxygenated and the medium reservoir. The hollow fibre unit is composed 
of a bundle of semi-permeable fibres that run through a chamber that contains the 
hybridoma cells grown at a high density. The molecular weight cut-off of the 
membrane allows the cells to grow to a high density by not allowing them through, 
while it does allow the movement of nutrients and waste products. The hollow fibre 
bioreactor can produce large amounts of antibody.
4.1.6 Recombinant antibodies
Advances in molecular biology in the last ten to twenty years have transformed 
antibody production. The principles behind chimeric and humanised antibodies are 
discussed below. One very important technique crucial to the production of 
recombinant antibodies is PCR, the polymerase chain reaction, (Chaudhary et al., 
1990). The generation of different antibody fragments can be achieved through 
recombinant antibody display technology. The generation of antibody libraries and 
developments in display technologies have synergistically driven this field. One major 
feature distinguishing hybridomas from recombinant antibody technology is that 
hybridomas are confined to non-human antibodies whereas conceptually antibody 
libraries allow the generation of antibody fragments from any species including humans 
whose immunoglobulin genes are identified. A huge degree of antibody diversity can 
be created through production of recombinant antibody fragments and then the specific
4.1.5.2 Semipermeable membrane-based systems
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fragments of interest can be selected for by screening or panning. The variable chain 
genes, from naive or immunised cell DNA are combined at random and cloned into a 
phage genome for fusion with a coat protein that is then subsequently expressed and 
displayed. (Hoogenboom et al., 1998). The array of antibody fragments that can be 
created through this means is huge, and it allows for fusion of the fragments with other 
antibody fragments or other peptides or enzymes. The genomic DNA of the antibody 
fragments can be obtained from many sources as mentioned above including naive or 
immunised cells (Hoogenboom, 1992), or mRNA can be extracted from hybridoma 
cells (Winter and Milstein, 1991; Krebber et al., 1997).
4.1.7 Chimeric and Humanized Antibodies
The use of monoclonal antibodies has contributed to changes in the field of analytical 
science and diagnostics. However, in the field of therapeutics the use of monoclonal 
antibody has not provided the expected breakthroughs and we have only a limited 
number of antibody-based therapeutic agents. One major disadvantage of the 
hybridoma technology with respect to therapies is the inefficiency in immortalising 
human B cells. The inherent problem of using rodent antibodies as part of a treatment is 
that the antibodies will be detected by the host immune system. To overcome this, it is 
necessary to reduce the immunogenicity of the therapeutic antibodies. The many 
advances in engineering of antibodies and their fragments have led to major 
advancements in this field and, as a result we are closer to Paul Erlich’s ‘magic bullets’. 
However, while reduction of the immunogenicity of the antibody or antibody fragment 
can be achieved through genetic engineering, other key aspects of the antibody can be 
jeopardised, particularly in the case of humanised antibodies where the mouse 
complementarity determining regions (CDRs) are grafted into the human variable 
regions. These problem areas include antigen binding and recruitment of human 
effector cells.
Initially, the basis of antibody treatment for cancer was dependent on the antibodies’ 
ability to elicit the patients’ defence mechanisms to kill tumour cells. Successful 
techniques have been developed to reduce the antigenicity of murine antibodies for 
human therapeutic use. The chimeric antibody is created through the cloning of the 
heavy and light mRNAs of the murine hybrid myeloma line, and the fusion of the DNA 
of the mouse VH and VL domains to the human constant domains, Chi, hinge, Cm, and
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Ch3 (Morrison el al., 1984) This technology has progressed to producing humanised 
antibodies, where all of the antibody is of human origin with the exception of the CDR 
regions which are derived from a mouse as shown in Figure 4.3, (Jones et al., 1986; 
Riechmann el al., 1988; Sheets et al., 1998). The theory is that the immunogenicity of 
such an antibody would be weakened as the number of epitopes recognised as foreign is 
decreased as compared to the traditional murine monoclonal antibodies. The specific 
antigen binding ability of the antibody can be approached through novel molecular 
biology tools such as molecular modeling, and cloning and sequencing of regions, 
(Nagahira et al., 1999; Saldanha et al, 1999). Developments in the field of humanised 
antibodies have led to antibodies that do exhibit potent anti-tumour cell activity against 
the target cells by antibody-dependent cell-mediated cytotoxicity (Ono et al., 1999). 
Another exciting prospect in the field of development of human antibodies is the 
transgenic mouse. Cell Genesys Inc, California, USA (Green et al., 1994; Jakobovits et 
al., 1995), developed a strategy for producing human monoclonal antibodies in mice by 
the introduction of large segments of the human heavy and light chain immunoglobulin 
genes on yeast artificial chromosomes into the mouse germline. High levels of human 
antibodies are produced by these transgenic mice. This provides another avenue for 
production of human monoclonal antibodies and also provides a model for looking at 
the human antibody response. The possibilities of this technology makes one wonder if 
the transgenic mouse could be renamed the ‘Mighty Mouse’.
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Figure 4.3: The structure of the chimeric and humanised antibodies. The chimeric 
antibody is composed of the mouse variable region and the human constant region. The 
humanised antibody is composed of a human antibody, with the specific mouse CDR 
regions grafted into the variable region.
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4.1.8 Clinical applications o f antibodies
Antibodies play a key role in the clinical analysis of many biological constituents. The 
sensitivity and specificity of antibodies have been exploited to a large degree over the 
last decade for the development of diagnostic tests. These rapid, non-invasive antibody- 
based tests have dramatically improved screening and diagnosis of a wide range of 
clinical conditions from detection of drugs of abuse to cancer. There is an ever 
expanding range of approved kits available now that detect minute amounts of 
hormones, drugs, and specific disease markers. The approval of many of these tests for 
use at home, at the bedside, in the local physician’s clinic and in the laboratory has 
accelerated the screening and monitoring of medical conditions (Fitzpatrick et al., 
2000).
4.1.8.1 Detection o f drugs o f abuse
The detection of drugs of abuse can range in complexity from immunoassays to gas 
chromatography/mass spectroscopy (GC/MS) (Braithwaite et al., 1995). Quicker less 
invasive methods are being developed for use in screening for drugs of abuse in the 
work place, and rehabilitation clinics. The development of rapid immunoassays for the 
detection of illicit drug use that would be suitable for roadside testing would mean that 
screening could be performed in the same manner as current alcohol testing. The 
confirmatory test for these assays would be the existing gold standard, GC/MS. 
Currently, the most popular biological matrices for quantitative measurement of illicit 
drugs are plasma and urine. However, saliva is now becoming common because of the 
obvious advantage of the non-invasive nature of collection and the correlation between 
psychological impairment and the level of detection of the illicit drugs and metabolites. 
There are many different immunological test formats available now, as outlined in 
Chapter 1. In the development of the rapid roadside tests, the following considerations 
should be taken into account. The test must be specific and sensitive, with positive 
results correlating to the legal cut off level as determined by authorities such as the 
National Institute of Drugs of Abuse (NIDA). The recognition of metabolites of the
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drugs of interest, and closely related designer drugs, such as the amphetamine 
derivatives, MDMA, or MDEA by the test antibodies should also be taken into account.
4.1.8.2 Detection o f cancer
The presence of specific protein markers on cancer cells is exploited for the detection of 
cancer using antibodies specifically directed to these markers. This is commonly used 
for detection and for the management of cancer patients. In order to detect cancers as 
early as possible, researchers are focusing on molecular methods including protein 
products of oncogenes and tumour suppressor genes as targets of detection in 
immunoassays. An example of one such test is the BTA test™, manufactured by Bion 
Diagnostic Sciences Inc. It allows recovering bladder cancer patients to monitor their 
risk for a recurrence of cancer. The BTA stat test™ is a lateral flow immunoassay that 
detects tumour antigens in urine. The solid phase monoclonal antibody reacts with 
human complement factor H-related protein (hCFHrp), which is secreted in urine by 
bladder cancer cells (Sarosdy et al., 1997; Kinders et al., 1998). The test is used as an 
adjunct to cystoscopy and based on the outcome of the test, the physician can decide the 
next investigative step.
The coupling of antibodies to radioactive isotopes can serve as contrast agents in 
diagnostic imaging products and are also used in the development of 
radioimmunotherapy. Firstly, for the purposes of detection, the antibodies that are 
specific to the disease marker are labelled with the radioactive isotope and travel to the 
disease site. This is then detected using sophisticated nuclear medical equipment. 
Antibody tracers are currently available for diagnosis of colorectal, lung, prostate and 
ovarian cancer. One such example is the Prostascint™ test (Cytogen Corporation) used 
to determine if prostate cancer has remained local within the prostate or if it has spread 
to lymph nodes in the body (Prostascint Package Insert). An example of 
radioimmunotherapy is the monoclonal antibody directed toward prostate-specific 
membrane antigen (PSMA). It is attached to a radioactive tracer, indium 111, and is 
injected into the patient. Expression of the antigen is higher in prostate adenocarcinoma 
cells than in non-malignant tissue and higher in metastatic lesions than in tumours 
(Sodee et al., 1996). Lymph nodes that have been invaded by the prostate cancer cells 
appear as hot spots on the imaging detection system.
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Goldenburg (2001) has reviewed the role of radiolabeled antibodies in the treatment of 
non-Hodgkin’s lymphoma (NHL). Four radiolabeled antibodies are in clinical trials 
currently for NHL. These are being tested in combination with chemotherapy or after 
chemotherapy and at least two of these products show very promising results.
The collaborative efforts of biotechnology companies have resulted in antibody based 
systems for the analysis and treatment of disease. One example of this is the 
HercepTest™ (DAKO) and Herceptin® (Genentech) treatment used in women 
diagnosed with breast cancer associated with the overexpression of the HER2 protein 
(Pauletti el a l 1996). The HercepTest™ is an immunohistochemical test used on 
biopsy samples from breast cancer patients. The Herceptin® treatment will be discussed 
in more detail below.
4.1.8.3 Antibodies as therapeutic agents
Antibodies have been developed as therapeutic agents in recent years and there are now 
approved antibody treatments for cancers, auto-immune diseases and graft rejection. 
The inherent problems of using antibodies have been discussed previously, along with 
the relevant developments in recombinant humanised antibodies. Initially, the basis of 
antibody treatment for cancer was dependent on the antibodies’ ability to elicit the 
patients’ defence mechanisms to kill tumour cells. Immunotoxins provide a new 
method for killing tumour cells. The immunotoxins contain an antibody or antibody 
fragment conjugated to toxins, produced by bacteria or plants. This has resulted in a 
vast array of possible immunotoxins. The antibodies bind to the specific cell surface 
receptor that is targeted on the cancer cell, the molecule is then internalised by the cell 
and the toxin part of the conjugate exerts its cytotoxic effects. The immunotoxins 
currently under investigation are reviewed by Kreitman and Pastan (1998) and Trail and 
Bianchi (1999).
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Table 4.1: Current Licenced Antibody Therapies in USA and Europe. Monoclonal 
antibodies account for over a quarter of the therapies currently being developed by
biotechnology companies. Adapted from Breedveld (2000) and Fitzpatrick et al., 
(2000).
Generic Name Trade Name Company Indication
Moromonab Orthoclone OKT3 Ortho Biotech Graft rejection
Basiliximab Simulect Novartis Prevention of renal 
graft rejection
Daclizumab Zenapax Roche Prevention of renal 
graft rejection
Infliximab Remicade Centocor Rheumatoid 
arthritis, Crohn’s 
disease
Rituzimab Rituxan Genentech-Roche Low grade and 
follicular non- 
Hodgkin 
lymphoma
Trastuzuamb Herceptin Genentech Metastatic breast 
cancer
Abciximab Reopro Lilly Prevention of 
cardiac ischemic 
complications
Palivizumab Synagis Abbott
Laboratories
Respiratory 
syncytial virus
4.1.8.4 Approved antibody therapies
The recent advances made in the field of antibody production and molecular biology in 
general, open up a world of possibilities, however the process, time and expenditure 
required to bring an idea from the lab bench to the pharmacy shelf is enormous. Table
4.1 shows the currently approved antibody therapies. Hopefully, we will see the rate of
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therapies available increase faster in the future as currently there are many antibody 
based therapies in clinical trials. The anti-beta amyloid human antibody treatment, AN- 
1792, for Alzheimers disease being developed by Elan in association with American 
Home Products and Cambridge Antibody Technology (Thatte, 2001), is one classic 
example of how a dream ‘magic bullet’ can make it so far but then meet with 
unexpected results and its development currently suspended. At the time of suspension, 
360 patients suffering from Alzheimers Disease had received AN-1792. The dosage 
was stopped when four patients in France developed clinical signs of inflammation of 
the central nervous system. The other side of this coin is the extreme success of the 
some of the approved treatments. Herceptin is an example of a humanised antibody. 
Abciximab, remicade and rituxan are examples of chimeric antibodies, while OKT3 is 
an example of a murine antibody. These are reviewed by Fitzpatrick et al, (2000), as an 
example Herceptin is described in the following paragraph.
Herceptin is a recombinant DNA-derived humanized monoclonal antibody that binds 
with high affinity to the extracellular domain of the human epidermal growth factor 
receptor 2 protein, HER2. The antibody is an IgGl kappa that contains the human 
framework regions with the complementarity-determining regions of a murine antibody. 
By binding to the HER2 receptor it mediates the antibody-dependent cellular 
cytotoxicity (Herceptin Package Insert, 1998). The clinical trials with herceptin have 
resulted in the approval of the medication with an indication for the treatment of 
patients with metastatic breast cancer whose tumours overexpress the HER2 protein and 
who have received one or more chemotherapy regimens for their metastatic disease. 
Herceptin is also indicated in combination with paclitaxel for treatment of patients with 
metastatic breast cancer whose tumours overexpress the HER2 protein and who have 
not received chemotherapy for their disease.
4.1.9 Current advances -  pharmacogenomics, proteomics
The application of pharmacogenomics and proteomics to the field of drug discovery 
means that specific therapies can be developed for specific patient genotype populations 
within a patient population. Clinical pharmacogenomics is the use of genetic 
information from a patient population to predict the efficacy and safety of a therapy. 
Disease populations are not homegenous for a particular disease. An example of this is 
rheumatoid arthritis (RA). A monoclonal antibody therapy is approved for RA,
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infliximab, however not all RA patients benefit from it. The concept behind 
pharmacogenomics is that candidate disease genes and polymorphisms can be identified 
and correlated to therapy and clinical outcome. An extension of this is the development 
of molecular genetic tests for detection of these sub-populations and the use of this 
information in deciding on the appropriate treatment strategy. It is becoming a common 
practice in drug development to explore pharmacogenetics and analyse clinical trial 
patient mRNA by microarray analysis. The powerful tools available such as micro 
array analysis, monoclonal antibody production, phage display antibody libraries, 
bioinformatic technologies and rapid biosenors, all contribute greatly to drug discovery 
research.
The following results detail the production, characterisation and application in ELISA 
of two different antibodies, i.e., the anti-amphetamine and the anti-methamphetamine 
monoclonal antibodies.
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4.2 Results
Two groups of mice were immunised with amphetamine-BSA (Group Ml) and 
methamphetamine-BSA (Group M2) for the production of monoclonal antibodies 
against amphetamine and its derivatives. Mice were immunised using the schedule 
described in Section 2.6.1. Tail bleeds were performed on the mice 7 days post 
immunisation boost. The blood was collected and the serum separated and a 
conventional ELISA was performed as described in Section 2.6.4 and 2.9.2 to determine 
the titre of antibodies raised against the conjugate. The same conjugate was used for 
both immunisations and screening so an additional ELISA was performed using the 
BSA as the coating protein. Serum from pre-immunised mice was used as a control in 
an initial ELISA. Figure 4.4 shows the titre obtained for the amphetamine-BSA 
immunised mice (Ml) and for the methamphetamine-BSA mice (M2) after ten months 
of immunisations.
4.2.1 Antibody Titre o f  mice usedfor monoclonal antibody production
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Figure 4.4: Final titre of serum from mice used for hybridoma production, Ml
immunised with amphetamine-BSA (upper), and M2 (lower) immunised with 
methamphetamine-BSA. For Ml, the coating conjugate used in the ELISA was 
amphetamine-BSA. The serum was also titred against BSA, with and without BSA in 
the diluent. For M2, the coating conjugate was methamphetamine-BSA. The serum 
was also titred against BSA, with and without BSA in the diluent. A sufficient titre was 
obtained for both mice and the spleens were extracted and used for the hybridoma 
production.
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4.2.2. Screening o f hybridoma supernatants from  Group M l fusion
Once a sufficient titre had been obtained, approximately 8 months after the initial 
immunisation, the final immunisation boost was administered to the mice. Five days 
later, a final tail bleed was taken and the final titre determined. The mouse was 
sacrificed and the spleen removed. The spleen cells were used for the hybridoma 
production as discussed in Section 2.7.3. Eight days after the fusion, supernatants from 
the wells of the hybridoma cells were screened for reactivity towards amphetamine 
using conventional ELISA format by immobilising amphetamine-BSA onto the well 
surfaces. Supernatants were also screened against BSA to confirm the reactivity 
towards the amphetamine molecule. Positive wells were taken to 48 well plates with 
0.2ml medium. Subsequent positives were scaled up to 24 well, 12 well, 6 well plates 
and to T-25 and T-75 flasks. As the volume of supernatants available increased, these 
supernatants were also screened using a competitive ELISA format with competition 
between the free drug (amphetamine and amphetamine derivatives at a concentration of 
50|ug/ml) and immobilised amphetamine-BSA conjugate. Cells were then cloned by 
limiting dilution. After the third step of cloning at 1-2 cells/well the cells were 
statistically monoclonal.
The concept behind the screening process for the anti-amphetamine antibody was to 
select a clone that would be specific for amphetamine but also recognise the 
amphetamine derivatives. Given the structures of the derivatives it was anticipated that 
the antibody would recognise the amphetamine molecule and derivatives to different 
degrees. In summary the results show that clones 10FP12F, 10FP13F, 4EP13C, 
4EP18E, and 4EP18F secreted monoclonal antibodies that recognised amphetamine and 
BDB primarily (approx 90% displacement), but also recognise MDMA, MDEA, MDA, 
and MBDB (approx 50% displacement). These clones showed little reactivity towards 
ephedrine, pseudoephedrine or ketamine. Clones D2P510D, D2P32F, D2P32F, 
D3P52C, D3P510C, 392D1G, 392D7B, 3925G showed similar reactivity towards 
amphetamines but did not show strong reactivity towards the amphetamine derivatives. 
Clone 4EP18E was subsequently scaled up and the monoclonal antibody purified and 
characterised.
The following graphs (Figure 4.5 -  4.9) represent the results obtained using the 
competitive ELISA format for the range of different supernatants from the monoclonal 
cell lines.
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Figure 4.5: Reactivity of the different clones of monoclonal antibody supernatant 
(D2P32F, D3P52C, D3P510C, D2P19B) in the presence of amphetamine, MDMA, 
MDEA, MDA, MBDB, BDB, ephedrine, pseudoephedrine, ketamine and PBS 
(control). The reactivity of the antibody to immobilised amphetamine-BSA in the 
presence of the free drugs, A(drug), is expressed as a percentage of the reactivity of the 
antibody in the presence of PBS alone, A0.
Drugs Tested
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Figure 4.6: Reactivity of the different clones of monoclonal antibody supernatant 
(D2510D, 3.9.2D1G, 3.9D7B, 3.9.2.5G) in the presence of amphetamine, MDMA, 
MDEA, MDA, MBDB, BDB, ephedrine, pseudoephedrine, ketamine and PBS 
(control). The reactivity of the antibody to immobilised amphetamine-BSA in the 
presence of the free drugs, A(drug), is expressed as a percentage of the reactivity of the 
antibody in the presence of PBS alone, AO.
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Figure 4.7: Reactivity of the different clones of monoclonal antibody supernatant 
(4EP13C, 4EP18E, 4EP18F) in the presence of amphetamine, MDMA, MDEA, MDA, 
MBDB, BDB, ephedrine, pseudoephedrine, ket amine and PBS (control). The reactivity 
of the antibody to immobilised amphetamine-BSA in the presence of the free drugs, 
A(drug), is expressed as a percentage of the reactivity of the antibody in the presence of 
PBS alone, AO.
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Figure 4.8: Reactivity of the different clones of monoclonal antibody supernatant 
(6BP17F, 6BP29F, 6BP29G) in the presence of amphetamine, MDMA, MDEA, MDA, 
MBDB, BDB, ephedrine, pseudoephedrine, ketamine and PBS (control). The reactivity 
of the antibody to immobilised amphetamine-BSA in the presence of the free drugs, 
A(drug)/A0, is expressed as a percentage of the reactivity of the antibody in the presence 
of PBS alone, AO. (The test against pseudoephedrine was not done for Clone 6BP29G.)
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Figure 4.9: Reactivity of the different clones of monoclonal antibody supernatant 
(10FP12F, 10FP13F, 10FP14F) in the presence of amphetamine, MDMA, MDEA, 
MDA, MBDB, BDB, ephedrine, pseudoephedrine, ketamine and PBS (control). The 
reactivity of the antibody to immobilised amphetamine-BS A in the presence of the free 
drugs, A(drug), is expressed as a percentage of the reactivity of the antibody in the 
presence of PBS alone, AO.
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4.2.3 Screening o f hybridoma supernatants from  Group M2 fusion
Supernatants from the wells of the hybridoma cells were screened for reactivity towards 
methamphetamine using conventional ELISA format by immobilising 
methamphetamine-BSA in the same format as the anti-amphetamine screening. 
Supernatants were also screened against BSA to confirm the reactivity towards the 
methamphetamine molecule. Positive wells were scaled up as described for the anti­
amphetamine monoclonal production in Section 4.2.2. As the volume of supernatants 
available increased, the supernatants were also screened using a competitive ELISA 
format with competition between the free drug (methamphetamine and amphetamine 
derivatives at a concentration of 50p.g/ml and 12.5fig/ml) and immobilised 
methamphetamine-BSA conjugate. This was to confirm that the clones were secreting 
antibodies that recognised free drug. Cells were then cloned by limiting dilution. By 
the third step of growing at 1-2 cells/well the cells were statistically monoclonal.
Graphs shown as Figure 4.10 -  4.12 represent the results obtained using the competitive 
ELISA format for the range of different supernatants from the monoclonal cell lines.
As discussed previously, the purpose behind the production of the anti-amphetamine 
and anti-methamphetamine antibody was to produce an antibody that would recognise 
the whole range of amphetamine and methamphetamine derivatives. Methamphetamine 
is a metabolite of many of the derivatives so it would be more likely that this antibody 
would recognise these designer amphetamine derivatives. In summary the results show 
that clones P18D, P26F and P211F secrete monoclonal antibodies that recognise 
MDMA MDEA, MBDB. They were tested against methamphetamine later when the 
analytical standard was replenished. These clones showed no reactivity towards 
ephedrine, pseudoephedrine or ketamine. The Clones P15E and P15G which originated 
from a different clone were shown not to be as reactive against the derivatives and they 
were not characterised further. The same results were seen with P16C, P17F, and P14F, 
these were not as reactive as the PI8D, P26F or P21 IF.
Clone P18D was subsequently scaled up as it was a robust cell line and showed good 
cross reactivity. The monoclonal antibody purified and characterised as described 
below. Stocks of the reactive clones were scaled up to 75cm3 (T75) flasks.
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Figure 4.10: Reactivity of the different clones of monoclonal antibody supernatant 
(P18D, P26F, and P211F) in the presence of amphetamine, MDMA, MDEA, MDA, 
MBDB, BDB, ephedrine, pseudoephedrine, ketamine and PBS (control). The reactivity 
of the antibody to immobilised methamphetamine-BSA in the presence of the free drugs 
(12500ng/ml MDMA, and 50000ng/ml for other drugs), A(drug), is expressed as a 
percentage of the reactivity of the antibody in the presence of PBS alone, A0. (The test 
against MBDB and BDB for P26F and P21 IF was not performed.)
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Figure 4.11: Reactivity of the different clones of monoclonal antibody supernatant 
(P16C, P17F, and P14F) in the presence of amphetamine, MDMA, MDEA, MDA, 
MBDB, BDB, ephedrine, pseudoephedrine, ketamine and PBS (control). The reactivity 
of the antibody to immobilised methamphetamine-BSA in the presence of the free drugs 
(12500ng/ml MDMA, and 50000ng/ml for other drugs), A(drug), is expressed as a 
percentage of the reactivity of the antibody in the presence of PBS alone, AO. (The test 
against MDA for P16C was not performed.)
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Figure 4.12: Reactivity of the different clones of monoclonal antibody supernatant 
(P15E and P15G) in the presence of amphetamine, MDMA, MDEA, MDA, MBDB, 
BDB, ephedrine, pseudoephedrine, ketamine and PBS (control). The reactivity of the 
antibody to immobilised methamphetamine-BSA in the presence of the free drugs 
(12500ng/ml MDMA, and 50000ng/ml for other drugs), A(drug), is expressed as a 
percentage of the reactivity of the antibody in the presence of PBS alone, AO.
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4.2.4 Purification o f monoclonal antibody from  hybridoma supernatant
The 4EP18E clone and P18D clones were grown up in T75 flasks. The cells were 
grown and the spend media was removed after 1-2 weeks. The media was collected and 
stored at 4°C. 50mls of media was then concentrated to 5mls using the Amicon 
Filtration System. The monoclonal antibody was then purified by applying this 
concentrate to a Protein G immobilised Sepharose 3B column. The monoclonal 
antibodies were eluted from the column with 0.1M glycine, pH 2, as described in 
Section 2.8.3. The fractions collected were neutralised with 2M Tris, pH 8.6. The 
fractions were then read spectrophotometrically at 280 nm to determine the protein 
content. Figure 4.13 shows a typical elution profile. As an extra step to ensure the 
fractions contained the specific antibody of interest, an ELISA was performed. The 
fractions containing the antibody were pooled and dialysed in PBS overnight at 4°C 
with a two changes of PBS.
A sample of the purified antibody fractions were also run on an SDS-PAGE to 
determine purity, as shown in Figure 4.14 and 4.15.
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Anti-Amphetamine Monoclonal Antibody
Fraction Number From Protein G Column
Anti-Methamphetamine Monoclonal Antibody
Fraction Number From Protein G Column
Figure 4.13: Typical elution profile for the purification of anti-amphetamine and anti- 
methamphetamine monoclonal antibody. The concentrated hybridoma media was 
applied to a 2.5ml protein G-sepharose column. The column was washed and the bound 
antibody was eluted with 0.1M glycine/HCl, pH 2.5. 0.9ml fractions were collected in 
tubes containing 0.1ml 2M Tris, pH 8.6. This served to neutralise the glycine. The 
absorbance of each fraction, (1-6), was read at 280nm and the fractions containing 
protein were pooled and dialysed.
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LANE 1 2 3 4 5
Light Chain 25KDa
Lane 1: anti-amphetamine MAb 
Lane 2: anti-amphetamine MAb 
Lane 3:anti-BEC PAb 
Lane 4:anti-BEC PAb 
Lane 5:Markers
a 2-Macroglobulin human plasma, 180KDa 
ß-Galactosidase (E.coli), 116KDa 
Fructose-6-phosphatase (Chicken), 84KDa 
Pyruvate kinase (Chicken), 54KDa 
Fumerase (Porcine), 48.5KDa 
Lactic dehydrogenase (Rabbit), 36.5KDa 
Triosephospliate isomerase (Rabbit), 26.6KDa
Figure 4.14: Characterisation by SDS-PAGE gel of the anti-amphetamine
monoclonal antibody. Two bands can be seen, the top one at 50KDa representing the 
heavy chain and the fainter lower band at 25KDa representing the light chains.
LANE
Heavy Chain 50KDa
-Light Chain 25KDa
Lane 1 Markers
Lane 2:anti-methamphetamine MAb 
Markers
ß-Galactosidase (E.coli), 1 l6KDa 
Phosphorylase b, (Rabbit), 97KDa 
Fructose-6-phosphatase (Rabbit), 84KDa 
Albumin Bovine Serum, 66Kda 
Glutamic dehydrogenase, Bovine, 55KDa 
Ovalbumin Chicken Egg, 45KDa 
Glyceraldehyde-3-phosphate dehydrogenase 
(Rabbit), 36.KDa
Carbonic anhydrase. (Bovine erythrocytes), 
29KDa
Trypsinogen, (Bovine pancreas), 24KDa 
Trypsin Inhibitor, (Soybean), 20KDa
Figure 4.15: Characterisation by SDS-PAGE gel of the anti-methamphetamine
monoclonal antibody. Two bands can be seen, the top one at 50KDa representing the 
heavy chain and the fainter lower band at 25KDa representing the light chains.
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4.2.5 Antibody Isotyping
The isotype of the purified anti-amphetamine monoclonal antibody was determined by 
ELISA as described in Section 2.9.5. Figure 4.16 shows the relevant reactivity towards 
the different secondary antibodies. The results show that the antibody is an IgGl, with 
kappa light chains.
4.2.5.1 Antibody Isotyping  -  anti-amphetamine monoclonal antibody Clone 4EP18E
Anti-amphetamine Monoclonal Antibody Clone 4EP18E
3 5
Kappa Lambda lgG1(H+L) lgG2a lgG2b lgG3 IgM IgG+A+M lgG(H+L)
lg Type
Figure 4.16: Isotype profile of purified anti-amphetamine monoclonal antibody, Clone 
4EP18E. ELISA plates were coated and blocked with amphetamine-BSA and milk 
protein, respectively. Anti-amphetamine monoclonal antibody was added and 
incubated. After washing, alkaline phosphatase-labelled goat anti-mouse 
immunoglobulins were added to the wells and the ELISA developed. The absorbance 
indicates the monoclonal antibody isotype. This antibody is composed of IgGl heavy 
chains and kappa light chains.
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4.2.5.2 Antibody Isotyping -  anti-methamphetamine monoclonal antibody Clone 
P18D
The isotype of the purified anti-methamphetamine monoclonal antibody was 
determined by ELISA as described in Section 2.9.5. Figure 4.17 shows the relevant 
reactivity towards the different secondary antibodies. The results show that the antibody 
is an IgGl, with kappa light chains.
Anti-Methamphetamine Monoclonal Antibody Clone P18D
Kappa Lambda lgG1(H+L) lgG2a lgG2b 
lg Type
lgG3 IgM IgG+A+M
Figure 4.17: Isotype profile of purified anti-amphetamine monoclonal antibody, Clone 
4EP18E. ELISA plates were coated and blocked with amphetamine-BSA and milk 
protein respectively. Anti-amphetamine monoclonal antibody was added and incubated. 
After washing, alkaline phosphatase-labelled goat anti-mouse immunoglobulins were 
added to the wells and the ELISA developed. The absorbance indicates the monoclonal 
antibody isotype. This antibody is composed of IgGl heavy chains and kappa light 
chains.
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4.2.6 Antibody Concentration Determination
The protein content of the purified antibody was obtained from the BCA assay and an 
idea of the concentration can be obtained by reading at 280nm on a spectrophotometer. 
However, these techniques give the total protein content of the solution and not the 
antibody concentration. The ELISA using purified polyclonal goat anti-mouse 
immunoglobulin was performed as described in Section 2.9.7.
Goat anti-mouse immunoglobulin was used to coat the wells of an ELISA plate.
Blocking was performed by adding 2% (w/v) milk. Serial dilutions of purified mouse
immunoglobulin were prepared in dilutions containing from lpg/ml to 76 pg/ml. The 
antibody dilutions were from 1/10 to 1/400.
4.2.6.1 Concentration o f active anti-amphetamine monoclonal Clone 4EP18E
A 4-parameter equation was fitted to the data using the BIAevaluation software. This 
program calculated the concentration of the purified antibody solution to be
5.31 x 10'7 g/ml, (Figure 4.18). The data was also fitted to an Excel linear standard 
curve. The concentration of the antibody determined by the linear regression analysis 
was 6.84 x 10'7 g/ml (Figure 4.19).
4.2.6.2 Concentration o f active anti-methamphetamine monoclonal Clone PI 8D
A 4-parameter equation was fitted to the data using the BIAevaluation software. This 
program calculated the concentration of the purified antibody solution to be
1.60 x 10'7 g/ml (Figure 4.20). The concentration of the antibody determined by the 
linear regression analysis was 1.55 x 1 O'7 g/ml (Figure 4.21).
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Figure 4.18: Mouse IgG calibration curve from BIAevaluation software. A 4-
parameter fit is applied to the data allowing for the calculation of the mouse IgG amount 
in the purified anti-amphetamine monoclonal antibody batch, Clone 4EP18E. The 
concentration of the antibody determined by the 4-parameter fit was 5.31 x 10'7 g/ml.
IgG Cone (ng/ml)
Figure 4.19: Mouse IgG calibration curve from Excel software. A linear regression 
curve is applied to the data allowing for the calculation of the mouse IgG amount in the 
purified anti-amphetamine monoclonal antibody batch, Clone 4EP18E. The 
concentration of the antibody determined by the linear regression curve was 6.84 x 10'7 
g/ml.
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Figure 4.20: Mouse IgG calibration curve from BIAevaluation software. A 4-
parameter fit is applied to the data allowing for the calculation of the mouse IgG amount 
in the purified anti-methamphetamine monoclonal antibody batch, Clone P18D. The 
concentration of the antibody determined by the 4-parameter fit was 1.60 x 10'7 g/ml.
Log IgG Cone (ng/ml)
Figure 4.21: Mouse IgG calibration curve from Excel software. A linear regression 
curve is applied to the data allowing for the calculation of the mouse IgG amount in the 
purified anti-methamphetamine monoclonal antibody batch, Clone P18D. The 
concentration of the antibody determined by the linear regression curve was 1.55 x 10'7 
g/ml.
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4.2.7  Application o f anti-amphetamine MAb in ELISA
The optimal coating concentration of amphetamine-BSA and the optimal antibody 
dilution to use was determined by an indirect checkerboard ELISA. The results can be 
seen in Figure 4.22, the conjugate coating concentration ranged from 1 pg/ml to 10 
fig/ml. BSA was also used to coat the plate at a concentration of 25 pg/ml. The 
antibody dilutions ranged from 1/10 to 1/13,107,200 in PBS/Tween containing 1% (v/v) 
milk powder. The coating concentration of the amphetamine-BSA analysed that gave 
the best sensitivity was 5 fig/ml and this was chosen as the concentration for the 
competitive ELISA. The optimum antibody dilution was 1 in 300.
The competitive assay was performed as described in Section 2.9.4. The standard 
amphetamine sample was prepared from a stock solution of 1 mg/ml standard in ethanol. 
The intra-assay calibration is the results from three replicates performed on the same 
day (Table 4.2). The values from five assays were used to calculate the inter-assay 
mean, coefficients of variation and percentage recovery are shown in Table 4.3. The 
plot of the normalised absorbance and the concentration of free amphetamine for the 
inter-day assay has been shown in Figure 4.23. The range of detection of the assay is 
97.7 to 6250 ng/ml. The percentage coefficients of variation for the intra-day assay and 
inter-day assay were very acceptable, being between 2.81 and 8.25%, and 7.71 and 
24.29%, respectively. The degree of accuracy is determined by calculating the percent 
recovery of the known value for each concentration. This percent recovery is a 
quantitative measure of the closeness of the observed result to its theoretical true value, 
expressed as a percent of this theoretical value. The percent recoveries for the inter-day 
assay were 85.41 to 107.29%. These values indicate a very good accurate, reproducible 
assay for the detection of amphetamine.
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Amphetamine-BSA Coating Concentration
—• — lug/m l 5ug/ml 10ug/ml 25ug/ml
Log Antibody Dilution Factor
Figure 4.22\ Indirect checkerboard ELISA for determination of optimal concentration 
of coating conjugate concentration and antibody dilution. Amphetamine-BSA was 
coated at a range of concentrations between 1 and 25 pg/ml. Dilutions from 1/ 10 to 
1/13,107,200 of the anti-amphetamine monoclonal antibody were carried out.
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Figure 4.23: Competitive ELISA for detection of free amphetamine. Anti­
amphetamine monoclonal antibody was added to a range of amphetamine standards 
containing 0.19 to 50,000ng/ml. The data was fitted to a 4-parameter fit equation using 
BIAevaluation software. The residual plot show the difference between the 
experimental and fitted data. The results presented are the mean of 5 intra-day assays. 
The coefficient of variation, and mean back calculated value for each standard within 
the accepted range for the equation was determined and the degree of accuracy 
determined as shown in Table 4.2 and Table 4.3 for the intra-assay and inter-assay.
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Table 4.2: Intra-assay variation (degree of precision) for the detection of amphetamine
using the anti-amphetamine monoclonal antibody-based ELISA. The results are the
mean of three replicates.
Actual 
Amphetamine 
Cone (ng/ml)
Back-Calculated 
Amphetamine 
Cone, (ng/ml)
CV
%
Recovery
%
97.7 88.8 4.57 90.96
195.3 193.8 2.81 99.24
390.6 403.2 8.25 103.22
781.3 757.7 8.22 96.99
1562.5 1639.4 5.14 104.92
3125.0 3099.4 3.36 99.18
6250.0 5376.5 3.30 86.02
Table 4.3: Inter-assay variation (degree of accuracy and reproducibility) for the 
detection of amphetamine using the anti-amphetamine monoclonal antibody-based 
ELISA. The results are the mean of five intra-day assays, each performed used three 
replicates.
Actual 
Amphetamine 
Cone (ng/ml)
Back-Calculated 
Amphetamine 
Cone, (ng/ml)
CV
%
Recovery
%
97.7 91.7 7.71 93.92
195.3 195.0 7.28 99.86
390.6 405.1 10.41 103.71
781.3 752.8 13.46 96.35
1562.5 1600.4 12.75 102.43
3125.0 3352.9 13.77 107.29
6250.0 5338.1 24.29 85.41
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4.2.8 Cross reactivity studies: anti-amphetamine monoclonal antibody, Clone 
4EP18E
The cross reactivity of the anti-amphetamine monoclonal antibody was determined 
against a range of amphetamine derivatives. From the previous section on screening the 
hybridomas, it was hoped that the anti-amphetamine clone would also recognise some 
of the derivatives to some degree. The structure of many of these popular designer 
amphetamines have a methylene dioxy group and substituted side chains. The structure 
of the MDA molecule is probably the closest to the amphetamine molecule. The degree 
of cross reactivity was determined with by a competitive ELISA described in Section 
2.9.4. The amphetamine derivatives were obtained from a stock solution of lmg/ml 
standard in ethanol. The degree of cross reactivity was determined as the concentration 
of cross reactant that gives a response of 50% or one-half of the observed maximum 
binding, ( E C 50 -  Cross Reactant) expressed a percentage of the specific analyte 
concentration that gives a 50% response(EC5o -  Specific Analyte).
% Cross Reactivity = Concentration of Analyte (ECso -  SA) X 100% 
Concentration of Cross Reactant ( E C 50 -  CR)
The degree of cross reactivity of the antiamphetamine antibody is expressed in 
Table 4.4. The point to note is that the assay does detect appreciable amounts of MDA 
and BDB.
Table 4.4: Cross reactivity of anti-amphetamine monoclonal antibody. The results 
presented are the mean of three replicates.
Drug % Cross Reactivity Range of Detection 
(ng/ml)
Amphetamine 100% 97.7-6250.0
MDA 2% 3125.0-50000.0
BDB 1% 12500.0-50000.0
MDMA 0% 0
MBDB 0% 0
MDEA 0% 0
Ketamine 0% 0
Ephedrine 0% 0
Pseudoephedrine 0% 0
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4.2.9 Application o f anti-methamphetamine MAb in ELISA
The optimal coating concentration of methamphetamine-BSA and the optimal antibody 
dilution to use was determined by an indirect checkerboard ELISA. The results can be 
seen in Figure 4.24, the conjugate coating concentration ranged from 1 pg/ml to 10 
(ag/ml. There was no response to the BSA covered plate. The BSA was coated at a 
concentration of 25 (ig/ml. The antibody dilutions ranged from 1/10 to 1/13,107,200 in 
PBS/Tween containing 1% (v/v) milk powder. The coating concentrations of the 
methamphetamine-BSA analysed all gave similar sensitivities, so 2.5 pg/ml was chosen 
as the concentration for the competitive ELISA. The optimum antibody dilution was 1 
in 20.
The amphetamine derivative standards were prepared from a stock solution of 1 mg/ml 
standard in ethanol. The intra-assay calibration is the results from three replicates 
performed on the same day, and these are shown in Table 4.5. The values from five 
assays were used to calculate the inter-assay mean, coefficients of variation and 
percentage recovery are shown in Table 4.6. The plot of the normalised absorbance and 
the concentration of free amphetamine for the inter-day assay is shown in Figure 4.25. 
The range of detection of the assay is 24.4 to 12500 ng/ml. The percentage coefficients 
of variation for the intra-day assay and inter-day assay are very acceptable, being 
between 0.94 and 5.68%, and 1.43 and 15.95%, respectively. The percent recoveries for 
the inter-day assay range from 87.23 to 145.42%. The highest value of 145.42% was 
obtained for the lowest value, 24.4ng/ml, of the range of detection. These values 
indicate a very good accurate, reproducible assay for the detection of amphetamine.
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Methamphetamine-BSA Coating Concentration
1ug/ml 2.5ug/ml 5ug/ml —K— 10ug/ml
Log Antibody Dilution Factor
Figure 4.24: Indirect checkerboard ELISA for determination of optimal concentration 
of coating conjugate concentration and antibody dilution. Amphetamine-BSA was 
coated at a range of concentrations between 1 and 25 pg/ml. Dilutions from 1/10 to 
1/13,107,200 of the anti-amphetamine monoclonal antibody were carried out.
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Figure 4.25: Competitive ELISA for detection of free methamphetamine. Anti-
methamphetamine monoclonal antibody, Clone P18D, was added to a range of 
methamphetamine standards containing 0.04 to 12,500ng/ml. The data was fitted to a 
4-parameter fit equation using BIAevaluation software. The results presented are the 
mean of 5 intra-day assays, ± standard deviation. The coefficient of variation, and mean 
back calculated value for each standard within the accepted range for the equation was 
determined and the degree of accuracy determined .
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Table 4.5: Intra-assay variation (degree of accuracy and reproducibility) for the
detection of methamphetamine using the anti-methamphetamine monoclonal antibody
based ELISA. The results presented are the mean of three replicates.______
Actual 
Methamphetamine 
Cone (ng/ml)
Back-Calculated 
Methamphetamine 
Cone, (ng/ml)
CV
%
Recovery
%
24.4 30.1 5.68 123.14
48.8 60.8 1.99 124.59
97.7 83.4 5.16 85.44
195.3 158.7 111 81.24
390.6 438.2 1.31 112.19
781.3 847.2 2.95 108.45
1562.5 1340.6 1.55 85.80
3125.0 3191.4 1.31 102.13
6250.0 8275.7 3.43 132.41
12500.0 9819.5 0.94 78.56
Table 4.6: Inter-assay variation (degree of accuracy and reproducibility) for the 
detection of methamphetamine using the anti-methamphetamine monoclonal antibody 
based ELISA. The results presented are the mean of five intra-day assays, each
Actual 
Methamphetamine 
Cone (ng/ml)
Back-Calculated 
Methamphetamine 
Cone, (ng/ml)
CV
%
Recovery
%
24.4 35.5 1.43 145.42
48.8 42.6 2.35 87.23
97.7 99.7 4.23 102.06
195.3 168.3 5.47 86.18
390.6 405.2 7.59 103.72
781.3 839.2 10.20 107.42
1562.5 1483.1 12.71 94.92
3125.0 3017.9 11.78 96.57
6250.0 6681.1 10.59 106.90
12500.0 12302.8 15.95 98.42
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4.2.10 Cross reactivity studies: anti-methamphetamine monoclonal antibody, Clone 
P18D
The cross reactivity of the anti-methamphetamine monoclonal antibody was determined 
against a range of amphetamine derivatives. As discussed previously, the planning 
behind the immunisations with methamphetamine-BSA was that the anti- 
methamphetamine clone would also recognise some of the derivatives to a better degree 
than the monoclonal produced with the amphetamine-BSA immunisations. The 
structure of many of the designer amphetamines have a methylene dioxy group and 
substituted side chains. The structure of the MDMA molecule is probably the closest to 
the methamphetamine molecule. The degree of cross reactivity was determined by 
competitive ELISA as described in Section 2.9.4. Basically, a typical ELISA was 
performed, substituing the methamphetamine for the drug of interest. The amphetamine 
derivatives were obtained from a stock solution of 1 mg/ml standard in ethanol. The 
degree of cross reactivity was determined as described above in Section 4.2.8.
The degree of cross reactivity of the antiamphetamine antibody is expressed in 
Table 4.7. The point to note is that the assay does detect appreciable amounts of 
MDMA MBDB, and MDEA.
Table 4.7: Cross reactivity of anti-amphetamine monoclonal antibody. The results 
presented are the mean of three replicates.
Drug % Cross Reactivity Range of Detection 
(ng/ml)
Methamphetamine 100% 24.4-12500.0
MDA 0% 0
BDB 0% 0
MDMA 146% 48.8-390.6
MBDB 47% 390.6-12500
MDEA 18% 390.6-12500
Ketamine 0% 0
Ephedrine 0% 0
Pseudoephedrine 0% 0
Phenylpropanolamine 0% 0
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4.2.11 Application o f anti-amphetamine monoclonal antibody in ELISA fo r  detection 
o f amphetamine in saliva samples
The competitive assay as described above, was repeated using saliva samples spiked 
with amphetamine. The saliva caused very little interference with the assay and similar 
results were obtained with regard to the level of detection. Each assay had three 
replicates for each standard concentration. The values from five assays were used to 
calculate the inter-assay mean, coefficients of variation and percentage recovery are 
shown in Table 4.8. The coefficient of variations were a little higher than the values 
obtained in the PBS model ELISA. This can be accounted for by variations in saliva 
itself that may be causing slight interference.
Table 4.8: Inter-assay variation (degree of accuracy and reproducibility) for the 
detection of amphetamine using the anti-amphetamine monoclonal antibody based 
ELISA. The results presented are the mean of five intra-day assays, each performed 
using three replicates.
Actual
Amphetamine
Cone (ng/ml)
Back-Calculated 
Amphetamine 
Cone, (ng/ml)
CV
%
Recovery
%
97.7 78.4 8.83 80.23
195.3 226.6 5.05 116.02
390.6 386.9 10.99 99.03
781.3 737.7 19.43 94.43
1562.5 1663.2 21.54 106.45
3125.0 3025.6 20.53 96.82
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4.2.12 Application o f anti-methamphetamine monoclonal antibody in ELISA for  
detection o f methamphetamine in saliva samples
The competitive assay, as described above, was repeated using saliva samples spiked 
with methamphetamine. Each assay had three replicates for each standard 
concentration. The values from five assays were used to calculate the inter-assay mean, 
coefficients of variation and percentage recovery are shown in Table 4.9. Similar results 
were obtained with regard to the level of detection. However, the percentage recovery, 
which is a measure of the accuracy was lower for the lower values of the detection 
limit, as shown in Table 4.9 below. This can be accounted for by variations in saliva 
itself that may be causing slight interference. So in this case, the lower limit of 24.4 
ng/ml should not be included in the acceptable range of detection.
Table 4.9: Inter-assay variation for the detection of methamphetamine using the anti- 
methamphetamine monoclonal antibody based ELISA. The results presented are the 
mean of five intra-day assays, each performed using three replicates.
Actual 
Methamphetamine 
Cone (ng/ml)
Back-Calculated
Methamphetamine
Cone, (ng/ml)
CV
%
Recovery
%
24.4 10.5 1.07 42.93
48.8 70.6 3.96 144.65
97.7 133.2 4.10 136.43
195.3 150.7 4.07 77.17
390.6 412.5 6.03 105.60
781.3 724.0 5.82 92.68
1562.5 1447.9 8.68 92.67
3125.0 3707.0 5.10 118.62
6250.0 6924.1 8.70 110.79
12500.0 10404.4 13.21 83.24
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4.3 Discussion
Monoclonal antibody production was described in this chapter. The aim of the work 
was to prepare antibodies that would recognise amphetamine and amphetamine 
derivatives. This was at the outset a challenging task as the range of designer 
amphetamine derivatives made by clandestine laboratories is continually increasing, 
correlating with the increased use of these so called ‘recreational’ drugs. The other 
major consideration that had to be taken into account was the other ‘amphetamine-like’ 
derivatives that are used in common over the counter cold and flu medications, for 
example ephedrine, pseudoephedrine, and phenylpropanolamine, (Figure 4.26).
The original application for these antibodies is in the screening of saliva samples from 
drivers being tested for drugs of abuse. A key aspect of such a test is that the amount of 
false positives be kept to the absolute minimum. Otherwise the screening would not 
advantageous, or contributing to, different screening methods, for example, 
psychometric testing by specialised police personnel. Therefore, the aim of the project 
presented two challenges, i.e. (a) to produce antibodies that would be specific for the 
amphetamine designer drugs, and (b) that would not cross react with structurally-related 
legal medications.
The immunogens chosen for the in vivo immunisations were amphetamine-BSA and 
methamphetamine-BSA. The only structural difference between amphetamine and 
methamphetamine is as the name suggests, the presence of a methyl group on the 
carbon side chain. Amphetamine was chosen as it is the main parent structure of these 
drugs. Methamphetamine was chosen as it is abused in this form, and the designer 
amphetamine derivatives have substituted amphetamine side chains, and so this 
structure would be more closely related to these. There is very little work published 
concerning the form of these amphetamine derivatives that are present in saliva after 
ingestion. From discussions, with our collaborators on the SMT project, the emphasis 
with regard to detection was placed on amphetamine, methamphetamine, MDMA 
MDA and MDEA. It is the ¿/-isomer of amphetamine that has potent psychological 
affects and so it was this form that was examined in all assays.
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Due to the large amounts of amphetamine and methamphetamine that are needed to 
derivatise these drugs for conjugation to proteins, and the time needed, it was decided to 
use commercially available conjugates as they could be acquired without a need for an 
import licence.
MDMA R,=CH, R2=CH3
MDA Rj=H R2=CH3
MDE R,=C2Hs R2=CH3
MBDB R,=CH3 R2=C2H5
R
Amphetamine Ephedrine
CH3
Figure 4.26: Structure of amphetamine and the main amphetamine derivatives
The screening procedure for the antibodies was complicated by the fact the same 
conjugate used for immunisation had to be used for the screening. This goes against all 
the recommendations, mentioned in the introduction, that the screening conjugate 
should be a different conjugate, in terms of the protein used, and the chemistry used. In 
order, to compensate for this, it was decided that extensive screening needed to be 
performed. This screening took the format of an inhibition ELISA. If a supernatant 
was positive on the amphetamine-BSA (Ml Fusion) or methamphetamine-BSA (M2 
Fusion), it was then screened in the inhibition ELISA against all the derivatives. This 
required a substantial amount of time to perform but the end result was very successful.
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The successful clones were grown up in T75 flasks. Sufficient quantities were 
produced by this method for the purposes of characterisation and testing in an ELISA 
format.
A competitive ELISA was developed for the detection of amphetamine with the anti­
amphetamine monoclonal antibody, and a 4 parameter fit was applied to the data. This 
antibody showed a range of detection between 97.7 to 6250 ng/ml amphetamine. The 
degree of cross reactivity at 50% was 2% for MDA and 1% for BDB. Although, a 2% 
cross reactivity may seem low, perhaps a better idea of cross reactivity can be seen from 
looking at the range of detection of MDA by the anti-amphetamine antibody, which is 
3125.0 to 50000.Ong/ml. This means that the presence of 3125ng/ml MDA will cause 
an appreciable decrease in the absorbance of the assay and this is taken as a positive 
result. It is interesting that of all the other amphetamine derivatives, the only one that 
could be detected was BDB. This recognition of MDA can be explained by its structure 
as it contains the amphetamine structure substituted with the methylene dioxy group on 
the phenyl ring. BDB does not have the methylene dioxy group at the phenyl ring, but 
is substituted on the carbon side chain. The important issue with regard to cross 
reactivity was that it did not recognise ephedrine or pseudoephedrine. The assay also 
showed very good precision as determined by the intra-assay coefficients of variation 
(2.81% to 8.25%), and very good reproducibility as determined by the inter-assay 
coefficients of variations (7.71 -  24.29%). The high percentage CV of 24.29% was 
obtained for the value of 6250 ng/ml amphetamine. This large CV could have been a 
result of the fact that it is at the high end of the range of detection, and so there is more 
variability as a result. The degree of accuracy was also determined by a calculation of 
the percentage recovery. As described by Findlay (2000) this is a concept that 
expresses the closeness of agreement between a measured test result and its theoretical 
true value. The percentage recoveries for the inter-assay were very good, between 
85.41% and 107.29%. Overall, the anti-amphetamine monoclonal antibody, Clone 
4EP18E, competitive ELISA for the detection of amphetamine was a very good, 
accurate, reproducible assay.
A competitive ELISA was developed for the detection of methamphetamine with the 
anti-methamphetamine monoclonal antibody, and a 4 parameter fit was applied to the 
data. This antibody showed a range of detection between 24.4 to 12500 ng/ml
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methamphetamine. The degree of cross reactivity at 50% was 146% for MDMA, 47% 
for MBDB, and 18% for MDEA. The 146% cross reactivity for MDMA can be 
explained by the fact that during the screening procedures, the lab supply of 
methamphetamine was exhausted and this necessitated using MDMA as the primary 
drug of interest, as it most closely related to methamphetamine. The range of detection 
of MDMA by the anti-amphetamine antibody, is 48.8 to 390.6ng/ml. This means that 
the presence of MDMA will cause an appreciable decrease in the absorbance of the 
assay and this is taken as a positive result. This recognition of MDMA can be explained 
by its structure as it contains the methamphetamine structure substituted with the 
methylene dioxy group on the phenyl ring. MBDB and MDEA have additional butyl 
and ethyl groups on the carbon side chain. Again, with this antibody, specific clones 
were chosen that did not recognise ephedrine, pseudoephedrine or 
phenylpropanolamine.
The assay also showed very good precision as determined by the intra-assay coefficients 
of variation (0.94 to 5.68%), and very good reproducibility as determined by the inter­
assay coefficients of variations (1.43 to 15.95%). The high percentage CV of 15.95% 
was obtained for the value of 12500 ng/ml methamphetamine. This larger CV value 
could have been a result of the fact that it is at the high end of the range of detection, 
and so there is more variability. The degree of accuracy was also determined by a 
calculation of the percentage recovery as discovered for the anti-amphetamine antibody. 
The percentage recoveries for the inter-assay were very good, between 87.27 and 
145.42%. This high CV of 145.42% was obtained for the low methamphetamine 
concentration of 24.4ng/ml. For an accurate assay, this value should be removed from 
the range of detection, changing the range to 48.8 to 12500ng/ml. All other CVs were 
within an acceptable range of 87.27% to 106.9%. Overall, the anti-methamphetamine 
monoclonal antibody, Clone P18D, competitive ELISA for the detection of 
amphetamine is a very good, accurate, reproducible assay. It also has the added benefit 
of detecting appreciable amounts of MDMA MBDB and MDEA, without interacting 
with ephedrine, pseudoephedrine or phenylpropanolamine.
The assay format was then applied to saliva samples spiked with amphetamine and 
methamphetamine. There was a very good correlation between the model assay in PBS 
and the assay in saliva. The competitive assay for saliva samples spiked with
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amphetamine, showed similar results were obtained with regard to the level of 
detection. The coefficient of variations were a little higher than the values obtained in 
the PBS model ELISA. This can be accounted for by variations in saliva itself that may 
be causing slight interference. These could involve proteins or extraneous components. 
The protein content of saliva is composed of the same constituents as blood, in that it 
contains lipoproteins and digestive enzymes. However, the total protein concentration 
in saliva is significantly less (under 1%) than that in plasma. There are also additional 
constituents in saliva such as dead epithelial cells and usually some food debris also, 
(Samyn et al., 1999).
The competitive assay for saliva samples spiked with methamphetamine, again, showed 
similar results with regard to the level of detection, however the percentage recovery, 
which is a measure of the accuracy was lower for the lower concentrations of the 
detection limit. Again, this can probably be accounted for by variations in saliva itself 
that may be causing slight interference.
The production of the two monoclonal antibodies was a success. The key to selecting 
the specific antibodies was the intensive screening process, in which not only reactivity 
towards the drugs of interest was investigated but also the reactivity towards the 
structurally close relatives that it was hoped would not be detected. The reactivity of 
the antibodies in saliva mirrored that seen in the PBS assay and so these assays can be 
directly applied to testing saliva samples for amphetamine, MDA methamphetamine, 
MDMA, MBDB, and MDEA.
The next chapter, continues the characterisation of these monoclonal antibodies and 
their application in a BIAcore competitive assay for the detection of amphetamines.
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Chapter 5
Characterisation and Application o f Anti-Amphetamine and 
Anti-Methamphetamine Monoclonal Antibodies
168
5.1 Introduction
5.1.1 Biosensors
The basis of a sensor is the ability to detect a change in an environment, and then to 
process this information and display it to the user. A biosensor consists of three main 
components, a biosensing material, a tranducing mechanism and a processing unit. One 
definition of a biosensor is a sensor that uses a biological component, for example an 
antibody or enzyme (Figure 5.1 A). McCormack et al. (1998), have reviewed the 
different biomaterials that can be used for biosensors. These include enzymes, 
antibodies, modified by labeling and also by the production of hybrid immunoglobulin 
molecules that have been changed to either enhance the specificity or to incorporate a 
signal generating component. Other biomaterials include cells, used in place of purified 
enzymes, microorganisms, which are commonly used as indicators of toxicity, 
mammalian tissue slices, plant tissue, DNA and KNA, and cell receptors. There are 
many different types of biosensors and other chemical sensors that are not specifically 
biosensors but that are used in analysis of biological systems. An example of one 
would be ion-selective electrodes. These are chemical sensors in that they do not 
possess a biological component but can be used for direct in vivo measurements in 
mammalian muscle cells (Fanning, 1995).
The ideal properties of a sensor include the following (Diamond, 1998):
• Rapid measurement
• Sensitive
• Selective
• Sensor signal should return to baseline after measurement
• Noise to signal ratio must be low as this determines the limit of detection
• Signal output must bear mathematical relationship to amount of analyte in sample.
5.1.2 Surface Plasmon Resonance
Surface plasmon resonance is a method for measuring biomolecular interactions. 
BIAcore is an analytical system based on surface plasmon resonance. It detects and 
measures binding interactions in ‘real-time’. The detection system depends on changes 
in concentration at the sensor surface. The sensor chip is a glass slide coated on one 
side with a gold film to which a matrix of carboxymethylated dextran is covalently
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attached. Surface plasmon resonance is a property of thin metal layers. When a wedge 
of light is focused on the rear side of the sensor chip, total internal reflection occurs 
above a certain angle of incidence, and a photodiode array detector detects the intensity 
of the reflected light. At an angle of incidence to the gold layer, total internal 
reflectance occurs, the photons from the light resonates with the free electrons 
(plasmons) in the gold layer creating an evanescent wave. The angle at which the 
surface plasmon resonance occurs is dependent on the refractive index of the other side 
of the gold film. A change in mass bound to the gold layer is proportional to a change 
in refractive index. When binding occurs between the immobilised molecules in the 
dextran layer and the molecules from the solution that is continuously passed over the 
chip, changes in mass bound occur causing changes in refractive index and subsequent 
changes in the SPR angle (Figure 5.IB). The output of the data is in the form of a 
sensorgram (Figure 5.2). Kinetic data on the interaction between the antigen and ligand 
can be obtained by this ‘real-time’ measurement.
SPR-based biosensors have considerable advantages over other technologies, including 
the following:
• There are no labeling requirements, so the mechanisms of the interactions are not 
effected by a modification. This also involves less preparatory work.
• The reactions are monitored in ‘real-time’, so providing rapid, quantitative data.
• The stability of the sensor surface can be monitored by the sensorgram readings.
• The systems are fully automated and can handle large amounts of samples.
• The assays developed require little or no sample preparatory steps. Reports include 
assay development in blood (Quinn et al., 1997), cell culture supernatant (Fanning, 
unpublished data), urine (Dillon, 2001), saliva (as detailed in Section 5.2 and 
Chapter 6), and bile (Fitzpatrick et a l, unpublished data).
• Kinetic and affinity data over a wide range of constants can be determined, (ka: 103- 
108 M'1Sec'1, kd: 10'6-10'L Sec'1, KD = 10'3 -  10'13) (Myszka and Rich, 2000).
• The feature of multi-channel analysis, means that the interactions can be monitored 
over different immobilised ligand sensor surfaces, and provide direct comparison.
• The amount of materials required for immobilisation of ligands and regeneration 
solutions are minimal.
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Pharmacia were the first company to introduce a commercial SPR biosensor, BIAcore, 
onto the market in 1990. In recent years, other optical biosensors have been developed 
and are also available. These include systems by Affinity Sensors, (IAsys), IBIS 
Technologies BV, (IBIS), BioTul AG, (Kinomics), Nippon Laser and Electronics Lab, 
(SPR 670), and Texas Instruments, (TI-SPR), Artificial Sensing Instruments, (OWLS), 
Aviv, (PWR-400), amd Quantech Ltd., (FasTraQ), (Rich and Myszka, 2000; 
McDonnell, 2001).
Biological Transducer Data Acquisition &
Component Presentation
Figure 5.1A: Basic diagram of a biological sensor. It is composed of three main 
elements, the biosensor where the biological interaction occurs, a transducer component 
and, a data acquisition and presentation part. Figure 5.IB shows a schematic of the 
surface plasmon resonance, which is the basis of the BIAcore biosensor.
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Figure 5.IB: Schematic of the basis of surface plasmon resonance. In this example 
the antigen is immobilised on the sensor chip surface. Light from a high intensity 
emitting diode is focused onto the gold sensor chip surface by means of a glass prism 
under conditions of total internal reflection. The reflected light is measured using a 
two-dimensional photo-diode array. Under conditions of total internal reflection at 
the gold surface, an evanescent wave propagates into the medium of lower refractive 
index. The angle at which this occurs is known as the resonant angle. This angle is 
sensitive to changes in the refractive index of the layer adjacent to the gold surface. 
This can be used to monitor the interaction occurring at the surface in ‘real-time’. In 
the above schematic the following is represented: the binding of the antibody to the 
immobilised antigen causes in a change in the refractive index at the sensor surface 
which resulted in a change in the angle of incidence of the reflected light, from A to 
B.
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Figure 5.2: The change in the angle of incidence as described in Figure 5.IB is 
translated by the BIAcore software to display the SPR response curve. The 
interaction between the immobilised antigen and antibody as the antibody solution 
was passed over the surface, caused a mass change and an increase in the SPR angle. 
The result is the increase in response unit seen in the sensorgram.
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5.1.3 Applications o f BIAcore Technology
BIAcore was introduced onto the market in 1990, as the first SPR biosensor. Since 
then, extensive investigations have been performed in many different areas. This 
section will focus on BIAcore biosensors as it is the most publicised, however, it is 
possible that other SPR sensors could also be used in similar applications. The 
underlying characteristic of BIAcore is it’s ability to monitor biomolecular interactions. 
This opens up a plethora of potential uses for the BIAcore as this is an elemental step in 
basic research, analytical assays and drug discovery. Briefly, these applications include 
quantitative concentration determination of an analyte, measurement of binding 
constants to see how fast a complex forms and dissociates, measurement of the affinity 
of an antigen: antibody complex, and epitope mapping of monoclonal antibodies. These 
applications have been well documented over the last decade. (Malmqvist, 1993; 
Fagerstam & O’Shannessy, 1993; Johne, et al., 1993; Daly el al., 2000; Quinn & 
O’Kennedy, 2001).
BIAcore introduced the new BIAcore 3000 in 2001, this offers increased sensitivity 
over existing sensors and an ‘on-line’ reference curve subtraction. BIAcore could 
potentially be utilised for screening during the production of antibodies. Chapter 4 
described the screening process for the monoclonal antibodies using ELISA. This is a 
very labour and time-intensive process. It is possible that the supernatant samples, 
which at the initial stages could number over 1000, could be screened using the 
BIAcore. The regeneration profile of the assay would have to be successful for this 
high number of samples. In the production of an antibody against a hapten, it is ideal 
that the antigen of interest would be immobilised onto the chip surface directly, without 
the need for a protein conjugate. If, however, the hapten-protein conjugate is 
immoblised, the on-line reference curve subtraction can be used to detect the non­
specific binding of the supernatant components to the immobilised protein compared to 
the binding to the hapten-protein immobilised surface. The reason behind the 
preference for direct immobilisation of the hapten are two-fold. Firstly, the supernatant 
that interacted with the hapten would have a higher possibility of being specifically 
bound by it, as opposed to the case of a antigen-protein conjugate being immobilised, 
whereby, the antibody may recognise the linker region or protein part of the conjugate. 
Secondly, previous studies have shown, (Fitzpatrick, 2001) that a directly immobilised 
small hapten gives better reproducibility and stability leading to increased number of
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regeneration cycles, compared to the hapten-protein conjugate. The direct 
immobilisation of a hapten is dependent on the presence of suitable reactive groups and 
the ease of derivatisation of the molecule if such reactive groups are not already present. 
The ability of BIAcore biosensors to collect eluted samples after binding to the 
immobilised surface on the sensor chip expands the potential applications. Malmborg 
& Borrebaeck (1995) panned a phage display library for the selection of phage- 
displayed antibody fragments. The specific bound phage particles were eluted from the 
immobilised surface and collected.
BIAcore have introduced a range of alternative sensor chip surfaces that provide 
different immobilisation chemistries to couple ligands to the sensor surface so that the 
interaction can be studied in the most appropriate manner. The basic chip has a layer of 
carboxymethylated dextran and this is suitable for most applications. Other chips 
include the Bl, which has less carboxyl groups available, and the FI that has a thinner 
dextran layer. This is suitable for analysis of solutions with large particles that may be 
hindered in the longer dextran matrix. The NTA chip is able to bind histidine-tagged 
molecules. This complements other laboratory techniques that involve His-tags, such as 
chelation chromatography. On the Cl chip the carboxyl groups are directly attached to 
the sensor surface. This chip without the dextran layer could be useful in work 
involving large particles such as cells.
Recent developments in the field of SPR include coupling the technique to mass 
spectroscopy. Common techniques for protein characterisation include the laborious 
two dimensional gel separation, and subsequent sequencing. Mass spectroscopy has 
many advantages including specificity and sensitivity. The coupling of SPR biosensors 
to mass spectroscopy mean that the SPR technology can detect and capture specific 
proteins and then they can be analysed by MS. The combination of the technologies 
could result in a powerful tool for microarray analysis in proteomics, (Williams and 
Addona, 2000; Natsume et al., 2001). Another application for SPR in proteomics is in 
the area of orphan ligand screening in drug development. The SPR biosensor can detect 
such ligands from a variety of sources of fluids and media (Myszka & Rich, 2000). 
Another area where SPR is becoming popular is in the analysis of biological 
interactions with biomaterials (Green et al., 2000). The SPR sensor flow cell can be 
modified with a range of different surfaces by coating of thin layers above the gold 
surface. These surfaces can include dextran, lipid bilayers, adsorbed copolymers or 
self- assembled monolayers.
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5.1.4 Antibody Affinity
The affinity of an antibody describes the strength of the bond between the antibody and 
its specific antigen. It is not just a theoretical value as it is important in determining a 
key physiological property of the antibody and this in turn determines its potential 
usefulness. It is important to include the affinity of an antibody in the characterisation 
process. Determination of affinity can be done by many different methods. However, 
all are based on a system that allows the antibody and antigen to come to equilibrium. 
The interaction of the antibody and antigen at equilibrium can be described by:
ka
[A] + [B] <-> [AB] Equation 5.1
ka
[A] = Free Antigen Concentration
[B] = Free Antibody Concentration
[AB] = Antigen: Antibody Complex
ka Association Rate Constant
kd Dissociation Rate Constant
By applying the Law of Mass Action the affinity constant can be determined:
kJ  kd= Ka = [AB]/[A] [B] Equation 5.2
Where Ka = Equilibrium association rate constant
K a =  1 / K d
Kd = Equilibrium dissociation rate constant
The common perception is that antibodies with high affinities for their specific antigen 
are better than those with lower affinity, given that the affinity is a measure of the 
strength and stability of the antibody-antigen complex. This is true in the case of many 
biological processes. However, in the case of an antibody-based detection assay an 
antibody of high affinity can cause problems. An example of this is an assay developed 
on the BIAcore system. The antigen of interest is immobilised onto the dextran layer of 
a gold sensor chip surface. Antibody is then injected over the immobilised surface and 
the binding causes a change in mass bound to the sensor chip surface. The change in
176
the refractive index at the surface causes a shift in the resonant angle of reflected light 
and this shift is proportional to the change in mass of antibody bound. This 
immobilised surface has to be used many times in some cases up to a couple of hundred 
for the assay to be considered efficient in terms of time and expense. The surface needs 
to be regenerated after each pulse of antibody:antigen solution, for example, in the case 
of an inhibition assay for the detection of an analyte, as discussed in Section 5.3.4. If 
the antibody is of a high affinity and is bound strongly to the immobilised antigen, a 
harsh regeneration solution is required to break the interaction. This has negative 
implications, as in some cases this could affect the immobilised antigen and cause 
degradation of the surface. It could also effect the dextran layer of the surface and 
destroy the immobilised surface. So, in this case an antibody of medium affinity is 
sufficient and more desirable.
5.1.5 Affinity Measurement by ELISA
Classical methods for the determination of affinity constants include equilibrium 
dialysis, immunoprécipitation, and fluorescence assays based on the changes in the 
fluorescent properties of the antibody or antigen occurring by the binding interaction. 
Friguet et al. (1985) described an ELISA-based method for the determination of the 
equilibrium dissociation constant, that compares favourably with results from 
immunoprécipitation and fluorescence transfer assays. A series of antigen standards are 
prepared and incubated with a constant nominal concentration of antibody. The 
mixtures are allowed to reach equilibrium overnight. Another set of dilutions of the 
antibody are set up and also left overnight. The solutions are then applied to ELISA 
plate wells that have been coated with the antigen of interest, and the ELISA is 
developed as described in Section 2.9.6. These antibody standards are used to construct 
a curve of nominal antibody concentration versus absorbance. A linear relationship 
can be seen from the amount of antibody added to the wells and the absorbance. If the 
antibody at a total concentration of io is incubated with antigen at a particular 
concentration, then i, the free antibody concentration, will be equal to the absorbance, 
divided by the absorbance of the antibody in the absence of antigen, as follows:
i/io = A/Ao Equation 5.3
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According to the mass conservation equations, the concentrations of bound antibody, x, 
and free antigen, a, at equilibrium can be calculated as follows:
x = i0 -  i and a = ao - x
where:
ao = total concentration of antigen
ao, x, and io are related to Kd by the Klotz equation:
1/x = 1/ i0— (K D/a x io) Equation 5.4
This can be related to the absorbance readings as follows:
x = io x (Ao -  A/Ao) Equation 5.5
a = ao -  io x (Ao -  A/Ao) Equation 5.6
And so the equation 5.4 can be rewritten as follows:
Ao/Ao-A = 1 + K D/(a0 -  io) (Ao-A/Ao) Equation 5.7
As one of the prerequisites of the Friguet assay is that the antigen concentration is at 
least 10 times molar excess of the antibody, then (a) can be approximated by ao, and the 
equation becomes the following:
Ao/Ao-A =  1 +  Ko/ao Equation 5.8
The fraction of total antibody, bound by the antigen, (Ao-A/Ao), abbreviated to (V), was 
calculated for each antigen concentration. The slope of the plot of 1/V versus 
l/[Antigen Concentration], known as the Klotz Plot, defined the equilibrium 
dissociation constant.
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5.1.6 Affinity Measurement by BIAcore
The BIAcore can be used to determine the affinity of an antibody based on the 
assumption that the antibody-antigen interaction follows pseudo-first order reaction 
kinetics. Measurement of affinity in solution with the BIAcore programs is based on 
the determination of the free concentration of one of the interactants in equilibrium 
mixtures. A standard curve of known concentrations has to be constructed, as well as 
the equilibrium mixtures for determination of the affinity. In the case of an antibody- 
antigen affinity, the antigen is immobilised on the sensor chip surface. A range of 
antibody dilutions of known molar concentrations are passed over the surface and a 
standard curve constructed. A constant concentration of the antibody is mixed with a 
series of known concentrations of the antigen and allowed to reach equilibrium. The 
mixtures are then passed over the sensor chip surface. The remaining free concentration 
of the unbound antibody is determined by reference to the standard curve. The affinity 
constant is determined by applying the solution affinity fit to the data using the 
BIAevaluation software. The equation used is:
[ B ] free = ( B - A - K D) / 2  +  V ( ( A + B + K D) / 4  -  ( A ) " ( B ) )  Equation 5 .9
B free = free concentration of component B  (antibody)
A = molar concentration of A 
B = molar concentration of B
A basic factor determining the kinetics of antibody and antigen interactions is the mass 
transport of analyte across a stationary layer of solution at the surface of the sensor chip 
flow cell. The mass transfer coefficient is dependent on the flow cell geometry and the 
flow rates. If the mass transfer is limiting, the mass transfer determines the rate of 
binding of the antigen to the immobilised ligand. For the correct determination of 
kinetic constants using BIAcore technology, the mass transfer limitation must be 
eliminated, so the rate of binding is only determined by the kinetic constants. This can 
be achieved by using a high flow rate to remove the mass transfer limitation.
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The development of BIAcore based immunoassays for the detection of amphetamine 
and derivatives is investigated in the following results sections, and applied to saliva 
samples. The anti-amphetamine and anti-methamphetamine monoclonal antibodies are 
used for this application. The affinities of the antibodies for amphetamine derivatives 
are also investigated using ELISA and BIAcore-based assays.
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5.2 Results
5.2.1 Development o f BIAcore-based competitive immunoassay fo r  the detection of 
amphetamine using anti-amphetamine monoclonal antibody, Clone 4EP18E
5.2.1.1 Preconcentration studies
It is necessary to run a preconcentration step as a preliminary to the immobilisation of a 
drug-protein conjugate to the carboxymethylated dextran layer of the sensor chip. This 
step ensures that the immobilisation process is maximised.
Solutions of amphetamine-BSA were prepared in lOmM sodium acetate, with a range 
of pH from 3.9 to 5.5. The pH of the sodium acetate was adjusted with 10% (v/v) acetic 
acid. Each protein solution was sequentially passed over an underivatised sensor flow 
cell for 2 minutes at a flow rate of 5(j.l per minute. The injection pulse of each solution, 
is followed by a pulse of Hepes buffered saline that is sufficient to dissociate the 
electrostatic attraction between the drug-protein conjugate and the carboxymethylated 
surface. The results of the preconcentration step are shown in Figure 5.3. The optimal 
pH determined for immobilisation of amphetamine-BSA is pH 4.0, as the dextran layer 
is unable to tolerate lower pHs, because protonation of the carboxy groups on the 
dextran occurs leading to collapse of this layer. All immobilisations were carried out at 
pH 4.0. Although this pH contributes to the immobilisation process, it is necessary to 
chemically modify the carboxymethylated dextran to achieve immobilisation of the 
amphetamine-BSA conjugate.
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Figure 5.3: Preconcentration study of amphetamine-BSA in sodium acetate at various 
pH values onto the carboxymethylated dextran surface of the CM5 sensor flow cell. 
Solutions containing 50jig/ml of amphetamine-BSA were passed over the surface for 2 
mins at a flow rate of 5pl/min. The response units for each solution is a measure of the 
electrostatic attraction between the negatively charged dextran and the positively 
charged protein conjugate. The ionic strength of the Hepes buffered saline is sufficient 
to dissociate the protein conjugate from the dextran layer. The optimal pH was 
determined to be pH 4.0 as shown on the figure. It is not advisable to use a pH lower 
than 4.0 on the dextran surface as this results in protonation of the carboxyl groups 
causing a collapse of the gel matrix.
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5.2.1.2 Immobilisation o f amphetamine-BSA
A solution of EDC/NHS was passed over the chip surface. The carboxyl groups on the 
dextran layer of the sensor chip were converted into active ester functional groups by 
the EDC, and stabilized by the NHS. The amphetamine-BSA conjugate in lOmM 
sodium acetate, pH 4.0, was passed over the chip. The NHS esters then react with the 
available amine groups on the amphetamine conjugate. Figure 5.4 shows a typical 
immoblisation profile.
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Figure 5.4: Sensorgram of a typical immobilisation of amphetamine-BSA onto a CM5
dextran chip surface.
1. HBS buffer was passed over the surface and baseline measurement recorded.
2. A solution of EDC and NHS, final molarity 0.2M and 0.05M, respectively, was 
passed over the surface for 7 minutes at a flow rate of 5jil/min to activate the 
carboxymethylated groups.
3. After the pulse of EDC/NHS}, the HBS buffer was run over the surface again. The 
activation of the surface was seen by the small change (approx 120-200) in response 
units.
4. A solution of 50fig/ml of amphetamine-BSA in lOmM sodium acetate, pH 4.0, was 
passed over the surface for 20 minutes at a flow rate of 5^1/min.
5. The HBS buffer was run over the surface and the excess conjugate eluted. The 
amount of bound conjugate was recorded as the change in response units from 
baseline.
6. The surface NHS-esters were deactivated by a pulse of 1M ethanolamine 
hydrochloride, pH 8.5. This also removed any excess non-convalently bound 
conjugate.
7. The HBS running buffer resumed flow over the surface and the amount of bound 
amphetamine-BSA can be seen from the change in the response units. 
Approximately 6,000RU’s of amphetamine-BSA were bound on the chip surface.
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The previous sections dealt with the immobilisation of the amphetamine-BSA conjugate 
on to the sensor chip. The regeneration conditions must also be optimised. It is 
preferable to be able to run multiple samples usually greater than 40 on a single cell of a 
sensor chip. To do this, the regeneration conditions must be examined and chosen 
carefully and a regeneration cycle set up to determine the effects of the regeneration 
solutions on the surface and on the binding of the antibody to the surface.
A 1/10 final dilution of anti-amphetamine monoclonal antibody was found to give a 
binding response of approximately 250 response units. A range of different molarities 
of HC1 and NaOH were tried. The optimum combination found to give reproducible 
results was a 15 second pulse of lOfil of 20mM HC1 and a 60 second pulse of 5(il 
7.5mM NaOH. The surface was found to be reproducible for over 60 cycles of 
antibody binding and regeneration with this protocol. Figure 5.5 shows the response 
units for each cycle. An increase in response units was seen for cycles 31-34. This may 
have been due to extraneous substances at the chip surface. The decreased response 
units for cycle 54 may also be an anomaly, for example, an air bubble in the system.
The interaction between the BSA portion of the conjugate and the antibody was 
examined by immobilising 50|ig/ml BSA in lOmM sodium acetate, pH 4.0. The 
response of the antibody to this surface was zero RU. This response to dextran was also 
examined and found to be zero also.
5.2.1.3 Regeneration Conditions
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Figure 5.5: Regeneration profile of the anti-amphetamine monoclonal antibody
binding to the amphetamine-BSA immobilised surface. A 1/10 dilution of antibody was 
passed over the surface for 4 minutes. The surface was regenerated with a 60 second 
pulse of 5pl of 20mM HC1 and a 60 second pulse of 5jal of 7.5mM NaOH. An increase 
in response units was seen for cycles 31-34. This may have been due to an artefact. 
The decreased response units for cycle 54 may also be an anomaly, for example, an air 
bubble in the system.
186
5.2.1.4 Determination o f  range o f detection o f amphetamine in the BIAcore 
competitive assay
To determine the working range for detection of amphetamine with this assay, a number 
of standard amphetamine concentrations were prepared in HBS buffer, ranging from
0.09 to 25,000 ng/ml. The anti-amphetamine monoclonal antibody, diluted in HBS, 
was mixed with equal volumes of each standard and allowed to come to equilibrium for 
15 minutes on the bench before being placed in the BIAcore for the assay run. The 
samples were passed over the amphetamine-BSA immobilised surface in random order. 
An example of the different sensorgrams are shown in the overlapped sensorgram 
diagram in Figure 5.6. Each cycle was followed by the regeneration cycle. Each drug- 
antibody solution was run over the surface three times in random order. This, therefore, 
eliminated any possible bias that could have been incorporated into the assay. Each 
value was normalised for that intra-assay by dividing the RU obtained by the RU for the 
positive control that only contained antibody and no amphetamine. An example of the 
intra-assay variability is shown in Table 5.1. The inter-assay calibration is the 
combination of three different assays run on three different days, (Table 5.2). The 
calibration curve for the inter-assay is plotted in Figure 5.7. The range of detection of 
the assay is 24.4 to 12,500ng/ml. The back-calculated values as determined by the four- 
parameter fit of the calibration curve for the amphetamine standards show the assay to 
very accurate for these values. The percentage recoveries ranged from 93.78 to 
108.41%. The degree of accuracy can be determined by calculating the percent 
recovery of the known value for different concentrations. This percent recovery is a 
quantitative measure of the closeness of the observed result (back-calculated result) to 
its theoretical true value, expressed as a percent of the nominal, theoretical 
concentration. The percentage coefficient of variation (CV) for the range of detection is 
very acceptable, being between 1.66 and 6.90%, for the inter-assay. The degree of 
precision of the assay is expressed in the percent coefficient of variation of the intra 
assay variation as shown in Table 5.1.
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Figure 5.6: Overlay plot showing examples of typical binding curves in the Biacore 
inhibition assay. This figure shows the binding response obtained when samples 
containing 0, 97.7, 390.6 and 3125 ng/ml amphetamine were incubated with anti­
amphetamine monoclonal antibody and allowed to reach equilibrium. The samples 
were then passed over the amphetamine-BSA-coated sensor chip surface and the 
binding response measured. The samples were passed over the surface in triplicate and 
the assay was repeated over three days. The results were normalised and were used to 
construct the inter-day calibration curve, as shown in Figure 5.7.
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Figure 5.7: Inter-day curve for the detection of amphetamine using the anti­
amphetamine monoclonal antibody on an amphetamine-BSA immobilised surface. The 
data was correlated to a four-parameter model fit and the plot constructed using 
BIAevaluation 3.1 software. Each point on the graph is the average of three results 
obtained on three different days from a set of three replicates. Each value was 
normalised for that intra-assay by dividing the RU obtained by the RU for the positive 
control that only contained antibody and no amphetamine. The coefficient of variation, 
back-calculated amphetamine concentration and the percentage recovery are shown in 
Table 5.2. The range of detection of the assay is 24.4 -  12500ng/ml.
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Table 5.1: Intra-assay variation (degree of precision) for the detection of amphetamine
in the BIAcore-based competitive assay using the anti-amphetamine monoclonal
antibody. The results are the mean of three replicates.
Actual 
Amphetamine 
Cone (ng/ml)
Back-Calculated 
Amphetamine 
Cone (ng/ml)
CV
%
Recovery
%
24.4 23.8 5.41 97.61
48.8 49.3 4.70 100.96
97.7 105.3 10.50 107.87
195.3 171.1 10.09 87.61
390.6 425.3 7.40 108.88
781.2 782.1 3.36 100.11
1562.5 1517.8 7.85 97.14
3125.0 3154.2 9.24 100.93
6250.0 6241.6 6.14 99.87
12500.0 12528.0 8.46 100.22
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Table 5.2: Inter-assay variation (degree of accuracy and reproducibility) for the
detection of amphetamine in the BIAcore-based competitive assay using the anti­
amphetamine antibody. The range of detection of the assay is 24.4 -  12500 ng/ml. The 
results presented are the means obtained from three intra-day assays, each performed on 
three replicates.
Actual 
Amphetamine 
Cone (ng/ml)
Back-Calculated 
Amphetamine 
Cone, (ng/ml)
CV
%
Recovery
%
24.4 26.5 6.81 108.41
48.8 45.8 3.34 93.78
97.7 91.8 2.97 93.98
195.3 209.4 6.90 107.20
390.6 393.8 4.81 100.81
781.2 773.3 2.70 98.98
1562.5 1508.2 2.83 96.53
3125.0 3159.0 1.66 101.09
6250.0 6295.7 3.23 100.73
12500.0 12771.1 5.54 102.17
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5.2.2 Development o f a BIAcore-based competitive immunoassay fo r  the detection 
o f  amphetamine in spiked saliva samples
Saliva was applied to the BIAcore-based inhibition assay for the determination of 
amphetamine. Negative control saliva samples were initially applied to the assay to 
determine the characteristics of the saliva with regard to the assay format. There was no 
interference noted between the saliva and the immobilised amphetamine-BSA. The 
inhibition assay was then established for the saliva samples containing amphetamine as 
described for the model assay.
An example of the intra-assay variability is shown in Table 5.3. The inter-assay 
calibration is the combination of three different assays run on three different days. The 
calibration curve for the inter-assay is plotted in Figure 5.8. The range of detection of 
the assay is 97.7 to 25,000ng/ml. The back-calculated values as determined by the four- 
parameter fit of the calibration curve for the amphetamine standards show the assay to 
very accurate for these values, ranging from 72.55 to 114.16%. The degree of accuracy 
can be determined by calculating the percent recovery of the known value for different 
concentrations. The range of the percentage coefficient of variations are higher for the 
saliva assay, (2.65 to 29.36%) as compared to the model assay in buffer. The range of 
detection is also different in buffer compared to saliva, 24.4 to 12500ng/ml in the model 
buffer assay, compared to 97.7 to 25000 ng/ml in the saliva-based assay.
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Figure 5.8: Inter-day curve for the detection of amphetamine in saliva samples using 
the anti-amphetamine monoclonal antibody on an amphetamine-BSA immobilised 
surface. The data was correlated to a four-parameter model fit and the plot constructed 
using BIAevaluation 3.1 software. Each point on the graph is the average of three 
results obtained on three different days from a set of three replicates. Each value was 
normalised for that intra-assay by dividing the RU obtained by the RU for the positive 
control that only contained antibody and no amphetamine. The coefficient of variation, 
back-calculated amphetamine concentration and the percentage recovery are shown in 
Table 5.3 (Intra-assay) and Table 5.4 (Inter-assay).
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Table 5.3: Intra-assay variation (degree of precision) for the detection of amphetamine 
in saliva samples in the BIAcore -  based inhibition assay using the anti-amphetamine 
monoclonal antibody. The results presented are the mean obtained from three
Actual 
Amphetamine 
Cone (ng/ml)
Back-Calculated 
Amphetamine 
Cone, (ng/ml)
CV
%
Recovery
%
97.7 101.8 2.93 104.23
195.3 191.1 1.51 97.82
390.6 374.5 3.96 95.87
781.2 830.9 0.99 106.37
1562.5 1481.4 9.70 94.81
3125.0 3239.2 2.46 103.65
6250.0 6366.3 4.05 101.86
12500.0 11390.2 11.63 91.12
25000.0 27153.4 14.40 108.61
Table 5.4: Inter-assay variation (degree of accuracy and reproducibility) for the
detection of amphetamine in saliva samples in the BIAcore -  based inhibition assay 
using the anti-amphetamine monoclonal antibody. The range of detection of the assay 
was 97.7 to 25,000ng/ml. The results presented are the means obtained from three
intra-day assays, each performed on three replicates.
Actual Back-Calculated CV Recovery
Amphetamine Amphetamine % %
Cone (ng/ml) Cone, (ng/ml)
97.7 91.2 7.40 93.39
195.3 222.9 21.62 114.16
390.6 357.3 20.62 91.46
781.2 814.6 18.58 104.27
1562.5 1664.8 14.73 106.55
3125.0 3404.2 2.65 108.94
6250.0 4534.5 25.74 72.55
12500.0 13156.3 22.10 105.25
25000.0 27960.7 29.36 111.84
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5.2.3 Development o f BLAcore-based competitve immunoassay fo r  the detection o f  
methamphetamine using anti-methamphetamine monoclonal antibody, Clone 
P18D
5.2.3.1 Preconcentration studies
A range of solutions of methamphetamine-BSA were prepared in lOmM sodium acetate 
of various pH, from 3.8 to 4.9. The pH of the sodium acetate was adjusted with 10% 
(v/v) acetic acid. Each protein solution was sequentially passed over an underivatised 
sensor as described previously. The results of the preconcentration step are shown in 
Figure 5.9. The optimal pH determined for immobilisation of methamphetamine-BSA 
is pH 4.0. All immobilisations were carried out at this pH.
Timo (S e o s )
Figure 5.9: Preconcentration study of methamphetamine-BSA in sodium acetate at a 
various pH values onto the carboxymethylated dextran surface of the flow cell. The 
solutions containing 50pg/ml of methamphetamine-BSA were passed over the surface 
for 2 minutes at a flow rate of 5|al/min. The response units for each solution is a 
measure of the electrostatic attraction between the negatively charged dextran and the 
positively charged protein conjugate. The ionic strength of the Hepes buffered saline is 
sufficient to dissociate the protein conjugate from the dextran layer. The optimal pH 
was determined to be pH 4.0 as shown on the figure.
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5.2.3.2 Immobilisation o f methamphetamine-BSA
The immobilisation of the methamphetamine-BSA was performed as described 
previously. A solution of EDC/NHS was passed over the chip. The carboxyl groups on 
the dextran layer of the sensor chip were converted into active ester functional groups 
by the EDC, and stabilized by the NHS. The methamphetamine-BSA conjugate in 
lOmM sodium acetate, pH 4.0, was passed over the chip. The NHS esters then react 
with the available amine groups on the methamphetamine conjugate. Figure 5.10 shows 
a typical immobilisation profile.
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Figure 5.10: Sensorgram of a typical immobilisation of methamphetamine-BSA onto 
a CM5 dextran chip surface.
1. HBS buffer was passed over the surface and baseline measurement recorded.
2.
3.
5.
7.
A solution of EDC and NHS, final molarity 0.2M and 0.05M respectively, was 
passed over the surface for 7 minutes at a flow rate of 5|al/min to activate the 
carboxymethylated groups.
After the pulse of EDC/NHS, the HBS buffer was run over the surface again. The 
activation of the surface was seen by the small change (approx 120-200) in 
response units.
A solution of 50^g/ml of methamphetamine-BSA in lOmM sodium acetate, pH 
4.0, was passed over the surface for 20 minutes at a flow rate of 5jil/min.
The HBS buffer was run over the surface and the excess conjugate eluted. The 
amount of bound conjugate was recorded as the change in response units from 
baseline.
The surface NHS-esters were deactivated by a pulse of 1M ethanolamine 
hydrochloride, pH 8.5. This also removed any excess non-convalently bound 
conjugate.
The HBS running buffer resumed flow over the surface and the amount of bound 
amphetamine-BSA can be seen from the change in the response units. 
Approximately 10,000RU’s of methamphetamine-BSA were bound on the chip 
surface.
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5.2.3.3 Regeneration Conditions
As discussed in the previous sections, the regeneration profile for the antibody and 
surface have to be established.
A 1/5 final dilution of anti-methamphetamine monoclonal antibody was found to give a 
binding response of approximately 200 response units. A range of different molarities 
of HC1 and NaOH were tried and the optimum combination found to give reproducible 
results was a 60 second pulse of 5 |j.l of lOmM HC1. The surface was found to be 
reproducible for over 50 cycles of antibody binding and regeneration with this protocol. 
Figure 5.11 shows the response units for each cycle and it can be seen that the first 8 
cycles gave variable results. For this reason, for all assays, a preliminary run of 10 
cycles of antibody binding and subsequent regeneration using 5|il lOmM HC1 were run 
in order to optimise the system and eliminate the variability. The interaction between 
the BSA part of the conjugate and the antibody was examined by immobilising 50(xg/ml 
BSA in lOmM sodium acetate, pH 4.0. The response of the antibody to this surface was 
zero RU. This response to dextran was also examined and found to be zero also.
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Figure 5.11: Regeneration profile of the anti-methamphetamine monoclonal antibody 
binding to the methamphetamine-BSA immobilised surface. A 1/10 dilution of 
antibody was passed over the surface for 4minutes. The surface was regenerated with a 
60 second pulse of 5jal of lOmM HC1. The first 8 cycles gave variable results. Hence, 
for all assays, a preliminary run of 10 cycles of antibody binding and subsequent 
regeneration using 5|al lOmM HC1 were run in order to optimise the system and 
eliminate the variability.
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5.2.3.4 Determination o f range o f detection o f methamphetamine in the BIAcore 
inhibition assay
To determine the working range of detection of amphetamine on this assay, a number of 
standard methamphetamine concentrations were prepared in HBS buffer, ranging from 
0.09 to 25,000 ng/ml. The inhibition assay was established as described in 
Section 5.2.1.3 for the anti-amphetamine assay. The values obtained were normalised 
as described previously. An example of the intra-assay variability is shown in Table 
5 .5. The inter-assay calibration is the combination of three different assays run on three 
different days, (Table 5.6). The calibration curve for the inter-assay is plotted in Figure 
5.12. The range of detection of the assay is 48.8 to 1562.5ng/ml. The back-calculated 
values as determined by the four-parameter fit of the calibration curve for the 
amphetamine standards show the assay to very accurate for these values, between 
95.49 and 102.52%. The high degree of precision of the assay is expressed in the 
percent coefficient of variation of the intra assay variation as shown in Table 5.5 and is 
acceptable.
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Figure 5.12: Inter-day curve for the detection of methamphetamine using the anti- 
methamphetamine monoclonal antibody on a methamphetamine-BSA immobilised 
surface. The data was correlated to a four-parameter model fit and the plot constructed 
using BIAevaluation 3.1 software. Each point on the graph is the average of three 
results obtained on three different days from a set of three replicates. Each value was 
normalised for that intra-assay by dividing the RU obtained by the RU for the positive 
control that only contained antibody and no methamphetamine. The coefficient of 
variation, back-calculated amphetamine concentration and the percentage recovery are 
shown in Table 5.6. The range of detection of the methamphetamine in the assay is
48.8 to 1562.5ng/ml.
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Table 5.5: Intra-assay variation (degree of precision) for the detection of
methamphetamine in the BIAcore-based competitive assay using the anti- 
methamphetamine monoclonal antibody. The results presented are the mean values 
obtained from three replicates.
Actual 
Methamphetamine 
Cone (ng/ml)
Back-Calculated 
Methamphetamine 
Cone (ng/ml)
CV
%
Recovery
%
48.8 48.8 15.21 100.02
97.7 100.9 13.98 103.57
195.3 181.7 7.77 93.19
390.6 399.0 5.64 102.32
781.2 817.6 8.49 104.82
1562.5 1510.2 18.45 96.75
Table 5.6: Inter-assay variation (degree of accuracy and reproducibility) for the 
detection of methamphetamine in the BIAcore -based inhibition assay using the anti- 
methamphetamine monoclonal antibody. The range of detection was 48.8 to 
1562.5ng/ml. The results presented are the mean results obtained from three intra-day 
assays, each assay had three replicates.
Actual 
Methamphetamine 
Cone (ng/ml)
Back-Calculated 
Methamphetamine 
Cone, (ng/ml)
CV
%
Recovery
%
48.8 47.5 17.60 97.37
97.7 99.2 17.83 101.70
195.3 199.9 22.02 102.49
390.6 372.4 17.52 95.49
781.3 784.2 12.70 100.53
1562.5 1600.3 23.79 102.52
202
5.2.4 Development o f a BIAcore-based inhibition immunoassay fo r the detection o f 
methamphetamine in saliva samples
Saliva was applied to the BIAcore-based competitive assay for the determination of 
methamphetamine, as described for the anti-amphetamine antibody. A successful assay 
was established as shown in the calibration curve in Figure 5.13. The range of detection 
of the assay is 97.7 to 6250ng/ml. The percentage coefficients of variation are 
acceptable and are shown in Table 5.7 and Table 5.8 for the intra-day and inter-day 
assays, respectively. The percentage recoveries for the standards are also displayed in 
these tables and show a very accurate assay, 89.41 to 108.0%.
There is a different range of detection in saliva as compared to the assay in buffer, i.e. 
97.7-6250 ng/ml compared to 48.8-1562.5 ng/ml. This follows the same trend as the 
anti-amphetamine antibody assay in the saliva-based assay.
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Figure 5.13: Inter-day curve for the detection of methamphetamine in saliva samples 
using the anti-methamphetamine monoclonal antibody on an methamphetamine-BSA 
immobilised surface. The data was correlated to a four-parameter model fit and the plot 
constructed using BIAevaluation 3.1 software. Each point on the graph is the average 
of three results obtained on three different days from a set of three replicates. Each 
value was normalised for that intra-assay by dividing the RU obtained by the RU for the 
positive control that only contained antibody and no methamphetamine. The coefficient 
of variation, back-calculated methamphetamine concentration and the percentage 
recovery are shown in Table 5.8.
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Table 5.7: Intra-assay variation (degree of precision) for the detection of
methamphetamine in saliva samples in the BIAcore -  based inhibition assay using the
anti-methamphetamine monoclonal antibody. The results presented are the mean values
Actual 
Methamphetamine 
Cone (ng/ml)
Back-Calculated 
Methamphetamine 
Cone, (ng/ml)
CV
%
Recovery
%
97.7 132.9 10.03 136.15
195.3 132.9 8.03 68.07
390.6 423.1 6.69 108.32
781.3 790.2 5.01 101.14
1562.5 1604.5 9.95 102.69
3125.0 2715.7 6.87 86.90
6250.0 7562.6 10.53 121.00
Table 5.8: Inter-assay variation (degree of accuracy and reproducibility) for the
detection of methamphetamine in saliva samples in the BIAcore -  based inhibition 
assay using the anti-methamphetamine monoclonal antibody. The range of detection of 
the assay was 97.65 to 6250 ng/ml. The results presented are the mean values obtained 
from three intra-day assays, each intra-assay had three replicates. ______
Actual 
Methamphetamine 
Cone (ng/ml)
Back-Calculated 
Methamphetamine 
Cone, (ng/ml)
CV
%
Recovery
%
97.7 105.5 10.20 108.00
195.3 198.3 22.47 101.53
390.6 349.3 12.76 89.41
781.3 840.2 14.89 107.55
1562.5 1535.9 5.13 98.30
3125.0 3096.1 11.99 99.07
6250.0 6301.6 22.08 100.83
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5.2.5 Determination o f affinity constant
Many different techniques are used for the determination of affinity constants, as 
discussed in Section 5.1.5 and Section 5.1.6. The two techniques used in this study are 
the Friguet method, (Friguet et al., 1985) and solution phase affinity determination 
using ‘real-time’ biomolecular interaction BIAcore technology.
5.2.5.1 Determination o f  anti-amphetamine antibody and anti-methamphetamine 
antibody affinity constant by ELISA
The Friguet method is based on the calculation of the dissociation constant of antibody- 
antigen mixtures at equilibrium in solution. A 96-well plate is coated with 
amphetamine-BSA. A series of antigen concentrations were incubated with a constant 
nominal amount of antibody. The antigen-antibody mixtures were allowed to reach 
equilibrium overnight. From a stock solution of antibody, serial doubling dilutions 
were made. These were used to construct a standard curve of nominal antibody 
concentration versus absorbance at 450nm. Following overnight incubation, the 
antibody standards and antigen-antibody mixtures were applied to the ELISA plate and 
the ELISA procedure completed. Absorbance readings at 450nm were related to the 
nominal concentration values, by reference to the constructed linear standard curve of 
nominal antibody concentration versus absorbance at 450nm. The fraction of total 
antibody that is bound by the antigen is represented by (V), and was calculated for each 
antigen concentration. The slope of the plot of 1/V versus l/[Antigen Concentration], 
known as the Klotz Plot, gives a straight line. The slope of the line defines the overall 
equilibrium dissociation constant for the antibody-antigen interaction at equilibrium. 
Some conditions must be obeyed to satisfy the conditions of the Friguet assay. The first 
stipulation is that there must be a correlation between free antibody concentration and 
enzymatic activity, in the form of a nominal antibody concentration versus absorbance 
calibration curve. This curve is then used to calculate the concentration of antibody 
bound at equilibrium in the mixtures. The other prerequisite is that there is no 
readjustment of the antibody-antigen equilibrium mixture during the incubation period. 
This can be verified by incubating serial dilutions of the antibody for a time period, then 
transferring the solution to another series of similarly coated wells for the same time 
period. The absorbances obtained for the two sets of incubations should not differ
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significantly. This would then imply that the amount of antibody bound by the solid 
phase immobilised antigen is negligible compared to the amount of antibody in 
solution, and, therefore, there is no significant displacement of the antibody-antigen 
mixture at equilibrium. The fraction of antibody (/), retained by the first series of wells 
can be determined by the following equation:
/  = { Ai(c) -  A2 ( c )  }/ Ai(c) Equation 5.10
Where Ai(c), A2 (c) are the absorbances in the first and second set of wells, 
respectively.
An example of such an assay is shown in Figure 5.14 for the anti-amphetamine 
antibody. The f  value obtained was 0.18 which is acceptable. It shows that the amount 
of antibody retained in the ELISA represents a small amount of the free antibody. 
Therefore, the ELISA does not cause a significant displacement of the antigen: antibody 
equilibrium.
Another prerequisite is that the incubation time of the mixture in the coated wells 
should be kept at a minimum in order to minimise the solution phase equilibrium. The 
incubation period used for these assays was 15 minutes. The final prerequisite is that 
the total antigen concentration is in large excess over the total antibody concentration. 
The standard antibody curve is shown in Figure 5.15. From this curve, the amounts of 
free antibody in the equilibrium solutions was calculated. The Klotz Plot for the anti­
amphetamine monoclonal antibody and amphetamine is shown in Figure 5.16. The line 
has a r2 value of 0.99. The equilibrium dissociation constant for the antibody was 
calculated to be 1 x 10'9 M.
Stevens,(1987), introduced a correction factor into the Friguet determination of the 
dissociation constant. Antibodies whether monovalently bound or unbound to an 
antigen in solution will be able to bind to the wells of the ELISA. The correction factor 
introduced by Stevens is that instead of plotting 1/V in the Klotz Plot, (1/V)1/2 is 
plotted. This takes into account the bivalent nature of the antibody.
Figure 5.17 shows the corrected Klotz Plot for the anti-amphetamine antibody and 
amphetamine, giving an equilibrium dissociation constant of 6 x 10'10M. Table 5.9 lists 
the equilibrium constants for the interaction between the anti-amphetamine antibody 
and amphetamine and MD A.
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Figure 5.18 and 5.19 show the Klotz Plots for the anti-amphetamine antibody and 
MDA, giving a Kd of 2 x 10'9M, and a corrected Kd of 6 x 10'9 M and 6 x 10‘10M.
For the anti-methamphetamine monoclonal antibody, similar plots were constructed as 
shown in Figure 5.22 -  5.29, for the determination of the equilibrium dissociation 
constant of the antibody with methamphetamine, MDMA, MBDB, and MDEA. Table 
5.10 lists the equilibrium dissociation constants determined for each derrivative.
5.2.5.2 Determination o f affinity constant o f anti-amphetamine antibody and anti- 
methamphetamine antibody by BIAcore solution phase real-time interaction.
The method of BIAcore for the determination of affinity constants is based on the same 
principle as the ELISA based Friguet method. The drug protein conjugate is 
immobilised on the sensor chip and serial dilutions of a known concentration of 
antibody are passed over the surface. A calibration curve is constructed of mass bound 
versus antibody concentration. A known concentration of antibody is incubated with a 
range of antigen concentrations and allowed to reach equilibrium overnight. The 
equilibrium mixtures were then passed over the immobilised surface and the response 
units measured. The response units were used to calculate the amount of free antibody 
in the equilibrium mixtures, from the calibrated curve. A graph was then constructed of 
the drug concentration versus the free antibody concentration and using the solution 
phase interaction model in the BIAevaluation software, the overall affinity constant was 
determined.
Figure 5.20, and 5.21 show the curve obtained from plotting the free antibody 
concentration against amphetamine and MDA concentration, respectively. The 
equilibrium dissociation constant obtained was 2.25 x 10'9M, and 4.24 x 10'9M, 
respectively. Table 5.11 lists the equilibrium dissociation constants obtained for the 
interaction between the anti-amphetamine antibody and amphetamine and MDA.
For the anti-methamphetamine monoclonal antibody, similar plots were constructed as 
shown in Figure 5.30 - 5.33, for the determination of the dissociation constant of the 
antibody with methamphetamine, MDMA, MBDB, and MDEA. Table 5.12 lists the 
equilibrium dissociation constants obtained for the interaction between the anti- 
methamphetamine antibody and the different derivatives.
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Reciprocal of Antibody Dilution Factor
Figure 5.14: A prerequisate of the Friguet Assay is that there is no readjustment of the 
equilibirum between the antibody and antigen, during the incubation of the mixture in 
coated wells. This can be verified by incubating the antibody at various known 
concentrations in the coated wells for the specified incubation time of the assay, (Set 1). 
The contents of the wells are then transferred into another set of coated wells (Set 2) and 
incubated for the same time. The captured antibody is then detected by the anti-mouse 
enzyme labeled antibody. The value for,/, is then calculated as per equation 5.10. The 
value for f, represents the small amount of antibody that is captured in the ELISA and 
should represent a small fraction of the total free antibody. This, therefore, would prove 
that no readjustment of the antibody-antigen equilibrium occurs during the ELISA. The 
above figure shows that for the anti-amphetamine antibody, negligible readjustment 
occurred at the dilution range used, (1/300), for the determination of the affinity 
constant by the Friguet method.
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Nominal Antibody Concentration
Figure 5.15: The standard curve of the nominal antibody concentration versus
absorbance at 450nm. The highest antibody concentration was assigned the nominal 
antibody concentration of 1. Serial doubling dilutions were made an assigned a nominal 
concentration value. The antibody dilutions were applied to the wells of the ELISA 
plate for 15minutes. They had been incubating on the bench for the same time period as 
the antibody-drug mixtures. A linear plot of nominal antibody concentration versus 
absorbance at 450nm was used to determine the bound and unbound fraction of 
antibody at equilibrium in these drug-antibody mixtures. The results shown are the 
average of triplicate measurements ± standard deviation.
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1/[Amphetamine Concentration] (1/M)
Figure 5.16: A plot of the reciprocal of the amphetamine concentration against the 
reciprocal of the bound antibody nominal concentration for the Friguet assay for the 
determination of the equilibrium dissociation constant. The value for the free nominal 
antibody concentration (NC), at each amphetamine concentration was determined from 
the antibody standard curve. The value of V, the bound antibody concentration, was 
determined as 1-NC. The slope of the above plot describes the KD of the overall 
interaction. The KD for the interaction of the anti-amphetamine monoclonal antibody 
and amphetamine is 1 x 10'9M.
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Figure 5.17: An adjustment of the antibody concentration, as described by Stevens, 
(1987), to account for the bivalency of IgG. A plot of the reciprocal of the 
amphetamine concentration against the reciprocal of square root of the bound antibody 
nominal concentration for the Friguet assay for the determination of the equilibrium 
dissociation constant. The bound antibody nominal concentration, V, was determined 
as described in legend to Fig 5.16. The slope of the above plot describes the Kd of the 
overall interaction. The KD for the interaction of the anti-amphetamine monoclonal 
antibody and amphetamine is 6 x 10'10M.
2 1 2
1/[MDA]
Figure 5.18: Friguet affinity determination of equilibrium dissociation constant for the 
interaction between anti-amphetamine monoclonal antibody and MDA. The Kd for the 
interaction of the anti-amphetamine monoclonal antibody and MDA is 2 x 10'9M.
1/[MDA]
Figure 5.19: Friguet affinity determination of equilibrium dissociation constant using 
corrected IgG nominal concentration to account for bivalency of IgG. The Kd for the 
interaction of the anti-amphetamine monoclonal antibody and MDA is 6 x 1 O'10 M.
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Figure 5.20: Determination of equilibrium dissociation constant of the anti­
amphetamine monoclonal antibody and amphetamine on an amphetamine-BSA coated 
chip surface. The solution phase affinity model was fitted to the data using 
BIAevaluation software. The KD value determined was 2.25x1 O'9 M, with a standard 
error of 1.09x1 O'10 M.
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Figure 5.21: Determination of equilibrium dissociation constant of the anti­
amphetamine monoclonal antibody and MDA on an amphetamine-BSA coated chip 
surface. The solution phase affinity model was fitted to the data using BIAevaluation 
software. The Kd value determined was 4.24x1 O'9 M, with a standard error of 
6.90x10'*1M.
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1 /[Methamphetamine]
Figure 5.22: Friguet affinity determination of equilibrium dissociation constant for the 
interation between anti-methamphetamine monoclonal antibody and methamphetamine. 
The Kd for the interaction of the anti-methamphetamine monoclonal antibody and 
methamphetamine is 5 x 10'10M.
1/[Methamphetamine]
Figure 5.23: Friguet affinity determination of equilibrium dissociation constant using 
corrected IgG nominal concentration to account for bivalency of IgG. The Kd for the 
interaction of the anti-methamphetamine monoclonal antibody and methamphetamine is 
2 x 10~10M.
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Figure 5.24: Friguet affinity determination of equilibrium dissociation constant for the 
interaction between anti-methamphetamine monoclonal antibody and MDMA. The KD 
for the interaction of the anti-amphetamine monoclonal antibody and MDMA is 
6 x 10'10M.
1/[MDMA]
Figure 5.25: Friguet affinity determination of equilibrium dissociation constant using 
corrected IgG nominal concentration to account for bivalency of IgG. The Kd for the 
interaction of the anti-methamphetamine monoclonal antibody and MDMA is 
2 x 10'10M.
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Figure 5.26: Friguet affinity determination of equilibrium dissociation constant for the 
interaction between anti-methamphetamine monoclonal antibody and MBDB. The Kd 
for the interaction of the anti-amphetamine monoclonal antibody and MBDB is 
4 x 10'10 M.
1/[MBDB]
Figure 5.27: Friguet affinity determination of equilibrium dissociation constant using 
corrected IgG nominal concentration to account for bivalency of IgG. The KD for the 
interaction of the anti-methamphetamine monoclonal antibody and MBDB is 
1 x lO '10M.
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Figure 5.28: Friguet affinity determination of equilibrium dissociation constant for the 
interaction between anti-methamphetamine monoclonal antibody and MDEA. The Kd 
for the interaction of the anti-amphetamine monoclonal antibody and MDEA 
is 2 x 10‘9 M.
1/[MDEA]
Figure 5.29: Friguet affinity determination of equilibrium dissociation constant using 
corrected IgG nominal concentration to account for bivalency of IgG. The Kd for the 
interaction of the anti-methamphetamine monoclonal antibody and MDEA 
is 8 x 10'10 M.
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Figure 5.30: Determination of equilibrium dissociation constant of the anti- 
methamphetamine monoclonal antibody and methamphetamine on a methamphetamine- 
BSA-coated chip surface. The solution phase affinity model was fitted to the data using 
BIAevaluation software. The KD value determined was 2.42x1 O'10 M, with a standard 
error of 5.32x1 O'11 M.
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Figure 5.31: Determination of equilibrium dissociation constant of the anti- 
methamphetamine monoclonal antibody and MDMA on a methamphetamine-BSA 
coated chip surface. The solution phase affinity model was fitted to the data using 
BIAevaluation software. The KD value determined was 5.12 x 10'10 M, with a standard 
error of 5.08 x 1011 M.
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Figure 5.32: Determination of equilibrium dissociation constant of the anti- 
methamphetamine monoclonal antibody and MBDB on a methamphetamine-BSA 
coated chip surface. The solution phase affinity model was fitted to the data using 
BIAevaluation software. The KD value determined was 5.3 x 10'10 M, with a standard 
error of 2.7 x 10'11 M.
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Figure 5.33: Determination of equilibrium dissociation constant of the anti- 
methamphetamine monoclonal antibody and MBDB on a methamphetamine-BSA 
coated chip surface. The solution phase affinity model was fitted to the data using 
BIAevaluation software. The KD value determined was 2.9 x 10'9 M, with a standard 
error of 4.89 x 10'10M.
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Table 5.9: Equilibrium dissociation constants, Ko, as determined by the method of 
Friguet et al., (1985), for the interaction between amphetamine, and MDA and the anti­
amphetamine monoclonal antibody (Clone 4EP18E).
Kd Corrected Kd
Amphetamine 1.0x1 O'5 6 . 0 x 1 0 4(J
MDA 2.0xl0 'y 6.0x 10'1u
Table 5.10: Equilibrium dissociation constants, K d ,  as determined by the method of 
Friguet et al., (1985), for the interaction between methamphetamine, MDMA, MBDB, 
and MDEA and the anti-methamphetamine monoclonal antibody (Clone PI8D).
Kd Corrected Kd
Methamphetamine 5.0 x 10"lü 2.0 x 10‘1U
MDMA 6.0 x 10'10 2.0 x 10'1U
MBDB 4.0 x 10'i(J 1.0 x 10"1(J
MDEA 2.0 x 10'9 8.0 x 10’1U
Table 5.11: Equilibrium dissociation constants, K d ,  and standard error (SE), as 
determined by the BIAcore solution phase assay, for the interaction between 
amphetamine, and MDA and the anti-amphetamine monoclonal antibody (Clone 
4EP18E).
Kd SE
Amphetamine 2.25 x 1 O’9 1.09 x 10'1U
MDA 4.24 x 10‘9 6.90 x 10'11
Table 5,12: Equilibrium dissociation constants, Kd, and standard error (SE), as 
determined by the BIAcore solution phase assay, for the interaction between 
methamphetamine, MDMA, MBDB, and MDEA and the anti-methamphetamine 
monoclonal antibody (Clone P18D).
Kd SE
Methamphetamine 2.24 x 10'1U 5.32 x 10'11
MDMA 5.12 x 10'1U 5.08 x 10‘n
MBDB 5.3 x 10’1U 2.70 x 10'11
MDEA 2.9 x 10'9 4.89 x 10'10
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5.3 Discussion
This chapter complements Chapter 4 which described the production and 
characterisation of an anti-amphetamine monoclonal antibody and an anti- 
methamphetamine monoclonal antibody, and the subsequent application of these 
antibodies in an ELISA format for the determination of amphetamine and derivatives in 
human salivary samples. It investigates the application of these antibodies in a BIAcore 
assay format, and additional characterisation studies to assess the affinity of the 
antibodies to amphetamine and derivatives. These affinity measurements were made 
using two different methods; the classic Friguet ELISA, and the solution affinity 
measurement using BIAcore technology.
Successful BIAcore-based competitive assays were developed in the model buffer 
system and also in the spiked saliva samples. For the model assay with the anti­
amphetamine monoclonal antibody, Clone 4EP18E, the range of detection was 24.4 to 
12,500ng/ml amphetamine. The percentage coefficients of variation ranged from 1.66 
to 6.81%. The percentage recoveries ranged from 93.78 to 108.41%. When the assay 
was applied to saliva samples, the range of detection changed to 97.7 to 25,000 ng/ml, 
the percentage coefficients of variations also increased with a range from 7.40 to 
29.36%. The percentage recoveries ranged from 91.46 to 114.16%, with value of 
72.55% for the 6,250ng/ml standard, which is considered outside an acceptable range. 
The increased coefficients of variation reflect decreased accuracy in the saliva assay as 
compared to the model buffer assay. This could be accounted for by the extraneous 
proteins and substituents of saliva that may have an adverse effect on the antibodies and 
on the fluid mechanics of the BIAcore assay system. A similar pattern regarding the 
level of detection was seen in the methamphetamine assay. Clone P18D, was 
established in an inhibition BIAcore-based assay for the detection of methamphetamine. 
The range of detection in the model assay was 48.8 to 1562.5 ng/ml methamphetamine, 
whereas when the assay was applied to saliva samples, the range of detection was 97.7 
to 6,250 ng/ml. In the model assay, the coefficients of variation ranged from 12.7 to 
23.79% compared to 5.13 to 22.47% in the saliva-based assay. Both assays exhibited 
very good percentage recoveries, ranging from 95.49 to 102.52% for the model assay 
and 89.41 to 108% for the saliva-based assay. Overall, these results show that the 
assays developed using the anti-amphetamine monoclonal antibody, Clone 4EP18E, and
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the anti-methamphetamine monoclonal antibody, Clone P18D, are accurate and 
reproducible. These clones are currently being evaluated for application in a 
commercial dip-stick test for the detection of amphetamines in human biological fluids.
In the affinity studies of the antibodies, there was general agreement between the results 
obtained from the Friguet method and those obtained from the BIAcore-based solution 
affinity measurement. The same conjugates were used for immunisations and screening. 
In the case of the anti-amphetamine it was amphetamine-BSA and in the case of anti- 
methamphetamine it was methamphetamine-BSA. Both were linked through the phenyl 
para position. These conjugates were considered appropriate as the amphetamine 
structures are differentiated through the other side of the molecule at the carbon side 
chain. The anti-amphetamine antibody showed similar affinity for amphetamine and 
MDA. This is an expected result as the structural difference between the molecules is 
the methylenedioxy group situated at the para-position of the phenyl ring, which is used 
as the point of conjugation with the protein. The anti-methamphetamine antibody 
showed similar affinity for methamphetamine, MDMA and MBDB. However, as the 
structure modified further, the affinity decreased as can be seen from the value for 
MDEA which showed a difference in an order of magnitude from the value for the 
methamphetamine. This is expected as the original fusion was performed using a 
spleen from a mouse immunised with methamphetamine-BSA. So, as the structure of 
the derivative becomes less like the methamphetamine structure the value of the 
equilibrium dissociation constant increases, meaning a decrease in affinity. Overall, 
the interactions of the antibodies with compounds differing from the amphetamine and 
methamphetamine through substitutions on the side chain were directly proportional to 
the similarity of their structure to amphetamine or methamphetamine (Figure 5.34). 
This, therefore, confirms that the antibodies are recognising the carbon side chain of the 
amphetamine structures.
The issue of affinity determination based on monovalent and bivalent theories was 
investigated in the ELISA Friguet method. It is presumed that an antibody is bivalent 
and so can bind two molecules of the drug. However, steric interference may prevent 
this, so a definitive bivalent model cannot be presumed. The determination of the 
affinity constant by ELISA was calculated using a monovalent and bivalent model. The 
BIAcore solution phase affinity model assumes a monovalent fit. The graphical fit of 
the data for the anti-methamphetamine antibody to this model, shows that it is not a
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very ideal fit. From this, it could be concluded that the interaction between the anti- 
methamphetamine and the methamphetamine structures is somewhere between a 
monovalent and bivalent.
The establishment of the successful BlAcore-based assay for the detection of 
amphetamine and methamphetamine is a good example of the usefulness of antibodies 
of intermediate affinities. This medium affinity allowed a successful regeneration cycle 
that is intrinsic for the development of the assay.
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Amphetamine
MDA MDMA
MBDB MDE
Ephedrine Pseudoephedrine
Figure 5.34: Three-dimensional répresentations of the structure of amphetamine,
methamphetamine, and structural derivatives.
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Chapter 6
Development o f ELISA, BIAcore Assay, and Envitec Device 
Assay for Detection o f Drugs in Saliva Samples
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6.1 Introduction
6.1.1 Background to Envitec Device
DCU collaborated with Envitec-Wismar GmbH on the European Commission 
Standards, Measurement and Testing Project, entitled, ‘On-site measurement of drugs 
of abuse in a saliva sample’. The aim of the project was to develop a new solid-phase 
format for the rapid detection of drugs of abuse in a saliva samples. Envitec developed 
an automatic device that could be used for this purpose. To achieve a safe and easy to 
use assay, the critical steps of the laboratory procedures for completing an 
immunoassay have to be simplified and the incubation steps shortened in time. The aim 
behind the development is that a simple test would be available whereby a non- 
scientific person could apply the saliva sample, press a button and within minutes have 
a result of positive or negative for the drugs under investigation.
DCU obtained a prototype of the Envitec device and concentrated on the development 
of an assay for detection of THC in saliva samples, using the anti-THC polyclonal 
antibody that was produced and characterised as described in Chapter 3.
Figure 6.1: Envitec prototype device for rapid analysis of drugs of abuse in saliva 
samples.
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6.1.2 Stability o f  drugs in storage samples
The reliable detection of drugs in saliva samples is dependent on the internal controls in 
a particular assay. The importance of the accuracy of the standards cannot be over 
stated for obvious reasons. To reliably interpret analytical results the stability of the 
target molecule must be understood and, in particular, the stability of the molecule in 
the matrix used for the investigation. In the clinical and forensic setting, many samples 
need to retained for additional confirmatory testing or retesting. In the case of forensic 
testing the samples sometimes need to be stored for long periods of time. This means 
information regarding the stability of the drugs in different biological matrices must be 
available so that an informed interpretation of the analytical result can be made.
6.1.2.1 THC
Our first experience with the assay development for detection of THC using commercial 
antibodies did suggest that the robustness of the THC assay was not as good as the other 
assays such as morphine, cocaine and amphetamines. A contributory factor to this was 
that the stock solution of THC was prepared in ethanol and it did not go folly into 
solution in aqueous buffers such as PBS. This situation was resolved by using dilute 
solutions with a final ethanol solution of 0.2% (v/v) in PBS. For one assay using a 
commercial clone of anti-THC monoclonal antibody, the percentage coefficients of 
variation approached 20% and even greater, which is not an acceptable level. Part of 
the problem may have been the antibody (as suggested by the supplier, Fitzgerald 
Industries; personal communication). An additional complication contributing to the 
variation may have been the instability in THC samples on storage. Further experience 
in the development and optimisation of the THC assays demonstrated that there was an 
inherent problem with all of the assays with respect to the robustness and 
reproducibility of the results both with standard solutions, spiked saliva samples and 
‘real’ patient samples.
Christophersen et al. (1986) examined the stability of THC in whole blood, in samples 
stored in glass vials and plastic tubes, after storage for four days at room temperature 
followed by storage at -20°C for four weeks. They found that in THC spiked blood 
samples, stored in glass vials, there was no significant difference in the concentration of 
THC detected after storage. However, for the samples stored in plastic vials, there was 
a significant decrease in the THC concentration detected after storage, from 60 to 100%
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of the original amount was not being detected. Likewise, in a set of samples from 
cannabis users, they showed a significant difference between the aliquots that were 
stored in glass vials compared to the duplicate aliquot stored in plastic tubes. This study 
clearly showed that in the case of blood, the samples should be stored in glass vials. 
Joern (1987), also expressed frustration at attempts to demonstrate linearity in 
quantifying THC by a modified GC/MS procedure. He suggested that if the THC- 
COOH was stored either in strongly basic solution, or in an organic solvent, the 
adsorption onto plastic and glass surfaces seemed to be minimised. For all his working 
stock solutions, he added the stock solution in ethanol to a 0.1M sodium hydroxide 
solution. He found that spiked urine samples prepared in this way were stable for at 
least 18 months when stored at -80°C. This is appropriate for his chromatographic 
assays. However, in the case of immunoassays, this could interfere with the activity of 
the antibodies and therefore would not be suitable. Giardino (1996) found that storage 
of a solution of THC in control urine at a concentration of 75ng/ml under refrigerated 
conditions, for up to 40 days, were appropriate storage conditions and the results were 
certified to be within 20% of 75 ng/ml after such time. This is put forward as valid 
control standard for the analysis of urine samples. Golding et al. (1998) examined the 
stability of cannabinoids in urine samples after storage in freezing conditions for 40 
days, 1 year and 3 years. They found a decrease in the concentrations of the 
cannabinoids found of 8.0, 15.8 and 19.6% after these periods. Fairbairn et al. (1976) 
found that light exposure had an adverse effect on cannabinoids. Johnson et al. (1984) 
investigated the stability of THC, and its metabolites, THC-OH and THC-COOH, in 
blood and plasma stored at -10° and 4°C, and at room temperature over a six month 
period. No significant difference was found in the concentrations stored at 4° and 
-10 °C. Six months after storage at room temperature, the concentrations of THC and 
THC-OH had decreased by 90 and 44%, respectively, but the concentration of THC- 
COOH had remained stable. In the same lab, Moody et al. (1999) looked at the 
stability of drugs of abuse in blood and urine samples stored over hundreds of days at -  
20°C, in silanised glass vials. In plasma they found that the concentration of THC and 
THC-COOH had decreased by 15% at both 304 and 354 days. In urine, they found 
THC-COOH to be stable over the period measured of 482 days. Dugan et al. (1994) 
also found an average decrease of 1% in urine samples stored frozen for 12 months. 
However, of these, 44% of samples did have a decrease in THC-COOH concentration 
of between 0 and 25%. This contrasts with Romberg & Post (1991) who found a
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decrease of 19% in the concentration of THC-COOH after two months of storage in 
frozen conditions.
Another interesting finding regarding quantification of THC is the statistic from the 
CAP FUDT proficiency test survey, in which the average coefficient of variation of 
THC-COOH assay results was 25.1%. This instability of the THC in storage is 
probably contributing to this. An additional interesting point in the survey was that one 
sample had a target value of lOOng/ml, however, the average value determined by 72 of 
the survey participants was 21.0 ±7.8 ng/ml, (Joern el al., 1992). The results presented 
in this chapter with regard to the ‘real’ and ‘spiked’ saliva samples would appear to 
support the theory that there is considerable adsorption to both plastic and glass vials. 
This is evident in the low percentage accuracies seen in the assays, and the 
compromised robustness of the assays compared to the other assays described in the 
previous chapters.
Another problem with the quantification of THC is the purity of the reference stock. 
Verification of the true purity content can be difficult for a standard laboratory. This 
results in subsequent errors in the preparing of working dilutions. Poortman-van der 
Meer & Huizer, (1999) reported on a new method for the quantification of THC, 
performed by gas chromatography with a flame ionisation detector. The effective 
carbon number concept was used to predict the GC/FID response factors. Cannabinol 
and cannabidiol are structurally very closely related to THC. Their work showed that 
the response factors of cannabidiol and cannabinol can be used for the calculation of the 
THC content of standards or samples. Interestingly, in this study, there was no 
degradation of the THC after storage at -70°C.
6.1.2.2 Morphine
Morphine is a frequently used drug and so there is a lot of information regarding the 
stability of morphine in aqueous solutions. Morphine is sensitive to oxygen and the 
products of oxidation are morphine-N-oxide and pseudomorphine. For clinical 
morphine injections, the addition of the antioxidant sodium metabisulphite protects the 
morphine. The shelf-life of the injections is around 15 months, (Gleditsch & Waaler, 
2001). The situation with regard to the stability of morphine and opioids in saliva is 
more favourable to analytical testing than that for THC. Niedbala et al. (200IB) 
investigated the stability of morphine from the saliva collected on a device pad for
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samples stored up to 90 days after collection, at -80, 4, 25 and 37°C. The samples were 
analysed using the Orasure immunoassay kit (Orasure, Bethlehem, PA, USA). There 
was no significant decrease in the amount of morphine detected after storage. In this 
study, the pad used for the collection is stored in preservative fluid, provided with the 
Intercept Oral Specimen Collection Device (Orasure Technologies, Bethlehem, PA 
USA), and, on arrival at the lab, the tube is centrifuged and the oral fluid collected.
The stability of morphine in urine stored at -20°C for 12 months was investigated by 
Dugan et al., (1994). The average percentage change in the concentration of morphine 
detected by GC-MS was a 9% increase. However, the range of difference was -68% to 
+63%. Moody et al. (1999) found that the concentration of morphine in urine stored 
frozen had not exceeded a 15% decrease after 852 days of storage in frozen conditions. 
Giogi & Meeker (1995) looked at the stability of morphine in blood stored at ambient 
temperature. The morphine was stable at 3 and 6 months but then the results became 
erratic and showed an increase at the 3 year time point and decrease at the 4 and 5 year 
interval. The ranges for the 3 and 4 year intervals were -56 to 153% and -77 to 133%, 
respectively.
Skopp et al. (2001A), examined the stability of morphine, morphine-6-glucuronide and 
morphine-3-glucuronide in spiked fresh blood and plasma and also in authentic 
postmortem blood samples. The samples were stored in glass vials at -20, 4, and 20°C 
for up to six months. Morphine and the glucuronide metabolites were not effected by 
storage at 4°C. In the postmortem blood, the analytes were only stable when stored at 
-20°C. In the postmortem samples, the morphine levels were increased due to the 
hydrolysis of the glucuronide metabolites. It is suggested that this happens through the 
migrating bacteria from the gastrointestinal tract , as heart blood samples often have 
high activities of P-glucuronidase. For these reasons, it is important to obtain 
information regarding the stability of the parent drug and its metabolites, so a profile 
can by interpreted appropriately. The detoriation of the analytes in plasma samples 
exposed to light suggests that it is an oxidation process. It was noted also, that the 
samples of whole blood were not as affected by the light exposure, compared to the 
plasma samples. This could be due to the active oxygen species degradation by 
components in whole blood such as haemoglobin. So, overall, the stability of the 
morphine and its metabolites could be preserved by the appropriate storage conditions.
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6.1.2.3 Cocaine
As discussed in Chapter 1 and Chapter 3, cocaine is hydrolysed to benzoylecgonine, 
(BEC), in aqueous solutions. In blood, the BEC found could be the result of the non- 
enzymatic hydrolysis and enzymatic hydrolysis, (Fletcher & Hancock, 1981). 
Isenschmid et al. (1992) propose that the loss of cocaine seen in blood samples can be 
accounted for by the detection of EME, as BEC and ecgonine methyl ester (EME) are 
the breakdown products of cocaine in unpreserved blood samples. Cocaine is 
hydrolysed to BEC at physiological pH range by non-enzymatic hydrolysis and to EME 
by liver and plasma cholinesterases, (Stewart et al., 1977). Levine (1996) looked at the 
stability of EME in urine specimens and noted the decrease in the cocaine concentration 
over the storage time, but the EME concentration remained stable suggesting the 
conversion of cocaine to EME is an in vivo process.
Toennes & Kauert, (2001), investigated the importance of a vacutainer containing the 
cholinesterase inhibitor sodium fluoride and potassium oxalate, for the short transfer of 
blood samples from the police to the laboratory. The samples were tested using the 
Abbott fluorescence-polarization immunoassays followed by gas chromatography-mass 
spectrometry. The degradation of cocaine to ecgonine esters was inhibited in the 
fluoride containing samples. They also found that there was hydrolysis of 
benzoylecgonine (BEC) in the unstabilised samples. Brogan et al. (1992) also found 
that sodium fluoride, with or without potassium oxalate inhibited cocaine degradation 
up to 48 hours after storage. In this case, the cocaine was measured using gas- 
chromatography.
McCurdy et al. (1989), assessed the stability of cocaine, BEC, and THC-COOH in 
whole blood while stored at room temperature and refrigerated, for up to 30 days, in 
four different types of storage vials (EDTA-containing, heparin-containing, sodium 
flouride-containing and preservative, anti-coagulant free). The samples were tested 
using the Roche Diagnostics Abuscreen RIA tests for BEC and cannabinoids. They 
found that cocaine was not stable in blood, particularly when stored at room 
temperatures. They found that the storage in the different tubes and at different 
temperatures had no significant effects on the stability and RIA detectability of BEC 
and THC-COOH. Skopp et al. (2001B) investigated the stability of cocaine in whole 
blood and plasma samples stored for up to 15 days. They included ecgonine in the
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panel of analytes, along with cocaine, BEC and EME. They found the conversion of 
cocaine to BEC, EME and ecgonine to be stoichiometric at all time intervals.
There are many publications dealing with the retesting of drugs in frozen urine samples, 
(Dugan et al., 1994; Romberg and Past, 1994). With regard to cocaine, Romberg & 
Past (1994) found an average decrease of 19% (range +20% to -100%) in BEC 
concentration detected in samples frozen for up to 8 months. The average change 
reported by Dugan et al, (1994) was +10% (range -56% to +73%) for BEC and -37% 
(-87% to +20%) for cocaine. Hippenstiel and Gerson, (1994) reviewed the optimum 
storage conditions for cocaine and BEC in urine samples. The ideal storage conditions 
were found to be -15°C in unsilanized glass containers in the dark, and the pH adjusted 
to 5.0 with ascorbic acid. Lui et al. (1982) found that in refrigerated blood samples 
there was a 7% decrease in the concentration of cocaine after 1 day and a 30% decrease 
after 36 days. Moody et al. (1999) found that BEC was stable in frozen urine samples 
for the time measured up to 852 days, whereas cocaine had decreased by 15% after 165 
days of storage. In frozen plasma samples, cocaine and BEC had 15% decreases in 
concentration at 154 and 111 days, respectively. Giorgi & Meeker (1995) also found 
cocaine and BEC to be unstable in blood samples frozen at room temperature. The 
cocaine was not detected after three months of storage and the BEC concentration 
decreased steadily and was not detected in the half of the samples at the six moth and 1 
year time points. Both Isenschmid et al. (1989) and Moody et al. (1999) found that 
lowering the pH to 5 or 6, with the addition of an esterase inhibitor stabilises cocaine in 
solution.
The conclusion from the above is that care should be taken with regard to the storage of 
blood and urine samples for the analysis of cocaine. The analysis should include 
cocaine, BEC and EME and ecgonine. The concentration of cocaethylene should also 
be examined as this is the main metabolite of cocaine ingested with alcohol. 
Consideration must be given to the enzymatic degradation in postmortem samples and 
non-enzymatic processes in storage samples.
6.1.2.4 Amphetamine and methamphetamine
The stability of amphetamine and methamphatamine in biological samples seem to be 
very good in comparison to the other drugs discussed above. Dugan et al. (1994) 
assessed the stability of drugs in urine samples stored for 12 months at
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-20°C and found that the average change from the initial concentration detected of 
amphetamine and methamphetamine was +10% and -15 respectively. The range of 
change for amphetamine was -35% to +30%, and -48% to +25% for 
methamphetamine. Similarly in frozen blood samples, the stability of amphetamines is 
good as reported by Giorgi & Meeker (1995). They examined the stability of the drugs 
over a period of five years in frozen blood samples. They concluded that the stability of 
amphetamine and methamphetamine can be attributed to the presence of the 
phenethyiamine nucleus that does not contain functional groups that are susceptible to 
hydrolysis.
234
6.2 Results
6.2.1 Rapid assay fo r  THC detection
6.2.1.1 Development and format o f THC assay
The Envitec device is a laboratory prototype providing automation of a rapid ELISA for 
detection of drugs of abuse. The anti-THC polyclonal antibody described in Chapter 3 
was applied to the assay on this device for the detection of THC in saliva samples. The 
anti-THC antibody was chosen as the company, Envitec, had found that they were 
having problems with the optimisation and stability of this assay using commercial 
antibodies. To establish the test the following criteria had to be met:
• Determine optimum concentration of capture antibody; goat anti-rabbit 
immunoglobulin.
• Determine optimum concentration of anti-THC polyclonal antibody.
• Determine optimum dilution of THC-HRP conjugate.
• Determine effects of saliva as a matrix on the assay.
• Establish minimum level of detection of 200ng/ml.
• Examine batch variations in the THC-HRP conjugate and antibodies in relation to 
their effects on the assay performance.
The assay was initially set up on as an immunoplate-based ELISA as a lot of analyses 
were needed to determine the many different test parameters. This saved on the usage 
of the prototype specialised wells that were used on the device. Table 6.1 describes the 
different parameters that were examined and the final concentrations and dilutions that 
were used for the final assay.
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Table 6.1: The parameters that were investigated in the optimisation of the Envitec 
based assay for the detection of THC.
Parameters Variables
Assay
Parameter
Used
Dilution o f  capture 
antibody -  goat anti-rabbit 
IgG (1 mg/ml Stock)
0 1/625 1/500 1/1000 1/500
Dilution o f anti-THC 
polyclonal antibody
1/100 1/200 1/500 1/2000 1/100
Dilution o f  THC-HRP 1/50 1/100 1/250 1/500,
1/1000,
1/2000
1/500
Incubation time with TMB 5 mins 10 mins 5 mins
The above variables were examined over numerous assays and days. A new batch of 
THC-HRP was obtained from Fitzgerald industries as the first batch had been 
exhausted. This involved repeating many of the tests. All assays described below are 
used with the second batch.
The principles determining the parameters were as follows:
• to establish a minimum level of detection of 200ng/ml in saliva samples.
• to develop an assay to be as rapid as possible while maintaining 200ng/ml cut o ff.
• to test saliva samples with minimum preparation prior to analyses.
The well positions are shown in Figure 6.2, and the schedule of the final assay is 
described in Section 2.12 and outlined schematically in Figure 6.3.
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Figure 6.2: Schematic diagram of the carousel of the Envitec device and the different 
wells.
Well 1: Saliva sample mixed 1:1 with PBS (500pl total needed)
Well 2: TMB Substrate (1ml)
Well 3: Waste well
Wells 4-8: lOOpl THC-HRP (Saliva sample is transferred to these wells for mixing 
with THC-HRP)
Wells 9-13: Reaction wells (coated with anti-THC antibody, after incubation step with 
sample and THC-HRP mixture, the TMB is transferred here and the transmission read
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Wells coated with 250 fJs o f 1/500 
dilution o f goat anti-rabbit IgG, in 
PBS, at 4oC overnight. Followed by 
washing with PBS-Tween.
Wells coated with 250 ¡As o f 1/100 
dilution o f rabbit anti-THC 
«  — polyclonal antibody, in PBS, at 4°C
overnight. Followed by washing 
with PBS-Tween.
Wells blocked with 300 juls o f 2% 
milk protein solution for 30minutes 
at 37°C. Followed by washing with 
PBS-Tween.
Samples/standards and HRP 
labeled-THC are mixed in separate 
well and transferred to coated 
reaction well for 5 minute 
incubation. Followed by washing 
with tris buffer.
TMB substrate is added to reaction 
wells. An optical reading o f the 
transmission at 620nm is recorded. 
After 5 mins the second reading is 
made, and the fractional change in 
transmission is recorded.
Goat Anti-Rabbit Immunoglobulin
Y  Rabbit Anti-THC PolyclonalAntibody
Blocking Solution (Milk Protein)
V  THC
HRP-Labeled THC
Figure 6.3: Schematic diagram of the assay for detection of THC on Envitec Device
238
6.2.2.1 Optimisation in PBS samples
The initial optimisation tests were carried out using PBS as the sample diluent. The 
results were good and a limit of detection was obtained of 200ng/ml THC. However, 
these results were not easy to repeat. Figure 6.4a show the results obtained for the PBS 
samples spiked with THC from a working stock that had prepared greater than 24hours 
prior to experiment and stored at 4°C. Figure 6.4b shows the results obtained for PBS 
samples spiked with THC from a working dilution that had been freshly prepared. 
Table 6.2 shows the mean of four replicates ± standard deviation for each point on the 
graphs. For each value, a control well, which did not contain the anti-THC antibody, 
was run in the same cycle. The reading for each value was normalised by dividing by 
the control well. The important point to notice from this table and Figures 6.4a and 6.4b 
is that the results obtained using THC solutions that had previously being stored did 
show the same cut off level of detection compared to the results from days when fresh 
stock solutions of THC were prepared. The different variables were examined 
including stability of THC, stability of antibody, and stability of THC-HRP. The 
antibody and THC-HRP were found to be stable under the conditions used for the assay. 
In Section 6.1.2.1, the issue of THC instability was discussed, and this is most probably 
the reason behind the non-reproducibility of the results. For the optimisation studies, 
using PBS as diluent, it was necessary to prepare a fresh working dilution of lmg/ml 
THC in PBS daily, from a stock solution of 25mg/ml in ethanol. The plastic eppendorf 
tubes previously used for the storage of the working dilutions were substituted by glass 
vials, to eliminate any possible adsorption to the container surface, that could contribute 
to further inaccurate THC concentration determinations. As discussed previously, 
Christopher sen et al. (1986) found a significant decrease in THC concentration after 
storage in plastic containers.
6.2.2.2 Optimisation in saliva samples
The samples of saliva used for the optimisation of the assay were drug-free and 
obtained from lab colleagues. The samples were spiked using freshly prepared stock 
solutions of THC in ethanol, (lxlO'3, lxlO'4, lxl O'5 g/ml). A control well that did not 
contain the anti-THC antibody was included in every run. The biggest difference seen
6.2.2 Optimisation o f assay
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in the saliva samples, compared to the PBS samples, was the high background value as 
seen in the control well. These saliva results are not shown as the values are normalised 
by dividing by this control well. In the case of the samples in PBS, this control value 
was usually between 0.95 to 1.0, indicating negligible colour change in the control well, 
because there was no anti-THC antibody to bind the THC-HRP. However, in the saliva 
samples, this value could fall to 0.8. As there was no anti-THC antibody in the well to 
bind the THC-HRP, the change in colour in the well, has to be attributed to a 
background effect and the incomplete washing due to the viscosity and ‘stickiness’ of 
the saliva. The most likely reason is that the saliva could have caused residues of the 
THC-HRP to remain in the wash tubing. This is the same tubing that the TMB is 
dispensed through and the residues of THC-HRP would have reacted with the TMB that 
was being dispensed into the control well, causing a slight colour change. Another 
possibility is that the THC-HRP could be inadequately washed from the wells and so 
the residues in the well cause the colour change. As the value recorded is the fractional 
change in transmission of light at 620nm, this change in colour of the TMB would have 
caused the value to decrease to 0.8. To decrease this background value, the saliva 
samples were mixed 1:1 with PBS.
Since the saliva components of individuals differ so much, it was decided that the best 
way to account for these interferences was to normalise all values, by dividing the 
fractional transmission by the control well, as they have been plotted. For each four 
reaction well replicates, there was one control well. The results for the different days 
are shown in Figure 6.5. The values for each assay are displayed in Table 6.3 and 
clearly show that the presence of 200ng/ml THC in a saliva sample gives a significant 
decrease in the fractional normalised transmission, and so 200ng/ml is the cut off level 
of detection.
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Day 1 - Optimisation in PBS Samples
200 400
THC Cone ng/ml
600
Day 2 - Optimisation in PBS samples
0 500 1000 1500
THC Cone ng/ml
Figure 6.4a: Optimisation of the assay on the Envitee device using PBS as sample 
diluent. The above are the results obtained from two different days. These assays were 
run using PBS spiked with THC that was prepared from  a working dilution o f 1 mg/ml 
in PBS that had been stored at 4°C fo r  greater than 24 hours. The dilution of THC- 
HRP used was 1/500. Intra-day variation for the THC detection assay on the Envitee 
device. Each point on the graph is the mean of four replicates ± standard deviation. For 
each value a control well, which did not contain the anti-THC antibody, was run in the 
same cycle. The reading for each value was normalised by dividing by this control 
well. All graphs show a value for a PBS sample containing no THC.
Day 3 - Optimisation in PBS Samples
THC Cone ng/ml
Day 4 - Optimisation in PBS Samples
THC Cone ng/ml
Figure 6.4b: Optimisation of the assay on the Envitee device using PBS as sample 
diluent. The above are the results obtained from two different days. These assays were 
run using PBS spiked with THC that was prepared from  a working dilution o f lmg/ml 
in PBS that had been prepared fresh on the day o f the experiment. The dilution of 
THC-HRP used was 1/500. Intra-day variation for the THC detection assay on the 
Envitee device. Each point on the graph is the mean of four replicates ± standard 
deviation. For each value a control well, which did not contain the anti-THC antibody, 
was run in the same cycle. The reading for each value was normalised by dividing by 
this control well. All graphs show a value for a PBS sample containing no THC.
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Table 6.2: Mean value ± standard deviation for normalised readings of PBS samples 
spiked with THC. The results are plotted graphically in Figure 6.4a and 6.4b. The 
results show that the cut off level for the detection of THC by the assay is 200ng/ml. 
THC prepared from a freshly made working stock of 1 mg/ml, provided better results 
than the results obtained from the assay using THC that was prepared from a working 
dilution that had been stored for over 24 hours.
Day 1 
(Stored THC 
Spiked Sample)
Day 2 
(Stored THC 
Spiked Sample)
Day 3 
(Fresh THC 
Spiked Sample)
Day 4 
(Fresh THC 
Spiked Sample)
Cone
THC
ng/ml
Mean ±  
SD
Mean ±  
SD
Mean ±  
SD
Mean ±  
SD
0
100
200
500
1000
5000
0.702 ±0.022 
0.786 ± 0.02 
0.779 ±0.024 
0.876 ±0.007 
ND 
ND
0.737 ±0.03 
ND 
0.755 ±0.01 
0.818 ±0.024 
0.848 ±0.014 
ND
0.695 ±0.025 
ND 
0.77 ±0.01 
0.833 ±0.018 
0.843 ±0.074 
0.939 ±0.041
0.687 ±0.026 
ND 
0.835 ±0.013 
0.892 ±0.028 
ND 
ND
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Figure 6.5: Intra-day variation for the THC detection assay on the Envitec device. 
Each point on the graph is the mean of four replicates ± standard deviation. For each 
value a control well, which did not contain the anti-THC antibody, was run in the 
same cycle. The reading for each value was normalised by dividing by this control 
well. All graphs show a value for a saliva sample containing no THC. All of the 
above tests were performed using real saliva spiked with THC. The samples were 
then mixed in a 1:1 ratio with PBS before running on the device. The results show 
that the assay can be used as a screening test with a cut-off level of detection of 
200ng/ml. However, due to the variability of the results it is not suitable as a 
qunatitative assay.
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Table 6.3: Mean value ± standard deviation for normalised readings of saliva samples 
spiked with THC. The results are plotted graphically in Figure 6.4. The results show 
that the cut off level for the detection of THC by the assay is 200ng/ml. The THC was 
prepared from a freshly made working stock of lmg/ml. The results show that the 
assay can be used as a screening test with a cut-off level of detection of 200ng/ml, but 
due to the variability, it is not suitable as a quantitative test. This is justified on the 
difference in one standard deviation between the positive and negative samples. It 
would be preferable to have a greater difference than this.
Day 1 Day 3 Day 5
Cone Mean ±SD Mean ±SD Mean ±SD
THC
ng/ml
0 0.709 + 0.055 0.713+0.016 0.735 ±0.022
100
200 0.791+0.012 0.877 ±0.012 0.800 ±0.014
400 0.778 + 0.03 0.809 ± 0.037 0.845 ±0.018
1000 0.813+0.017 0.899 ±0.022 0.959 ±0.011
2000 0.979 ±0.015 0.909 ±0.011
Day 2 Day 4
Cone
THC
ng/ml
Mean ± SD Mean ± SD
0 0.697 ±0.036 0.656 ±0.053
100 0.715 ±0.023
200 0.788 ±0.027 0.814 ±0.043
400 0.908 ±0.01 0.823 ±0.017
800 0.851 ±0.036
1000 0.864 ± 0.02
2000 0.892 ±0.29 0.897 ±0.039
4000 0,93 ±0.018 0.927 ±0.039
8000 0.961± 0.008 1.014 ± 0.013
16000 0.943 ±0.031 0.953 ±0.043
32000 0.899 ±0.007
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6.2.3 Development o f ELISA fo r  the detection o f  THC and morphine in saliva 
samples
6.2.3.1 Development o f ELISA fo r detection o f THC in saliva samples
The optimal coating concentration of THC-BSA and the optimal antibody dilution to 
use was determined by an indirect checkerboard ELISA. The characterisation of the 
anti-THC polyclonal antibody was described in Chapter 3. The concentration of THC- 
BSA used was 5pg/ml and the dilution of antibody was 1/200, for this assay. The 
competitive assay was performed as described in Chapter 2. The inter-assay plot of the 
normalised absorbance at 450nm (A/AO) and the concentration of free THC in the 
samples is shown in Figure 6.6. The values from five assays were used to calculate the 
inter-assay mean, coefficient of variation and percentage recovery, as shown in Table 
6.4. The percentage recoveries are expressed as a percentage of the back-calculated 
value, obtained from the 4-parameter fit of the data, divided by the actual concentration 
of the standard. The percentage recovery is a measure of the accuracy of the assay. 
The percentage recoveries are quite acceptable for the range of detection of 96.7 - 
25000ng/ml, with the exception of the value for 390ng/ml. One explanation for the 
higher variability at the lower concentrations of the detection range is simply that these 
samples are more prone to diluting errors and so show more variation from day to day. 
The asymptotes of the curve are more likely to have higher variability, as the 
concentrations of drug reach the highest and lowest levels.
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Figure 6.6: Mean Inter-assay calibration curve for the detection of THC in saliva 
samples. The mean normalised value for each drug concentration from three replicates 
was calculated for each of the drug standards. These values from five assays were used 
to calculate the inter-assay mean, coefficient of variation and percentage accuracy. The 
calibration curve was plotted using BIAevaluation software.
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Table 6.4: Inter-assay variation (degree of accuracy and reproducibility) for the 
detection of THC using the anti-THC polyclonal antibody based ELISA in saliva 
samples. The results presented are the mean values obtained from five intra-day assays, 
each assay was performed on three replicates.
THC Standard 
Concentration 
(ng/ml)
Back-Calculated
THC
Concentration
(ng/ml)
CV
%
Recovery
%
96.7 71.3 8.53 72.95
390.6 724.9 3.99 185.57
781.1 865.8 1.32 110.82
1562.5 1339.1 0.89 85.70
3125 2983.2 3.71 95.46
6250 5737.9 4.46 91.81
12500 11197.6 5.86 89.58
25000 26703.3 0.33 106.81
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6.2.3.2 Development o f  ELISA fo r  detection o f morphine in saliva samples
The optimal coating concentration of morphine-3-glucuronide-ovalbumin and the 
optimal antibody dilution to use was determined by an indirect checkerboard ELISA. 
This was a repeat of the ELISA described in Section 3 for the characterisation of the 
anti-morphine polyclonal antibody. This was repeated as in this case the sample was a 
2 5 p.ls of saliva. The concentration of morphine-3-glucuronide-thyroglobulin used was 
lpg/ml and the dilution of antibody was 1/400. The competitive assay was performed 
as described previously. The relationship between the normalised absorbance at 450nm 
(A/AO) and the concentration of free THC in the samples is plotted in Figure 6.7. The 
values from five assays were used to calculate the inter-assay mean, coefficient of 
variation and percentage accuracy, as shown in Table 6.5. Overall, a very good 
reproducible assay was produced with a range of detection between 24.4 - 12,500 ng/ml 
morphine.
Table 6.5: Inter-assay variation (degree of accuracy and reproducibility) for the 
detection of morphine using the anti-morphine polyclonal antibody based ELISA. The 
results presented are the mean values obtained from five intra-day assays, each assay 
was performed on three replicates.
Actual Morphine 
Cone (ng/ml)
Back-Calculated 
Morphine conc. 
(ng/ml)
CV
%
Recovery
%
24.4 19.7 7.75 80.72
48.8 66.7 5.47 136.61
97.7 82.1 13.32 84.10
195.3 187.6 14.05 96.04
390.6 419.1 13.91 107.28
781.3 787.0 8,72 100.74
1562.5 1520.8 7.82 97.33
3125.0 2926.1 0.54 93.64
6250.0 7312.8 5.35 117.00
12500.0 11446.8 7.55 91.57
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Figure 6.7: Competitive ELISA for detection of morphine in saliva samples. Anti­
morphine polyclonal antibody was added to a range of morphine standards. The data 
was fitted to a 4-parameter fit equation using BIAevaluation software. The results 
presented are the mean o f 5 intra-day assays, ± standard deviation. The coefficient of 
variation, and mean back calculated value for each standard within the accepted range 
for the equation was determined and the degree of accuracy determined .
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6.2.4 Development o f a model BIAcore-based competitive immunoassay for the 
detection o f morphine
6.2.4.1 Preconcentration studies
It is necessary to run a preconcentration step as a preliminary step to the immobilisation 
of a drug-protein conjugate on to the carboxymethylated dextran layer of the sensor 
chip. This step ensures that the immobilisation process is maximised. The 
preconcentration studies show the degree of electrostatic binding of the protonated 
amine groups on the conjugate to negatively charged carboxyl groups on the dextran 
matrix.
Different solutions of 50jig/ml morphine-3-glucuronide-thyroglobulin were prepared in 
lOmM sodium acetate of various pH, from 3.8 to 4.95. The pH of the sodium acetate 
was adjusted with 10% (v/v) acetic acid. Each protein solution was sequentially passed 
over an underivatised sensor flow cell at a flow rate of 5|_il/min, as shown in Figure 6.8. 
Following the injection pulse of each solution, there is a pulse of Hepes buffered saline, 
(HBS), that is sufficient to dissociate the electrostatic attraction between the drug- 
protein conjugate and the carboxymethylated surface. The results of the 
preconcentration step are shown in Figure 6.8. The optimal pH determined for 
immobilisation of amphetamine-BSA is pH 4.2. All relevant immobilisations were 
carried out at this pH.
Although this pH is contributing to the immobilisation process, it is necessary to 
chemically modify the carboxymethylated dextran to achieve immobilisation.
6.2.4.2 Immobilisation o f  morphine-3-glucuronide-thryoglobulin
The immobilisation of the morphine-3-glucuronide-thyroglobulin was performed as 
described in Section 2.10.2. A solution of EDC/NHS was passed over the chip. The 
carboxyl groups on the dextran layer of the sensor chip were converted into active ester 
functional groups by the EDC, and stabilized by the NHS. The morhine-3-glucuronide- 
thyroglobulin conjugate in lOmM sodium acetate, pH 4.2, was passed over the chip. 
The NHS esters then react with the available amine groups on the morphine conjugate. 
Figure 6.9 shows a typical immoblisation profile.
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Figure 6.8: Preconcentration study of morphine-3-glucuronide-thyroglobulin in
sodium acetate at a various pH onto the carboxymethylated dextran surface of the flow 
cell. The solutions containing 50pg/ml of morhine-3-glucuronide-thryoglobulin were 
passed over the surface for 2 minutes at a flow rate of 5pl/min. The response units for 
each solution is a measure of the electrostatic attraction between the negatively charged 
dextran and the positively charged protein conjugate. The ionic strength of the Hepes 
buffered saline is sufficient to dissociate the protein conjugate from the dextran layer. 
The optimal pH was determined to be pH 4.2, as shown on the figure.
251
55000 
51000 
47000 
43000 
,  39000 
D 35000 
©
|  31000 
|  27000 
23000 
19000 
15000
0 300 600 900 1200 1500 1800 2100 2400 2700 3000
Time (Sec)
Figure 6.9: Sensorgram of a typical immobilisation of morphine-3-glucuronide-
thyroglobulin onto a CM5 dextran chip surface.
1. HBS buffer was passed over the surface and baseline measurement recorded.
2. A solution of EDC and NHS, final molarity 0.2M and 0.05M, respectively, was 
passed over the surface for seven minutes at a flow rate of 5pl/min to activate the 
carboxymethylated groups.
3. After the pulse of EDC/NHS, the HBS buffer was run over the surface again. The 
activation of the surface was seen by the small change (approx 120-200) in response 
units.
4. A solution of 50|_ig/ml of morphine-3-glucuronide-thyroglobulin in lOmM sodium 
acetate, pH 4.2, was passed over the surface for 20 minutes at a flow rate of 
5fJ,l/min.
5. The HBS buffer was run over the surface and the excess conjugate was eluted. The 
amount of bound conjugate was recorded as the change from baseline, in response 
units (RUs).
6. The surface NHS-esters were deactivated by a pulse of 1M ethanolamine 
hydrochloride, pH 8.5. This also removes any excess non-convalently bound 
conjugate.
7. The HBS running buffer resumes flow over the surface and the amount of bound 
morphine-3-glucuronide-thyroglobulin can be seen from the change in the response 
units. Approximately 18,000RUs of morphine-3-glucuronide-thyroglobulin were 
bound on the ship surface.
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6.2.4.3 Regeneration Conditions
The previous sections dealt with the immobilisation of the morphine-protein conjugate 
on to the sensor chip. Other conditions must also be optimised before a successful 
assay can be established. It is preferable to be able to run multiple samples usually 
greater than 40 on one sensor chip. To do this, the regeneration conditions must be 
examined and chosen carefully and a regeneration cycle set up to determine the effects 
of the regeneration solutions on the surface and on the binding of the antibody to the 
surface.
A l/l  00 final dilution of anti-morphine polyclonal antibody was found to give a binding 
response of approximately 250 response units. A range of different molarities of HC1 
and NaOH were tried to determine the optimal condition for generation of the sensor 
chip surface. The optimum combination found to give reproducible results was a 15 
second pulse of 5pls of 5mM NaOH and a 30 second pulse of lOpls 40mM HC1. The 
surface was found to be reproducible for over 80 cycles of antibody binding and 
regeneration with this protocol. Figure 6.10 shows the response units for each cycle and 
it can be seen that from the second cycle to the eighth cycle there is a decrease in 
reponse units of only 1.6%. A drop in RU was seen in approximately every 15th cycle. 
It is difficult to explain this, other than it may have be caused by the cycle changing in 
the BIAcore, as the program for the regeneration were arranged in 15 pulse cycles.
The interaction between the thyroglobulin portion of the conjugate and the antibody was 
examined by immobilising 50pg/ml thyroglobulin in lOmM sodium acetate, pH 4.2. 
There was no response of the antibody to this surface. The response to dextran was 
examined and also found to be zero. It was found later, however, that in the saliva 
samples, the addition of thyroglobulin and dextran contributed to decreasing the 
'stickiness' of the saliva, and so for all assays, 100|ag/ml thyroglobulin and 
carboyxmethylated dextran were added to the antibody diluent. The ‘stickiness’ of the 
saliva was seen as non-specific binding of the saliva to the immobilised surface.
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Figure 6.10: Regeneration profile of the anti-morphine polyclonal antibody binding to 
the morphine-3-glucuronide-thyroglobulin immobilised surface. A 1/100 dilution of 
antibody was passed over the surface for 4minutes. The surface was regenerated with a 
15 second pulse of 5p.ls of 5mM NaOH and a 30 second pulse of lOpls 40mM HC1. A 
drop in RU was seen in approximately every 15th cycle. It may have be caused by the 
cycle changing in the BIAcore, as the program for the regeneration were arranged in 15 
pulse cycles.
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6.2.4.4 Determination o f  range o f detection o f  morphine in the BIAcore competitive 
assay
To determine the working range of detection of morphine on this assay, standard 
morphine concentrations were prepared in HBS buffer, ranging from 0.09 to 25,000 
ng/ml. The anti-morphine polyclonal antibody, diluted in HBS containing 
thyroglobulin and dextran, was mixed with equal volumes of each standard and allowed 
to come to equilibrium for 15 minutes on the bench before being placed in the BIAcore 
for the assay run. The samples were passed over the morphine-3-glucuronide- 
thyroglobulin immobilised surface in random order. Each cycle was followed by a 
regeneration cycle. Each drug-antibody solution was run over the surface three times in 
random order. This eliminated any possible bias that could have been incorporated into 
the assay. Each value was normalised for that intra-assay by dividing the RU obtained 
by the RU for the positive control that contained only antibody and no morphine. The 
intra-assay variability is shown in Table 6.6. The inter-assay calibration is the 
combination of three different assays run on three different days. The calibration curve 
for the inter-assay is plotted in Figure 6.11. The range of detection of the assay is 1.52 
to 3125ng/ml. The back-calculated values as determined by the four-parameter fit of 
the calibration curve for the morphine standards show the assay to be accurate. The 
degree of accuracy can be determined by calculating the percent recovery of the known 
value for different concentrations. This percent recovery is a quantitative measure of the 
closeness of the observed result (back-calculated result) to its theoretical true value, 
expressed as a percent of the nominal, theoretical concentration. The high degree of 
precision of the assay is expressed in the percent coefficient of variation of the intra 
assay variation as shown in Table 6.6.
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Figure 6.11: Inter-day curve for the detection of morphine using the anti-morphine 
polyclonal antibody on an morphine-3-glucuronide-thyroglobulin immobilised surface. 
The data was correlated to a four-parameter model fit and the plot constructed using 
BIAevaluation 3.1 software. Each point on the graph is the average of three results 
obtained on three different days from a set of three replicates. Each value was 
normalised for that intra-assay by dividing the RU obtained by the RU for the positive 
control that only contained antibody and no morphine. The coefficient of variation, 
back-calculated morphine concentration and the percentage recovery are shown in Table 
6.7. The range of detection of the assay is 1.52 to 3125ng/ml.
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Table 6.6: Intra-assay variation (degree of precision) for the detection of morphine in
the BIAcore-based competitive assay using the anti-morphine polyclonal antibody.
The results presented are the mean values obtained from three replicates.
Actual Morphine 
Cone (ng/ml)
Back-Calculated 
Morphine conc. 
(ng/ml)
CV
%
Recovery
%
1.5 1.9 6.76 125.39
3.1 1.9 3.20 65.44
6.1 6.8 10.51 111.74
12.2 12.7 9.66 103.88
24.4 36.5 2.53 149.63
48.8 20.9 1.27 42.80
97.7 157.5 7.10 161.17
195.3 224.9 2.99 115.14
390.6 409.7 4.79 104.89
781.3 704.4 10.37 90.15
1562.5 1906.8 7.70 122.04
3125 2205.2 1.81 70.57
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Table 6.7: Inter-assay variation (degree of accuracy and reproducibility) for the
detection of morphine in the BIAcore -based competitive assay using the anti-morphine 
polyclonal antibody. The results presented are the mean values obtained from five 
intra-day assays, each assay was performed on three replicates.
Actual Morphine 
Cone (ng/ml)
Back-Calculated 
Morphine conc. 
(ng/ml)
CV
%
Recovery
%
1.5 1.6 10.15 103.09
3.1 2.6 9.10 86.36
6.1 6.8 6.64 110.67
12.2 12.8 3.64 105.26
24.4 26.7 2.88 109.47
48.8 43.8 12.27 89.74
97.7 99.2 3.52 101.56
195.3 181.8 6.38 93.06
390.6 329.4 9.27 84.33
781.3 779.4 15.02 99.76
1562.5 2036.1 16.24 130.31
3125 4655.1 14.07 148.96
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6.2.5 Development o f a BIAcore-based competitive immunoassay fo r  the detection 
o f morphine in saliva samples
Saliva was applied to the BIAcore-based competitive assay for the determination of 
morphine. Negative control saliva samples were initially applied to the assay to 
determine the characteristics of the saliva with regard to the assay format. A huge 
difference was seen with regard to the response units obtained when saliva was passed 
over the morphine-3-glucuronide-thyroglobulin immobilised surface. Additions were 
made to the saliva to try and decrease this response, including the addition of 
thyroglobulin and dextran. Another problem experienced with the saliva samples was 
that different negative control saliva samples gave different responses with regard to the 
non-specific binding. The relatively high inter-assay coefficients of variation for the 
saliva assay express this variation also. The working range of detection within this 
assay was 12.2-781.3ng/ml (Figure 6.12, Table 6.8).
The possibility of using undiluted saliva directly in the BIAcore assay was ruled out. 
Attempts were made to optimise the saliva assays by looking at three different aspects 
as follows:
• Dilution of saliva sample
• Ionic strength of HBS diluent for antibody, that would be mixed with saliva sample
• Sensor chip surface
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Figure 6.12: Inter-day curve for the detection of morphine in saliva samples using the 
anti-morphine polyclonal antibody on an morphine-3-glucuronide-thyroglobulin 
immobilised surface. The data was correlated to a four-parameter model fit and the plot 
constructed using BIAevaluation 3.1 software. Each point on the graph is the average 
of three results obtained on three different days from a set of three replicates. Each 
value was normalised for that intra-assay by dividing the RU obtained by the RU for the 
positive control that only contained antibody and no morphine. The coefficient of 
variation, back-calculated morphine concentration and the percentage recovery are 
shown in Table 6.8.
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Table 6.8: Inter-assay variation (degree of accuracy and reproducibility) for the
detection of morphine in saliva samples in the BIAcore -based competitive assay using 
the anti-morphine polyclonal antibody. The percentage coefficient of variation values 
are quite high. The results presented are the mean values obtained from five intra-day 
assays, each assay was performed on three replicates.
Actual Morphine 
Cone (ng/ml)
Back-Calculated 
Morphine cone, 
(ng/ml)
CV
%
Recovery
%
12.2 10.5 37.74 86.29
24.4 28.9 19.58 118.52
48.8 55.2 23.90 113.22
97.7 116.7 23.91 119.54
195.3 113.1 17.71 57.94
390.6 428.9 22.70 109.82
781.3 886.8 23.33 113.51
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6.2.5.1 Influence o f  saliva dilution on BIAcore assay
Figure 6.13 shows the results of saliva sample dilutions on the degree of competition 
seen on the BIAcore assay, as compared to that of the model assay in HBS. As 
expected the degree of competition and so level of detection of morphine increases as 
the saliva content is decreased. This clearly shows the constituents of saliva are directly 
effecting the assay and decreasing the sensitivity.
6.2.5.2 Influence o f ionic strength o f running buffer on saliva assay
The ionic strength of saliva may vary and so as a means to standardise the assay, the 
effect of varying the ionic strength of the antibody diluent, HBS, was investigated. As 
a control, samples were also run in HBS alone, with no saliva. It was seen from these 
samples that as the ionic strength of the buffer increase the level of competition seen in 
the assay was decreased. In the case of the saliva samples, the change in ionic strength 
did not contribute to increasing the level of competition (Figure 6.14).
6.2.5.3 Influence o f  different sensor chip surfaces on saliva assay
BIAcore design different sensor chip surfaces for different applications. The most 
common analytical chip is the CM5, and this is used for all the inhibition assays. The 
Pioneer range of products are available for more investigative applications, as these 
sensor chip surfaces are made of alternative matrices such as shorter dextran layers. As 
discussed above, the addition of 100(ig/ml cm-dextran to the diluent did reduce the non­
specific binding of saliva to the CM5 chip. To investigate if the dextran layer was a 
factor contributing to this non-specific binding, it was decided to try a different sensor 
chip that had a shorter dextran layer. The FI chip provides the same functionality as the 
CM5 chip but has a shorter dextran matrix. Due to the shorter matrix the immobilisation 
yield is reduced to about 30% of that obtained with the CM5 chip. To examine the 
influence of the dextran layer, the morphine assay was applied to the FI chip. The 
results were disappointing in that a inhibition assay was not achieved. The values for 
the intra-assay are displayed in Table 6.9. One reason for this lack of inhibition is the
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lower amount of immobilisation of the conjugate, and so the sensitivity is reduced to the 
point where inhibition cannot be detected.
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Figure 6.13: The effect of saliva on the BIAcore competitive assay for the detection of 
morphine is demonstrated above. The model assay was established in HBS buffer as 
described previously in Section 6.2.4.4. The RU obtained at different morphine 
concentrations are normalised by expressing as a fraction of the RU obtained for the 
antibody in HBS, with no morphine. Undiluted saliva, and saliva diluted, 1/10, 1/50 
and 1/100 in HBS were spiked with 20ng/ml and 50pg/ml morphine and mixed with 
antibody solution as per the assay described. The saliva interfered with the competition 
seen in the assay, with a decrease seen in the level of detection. This decrease was 
proportional to the dilution of the saliva sample used.
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Figure 6.14: The effect of ionic strength of the HBS buffer on the BIAeore inhibition 
assay for the detection of morphine is demonstrated above. The samples were run with 
the antibody diluted in different buffers: normal strength HBS, 0.5X HBS, 2XHBS and 
4XHBS. Samples of HBS and saliva were spiked with 50p.g/ml morphine, and samples 
containing no morphine were used as controls. The RU obtained for a morphine- 
containing sample was normalised by expressing it as a fraction of the RU obtained for 
the antibody in the corresponding buffer and HBS or saliva, with no morphine.
0 50
Morphine Cone (ug/mi)
265
Table 6.9: Intra-assay degree of competition (R/RO) and variation (degree of precision) 
for the detection of morphine in the BIAcore-based competitive assay on a FI Biacore 
sensor chip, using the anti-morphine polyclonal antibody. Competition was not found 
in this assay, as can be seen from the results. The results presented are the mean value 
of three replicates.
Morphine Cone (ng/ml) R/R0 CV%
0 1 14.23
3.05 0.867 6.97
6.1 0.927 18.91
12.2 0.942 15.72
24.4 0.967 20.71
48.8 0.914 7.67
97.7 0.848 11.31
195.3 1.001 22.49
390.6 0.896 5.15
781.3 0.879 1.67
1562.5 0.891 11.74
3125 0,887 15.32
6250 0.944 11.95
12500 0.903 8.58
25000 0.967 22.37
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6.2.6.1 Preconcentration studies
As described in a previous section, the preconcentation step is performed to assess the 
electrostatic binding of protonated amine groups on the conjugate to negatively charged 
carboxyl groups on the dextran matrix. Preconcentration can be facilitated by lowering 
the pH of the solution below the pi of the protein conjugate. The preconcentration 
studies were carried out for THC-thyroglobulin and THC-BSA by preparing a series of 
standards in lOmM sodium acetate buffer at pH from 4.0 to 5.3. The solutions were 
passed over the underivatised sensor chip and the degree of electrostatic binding was 
monitored. The preconcentration study with THC-thyroglobulin and THC-BSA showed 
negligible binding at the range of pH examined. It is not possible to lower the pH 
below 4.0 as the protonation of the carboxy groups on the dextran matrix occurs and 
this causes a collapse of the gel. It can concluded from these studies, that the pi of the 
THC-thyroglobulin and THC-BSA is less than 4.0. This is probably a result of the high 
degree of conjugation of the THC to the amine groups of the thyroglobulin and BSA. 
To overcome this problem an alternative process for the immobilisation of the THC 
conjugate had to be investigated.
6.2.6.2 Immobilisation o f  THC-protein conjugate through biotinylation and use o f 
streptavidin on the sensor surface
The strong avidity between strepavidin and biotin has being utilised in many processes. 
In this case, the THC-protein conjugate was biotinylated through the use of a 
biotin-S-NHS ester. The strepavidin was successfully immobilised on the dextran layer 
of the sensor chip using EDC/NHS chemistry. The biotinylated THC-thyroglobulin 
was then passed over the surface and the subsequent binding of the biotin to the 
streptavidin occurred, resulting in the immobilisation of the THC-thyroglobulin. The 
sensorgram for this procedure is shown in Figure 6.15.
6.2.6 Development o f a BIAcore-based competitive immunoassay fo r the detection
o f THC in saliva samples
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Figure 6.15: Sensorgram of a typical immobilisation of streptavidin followed by
biotinylated-THC-thyroglobulin onto a CM5 dextran chip surface.
1. HBS buffer was passed over the surface and baseline measurement recorded.
2. A solution of EDC and NHS, final molarity 0.2M and 0.05M, respectively, was 
passed over the surface for 7 minutes at a flow rate of 5pl/min to activate the 
carboxymethylated groups.
3. After the pulse of EDC/NHS, the HBS buffer was run over the surface again. The 
activation of the surface is seen by the small change (approx 120-200) in response 
units.
4. A solution of 12.5pg/ml of streptavidin in lOmM sodium acetate, pH 5.0, was 
passed over the surface for 7 minutes at a flow rate of 5pl/min.
5. The HBS buffer was run over the surface and the excess streptavidin eluted away 
from the surface. The amount of bound streptavidin was recorded as the change 
from baseline. Approximately 5,000 -7,000RU of streptavidin were bound on the 
chip surface.
6. The unreacted surface NHS-esters were deactivated by a pulse of 1M ethanolamine 
hydrochloride, pH 8.5. This also removes any excess non-convalently bound 
streptavidin.
7. The HBS running buffer resumes flow over the surface and the amount of bound 
streptavidin can be seen from the change in the response units.
8. A solution of biotin-NHS-THC-thyroglobulin (1/100 dilution in HBS, 
approximately lOpg/ml) was passed over the surface for 30mins at a flow rate of 
5pl/min. This was followed by the HBS running buffer resuming flow across the 
sensor surface. The amount of bound biotin-THC-thyroglobulin was seen by the 
change in response units. Approximately 3,000RU of biotin-THC-thyroglobulin 
were bound on the chip surface.
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6.2.6.3 Regeneration Studies
As discussed previously, the successful development of a BIAcore-based assay needs to 
establish the conditions for regeneration of the immobilised surface and demonstrate the 
reproducibility of the assay over a number of cycles of binding and regeneration.
Many different solutions at different molarities were tested for dissociating the anti- 
THC polyclonal antibody from the immobilised streptavidin-biotin-THC-thyroglobulin 
surface. These included ethanolamine, HC1 and NaOH. The solution that gave the best 
results was one pulse of 60mM NaOH for 4 minutes at a flow rate of 5|j,l/min. To 
establish the regeneration profile for the assay, the antibody solution was passed over 
the surface for 4 minutes at a flow rate of 5p.l/min. This was followed by the 
regeneration solution of 60mM NaOH for another four minutes. The study showed that 
there was a progressive decrease in the binding capacity as the cycles were repeated. 
This was the best solution of all those tested, but unfortunately only allowed 30 cycles 
of binding, after which, there was a >22% decrease in the binding capacity. This is 
shown graphically in Figure 6.16. From cycle 1 to 30 there was a 22% decrease in the 
binding capacity, from cycle 1 to 40, there was a 40% decrease in capacity and from 
cycle 1 to 50 there was a 36% decrease in binding. When this is compared to the 
regeneration studies for other assays, it does appear to be very low. However, in the 
case of this assay, it must be remembered that the immobilised surface has a number of 
different chemistries and interactions involved. This means that the regeneration 
solution has more potential interactions that it can effect. In this case the NaOH could 
be effecting the biotin-streptavidin interaction or the streptavidin-carboxydextran 
interaction. It could also effect the THC molecules on the immoblilised conjugate.
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Figure 6.16: Regeneration studies on the anti-THC polyclonal antibody on the
streptavidin-biotin-THC-thyroglobulin. Pulses of 60mM NaOH were used to dissociate 
the antibody from the immobilised surface. The ligand binding capacity was shown to 
progressively decrease with the cycles. Only 30 cycles of regenerations are 
recommended for this assay.
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6.2.6.4 Non Specific Binding
The degree of non-specific binding of the anti-THC polyclonal antibody to the 
streptavidin-biotin-THC-thyroglobulin surface must be determined, as a control in 
establishing the BIAcore-based assay. To do this, the sensor surface must be activated 
the same way as for the THC conjugate immobilisation by immobilising streptavidin, 
followed by biotin-thyroglobulin. The immobilisation was successful and 
approximately 3,000 response units of biotinylated-thyroglobulin were immobilised. A 
solution of antibody was then passed over the chip surface and a response of 
approximately 90 response units was seen. In order to eliminate this non-specific 
binding from the assay, thyroglobulin, at a concentration of 50(ig/ml, was included in 
the HBS used for the antibody diluent. This resulted in a decrease in the non-specific 
binding to 40 response units. The thyroglobulin was increased further, however this did 
not decrease the non-specific binding further. This can be explained by the polyclonal 
nature of the antibody. The production of polyclonal antibodies to an immunogen 
means that there are different antibodies recognising different epitopes of the 
immunogen. Antibodies could recognise regions between the THC and thyroglobulin 
and similar regions between the THC and biotin. These regions would not be on 
underivatised thyroglobulin and this would explain why the response was not 
eliminated completely by including the thyroglobulin in the diluent.
6.2.6.5 Determination o f range o f detection o f THC in the BIAcore competitive assay
To determine the working range of detection of THC in this assay, a number of standard 
THC concentrations were prepared in HBS buffer, ranging from 0.09 to 25,000 ng/ml. 
The anti-THC polyclonal antibody, diluted in HBS containing thyroglobulin, was mixed 
with equal volumes of each standard and allowed to come to equilibrium for 15 minutes 
on the bench before being placed in the BIAcore for the assay run. The samples were 
passed over the streptavidin-biotin-THC-thyroglobulin immobilised surface in random 
order. Each cycle was followed by the regeneration cycle. Each drug-antibody solution 
was run over the surface twice in random order. This, therefore, eliminated any 
possible bias that could have been incorporated into the assay. Each value was 
normalised for by dividing the RU obtained by the RU for the control that contained
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only antibody and no THC. An example of the intra-assay variability is shown in 
Table 6.10. The inter-assay calibration is the combination of five different assays run 
on five different days. The calibration curve for the inter-assay is plotted in Figure 
6.17. The range of detection of the assay is 48.8 to 3125ng/ml. The back-calculated 
values, as determined by the four-parameter fit of the calibration curve for the THC 
standards, show the assay to be quite accurate for values between 48.8 and 3125ng/ml. 
The degree of accuracy can be determined by calculating the percent recovery of the 
known value for different concentrations. This percent recovery is a quantitative 
measure of the closeness of the observed result (back-calculated result) to its theoretical 
true value, expressed as a percent of the nominal, theoretical concentration. The degree 
of precision of the assay is expressed in the percent coefficient of variation of the intra 
assay variation as shown in Table 6.11.
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Table 6.10: Intra-assay variation (degree of precision) for the detection of THC in the
BIAcore -based competitive assay, using the anti-THC polyclonal antibody. The
results presented are the mean of three replicates.
THC Cone (ng/ml) R/R0 %CV
0 1 9.70
6.1 0.993 7.78
12.2 0.944 4,66
24.4 0.928 10.78
48.8 0.894 8.19
97.7 0.891 10.34
195.3 0.866 11.23
390.6 0.850 6.36
781.3 0.838 6.77
1562.5 0.821 3.32
3125 0.772 5.36
6250 0.783 8.01
12500 0.713 7.81
25000 0.708 7.64
50000 0.659 0.12
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Figure 6.17: Inter-day curve for the detection of THC using the anti-THC polyclonal 
antibody on an streptavidin-biotin-THC-thyroglobulin immobilised surface. The data 
was correlated to a four-parameter model fit and the plot constructed using 
BIAevaluation 3.1 software. Each point on the graph is the average of two replicates 
obtained on five different days. Each value was normalised for that intra-assay by 
dividing the RU obtained by the RU for the Control that contained antibody and no 
THC. The coefficient of variation, back-calculated THC concentration and the 
percentage recovery are shown in Table 6.11. The range of detection of the assay was
12.2 to 3125 ng/ml THC.
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Table 6.11: Inter-assay variation (degree of accuracy and reproducibility) for the
detection of THC in the BIAcore-based inhibition assay using the anti-THC polyclonal 
antibody. The results presented are the mean of five intra-day assays, each assay 
performed on two replicates.
Actual THC Cone 
(ng/ml)
Back-Calculated 
THC Cone, 
(ng/ml)
CV
%
Recovery
%
12.2 15 1 17.59 124.1
24.4 13.9 18.97 57.1
48.8 41.4 4.21 84,9
97.7 101.8 6.53 104.2
195.3 265.3 4.80 135.8
390.6 380.6 9.58 97.4
781.3 603.4 17.16 77.2
1562.5 1656.0 18.31 106.0
3125.0 3448.3 21.67 110.3
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6.2.7 Real sample analysis for detection o f THC and opioids
A pilot study was undertaken to assess the feasibility of collecting and testing ‘real’ 
saliva samples from drug abusers. A number of samples were taken from clients 
attending the Trinity Court Drug Centre. During our interview with the clients, the 
saliva sample was collected and they were asked about their recent use of drugs. The 
project, including the method of saliva collection, the drug tests on the saliva and the 
confidentiality of the study were described fully to the clients. Samples were only taken 
from clients who gave written informed consent. A copy of the consent form was given 
to the clients. The samples were only taken from clients who were currently thought to 
be using drugs to some degree. The staff at the clinic identified these clients from their 
experiences with them and prior laboratory urine analysis. All patients, with the 
exception of one, were on methadone at varying dosages. Client No. 1 was on full dose 
methadone on the rehabilitation program, whereas the clients who had previously failed 
to stay off drugs, were on the low dose methadone program. This client population had 
a higher risk of concurrent drug abuse. Client No. 6 was attending the clinic for the first 
time and was not receiving any methadone. All clients were asked to provide 
information regarding their recent drug use. This was completed in the absence of the 
Trinity Court personnel to encourage the clients to give more information to us. They 
also expressed their views on giving urine and saliva samples. A summary of the 
information obtained from interviewing the clients regarding their recent drug use is 
shown in Table 6.12. It is important to remember that this information was obtained 
from clients who are not always willing to share such information as it can effect the 
program they are on and how much methadone they are prescribed.
All clients expressed their dislike of giving urine samples. They also mentioned that on 
several occasions they are unable to urinate. All clients, with the exception of client 
No. 8 were willing to use the saliva collection device. Client No. 8 did not like the 
texture of the material and gave a spit sample. On return to the lab this sample proved 
unsuitable for testing. The volume of sample provided by the clients varied from 
1.8mls for Client no. 1 to less than 25(ils Client no. 6. It was evident during our 
meetings with the clients that the greater the use of drugs the more likely they were to 
give smaller volumes of sample.
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Table 6.12: Summary of clients interviews regarding recent drug use.
Client
Number
Program Recent Drug Use
1 (A-D) Rehab -  High 
dose
Methadone
Heroin -  last taken within 5 days 
Benzodiazepines
Cannabis -  within 24 hours (smoked) 
Medications: Methadone
2 (S-C) Low dose 
methadone
Heroin -  last taken 15-20 minutes 
Diazapam -  lOmgs X 20 (just prior to visit)
Dalmane -  30mgs X 10 (just prior to visit)
Cannabis -  not taken
Medications: Methadone, Zimfme
(Unable to give urine on day of saliva collection and
interview)
3 (F-W) Low Dose 
Methadone
Heroin -  within 24 hours
Benzodiazepines -  within 24 hours 
(Unable to give urine on day of saliva collection and 
interview)
4 (JMK) Low Dose 
Methadone
Heroin -  within 24-48 hours 
Cannabis -  within 24 hours 
Medications: Methadone, Valium
5 (JOD) Low Dose 
Methadone
Heroin -  within 24 hours 
Cannabis -  within 24 hours
Medications: Methadone, Valium
6 (R-H) New client -  
first visit
Heroin -  within hours 
DF8’s -  within hours
7 (AOR) Low Dose 
Methadone
Heroin -  within 48 hours 
Cannabis -  not taken 
Medications: Methadone
8 (A-D) Low Dose 
Methadone
Heroin -  taken day before visit 
Cannabis -  within 24 hours (smoked)
Medications: Methadone, Stillnoc, Valium 
Benzodiazepines
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6.2.7.1 Detection ofTH C  in ‘real’ saliva samples
The saliva samples were collected as above and they were tested over several days for 
the presence ofTHC using the assay on the Envitec device and the conventional ELISA 
format as characterised above. Table 6.13 shows the results from the chronic drug users 
collected in Trinity Court Drug Treatment Centre. The samples were initially frozen at 
-20°C, and were defrosted before each assay. There was no correlation between the 
result obtained on ELISA and the normalised result from the Envitec device assay. The 
results presented show the instability of the THC to these conditions and this is most 
probably the reason behind the disparity in results from the ELISA and Envitec device. 
These sample were subject to more freeze-thaw cycles as additional testing for 
morphine was carried out on these samples. These repeated freeze-thaw conditions 
obviously degraded the THC between the time of the initial ELISA and being run on the 
Envitec device. As discussed at the beginning of the chapter, THC is a very unstable 
solution in storage. From the prospect of testing for drugs of abuse in a road-side or 
clinic environment, this should not pose a problem as the sample is tested immediately 
after it is taken. This was the case with the spiked samples that were run on the Envitec 
device. Positive results could be identified with a cut off level of detection of 
200ng/ml. It does however, present a problem if samples are to be stored for a 
quantitative analysis, as these results show there is a definite decrease in the level of 
THC detected after prolonged storage and freeze-thaw cycles.
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Table 6.13: Detection of THC concentration in samples from Trinity Court Drug
treatment clients on the ELISA and Envitec device assay.
Client
Sample
Number
THC Cone 
per ELISA 
(1)
THC Result from Envitec Device 
(2)
Repeat 
ELISA 
Results (3)
1 196.6 1/10 Dilution:
0.66+0.03 versus 0.68+0.03 for blank 
1:5 Dilution:
0.65+0.004 versus 0.64+0.03 for blank
0
2 0 ND 0
3 625.1 ND 0
4 28385 1/10 Dilution: 
0.78+0.006 versus 0.70+0.009 for 
blank 
1/100 Dilution: 
0.70+0.009 versus 0.70+0.009 for 
blank
0
5 7886.8 1/10 Dilution:
0.73+0.02 versus 0.70+0.04 for blank
0
6 Too high to 
extrapolate
ND 0
7 0 ND 0
8 Not suitable 
for testing*
ND 0
(1) After storage for 3 weeks at -20°C and one freeze-thaw cycle in plastic vials
(2) After repeated freeze thaw cycles and storage at -20 °C in plastic vials
(3) After repeated freeze thaw cycles and storage at -20 °C in plastic vials
Sample from client no. 8 was not suitable for testing because the sample was obtained by spitting 
and not using the collection device.
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6.2.7.2 Detection o f morphine in ‘real’ saliva samples
The samples collected from clients in Trinity Court were stored at -20°C, until testing. 
The samples were initially tested on ELISA and dilutions were needed as some of the 
results from the original undiluted samples were off the scale of the assay. These 
samples were then retested at appropriate dilutions, such as, 1/10 and 1/50. The 
samples were also applied to the BIAcore assay. The results of the ELISA and BIAcore 
assay are shown in Table 6.14. The unexpected part of the results was the high level of 
morphine found in these saliva samples. These results were verified by a lab colleague 
who tested them using an immunoassay developed with an anti-morphine scFv 
antibody. Similar results were obtained with this assay. It should be remembered that 
these were the same samples as the ones tested for THC. Unlike, THC, it appears that 
the presence of morphine is not affected to the same degree as THC, by storage or 
freeze thaw cycles. The disparity in the results obtained between the ELISA and the 
BIAcore assay can be explained by two factors. The first relates to the dilution of the 
saliva sample applied to the BIAcore assay. As discussed above, it was impossible to 
optimise a successful morphine BIAcore assay using saliva samples, unless the sample 
diluted appropriately so that none of the interferences caused by saliva were evident. 
This means the saliva samples should be tested at a dilution of at least 1/10. This 
dilution in itself also introduces another possible error factor. The second factor 
contributing to the disparity was the very high levels of morphine found in some of the 
samples. These were simply off the scale of the assay and so a reliable quantitative 
result could not be obtained even with diluted samples. Morphine is aqueous solutions 
has been reported to be stable over different storage conditions, as discussed in Section 
6.1.2.2, so this would not be considered to be factor involved in the disparity between 
the results. The samples were used for the THC and morphine testing and due to the 
limited volume available there was no more available for re-testing at more dilute 
concentrations.
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Table 6.14: Detection of morphine concentration in samples from Trinity Court Drug
Treatment Centre clients on the ELISA and BIAcore assay.
Cone of morphine 
as determined by 
BIAcore assay
(6 weeks post 
collection after 
multiple freeze- 
thaw cycles)
Cone of morphine 
as determined by 
ELISA
(3 weeks post 
collection)
% Correlation
Dilution
Used
ng/ml Dilution
Used
ng/ml
Client No. 1 1/10 168.4 Straight 99.9 168.58%
Client No. 2 1/10 542.4 1/10 866.7 62.58%
Client No. 3 1/100 13176.6 1/50 39469.4 33.38%
Client No. 4 1/10 89.3 Straight 128.1 69.72%
Client No. 5 1/10 767.9 1/10 2914.7 26.35%
Client No. 6 1/2000 28108.9 1/50 20430.1 137.59%
Client No. 7 1/20 1084.8 1/50 1439.2 75.37%
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6.3 Discussion
This chapter described the development of the assay for the detection of THC on the 
Envitec device using the anti-THC polyclonal antibodies; the application of anti-THC 
and anti-morphine polyclonal antibodies for the detection of THC and morphine in 
saliva samples by ELISA, and by BIAcore. A pilot study to determine the feasability of 
the assays was performed using ‘real’ saliva samples that were obtained from multi­
drug users who also received methadone at a drug treatment centre. The samples were 
analysed by the different assays.
The assay developed on the Envitec device for the detection of THC in saliva samples 
was successful as a screening test. The cut-off level of detection of THC was 200ng/ml. 
The assay is not suitable as a quantitative test due to the high levels of variability that 
were seen. There are a couple of factors that could be contributing to this variability 
over the days of the assay. These include the incubation times, the washing cycles 
between steps, the matrix effect of saliva, and the instability of THC in solutions. The 
incubation time for the saliva sample and THC-HRP in the antibody coated well is only 
five minutes for this assay. This is not a long enough period for the mixture to reach 
equilibrium binding with the immobilised anti-THC antibody. This is compared to a 60 
minute incubation period in the case of the ELISA developed for the quantitative 
measurement of THC, using the same polyclonal antibodies. The time restrictions for 
the assay run did not allow a longer incubation time. The washing of the reaction wells 
is automated and performed by the same pump that dispenses the fluids. This means 
that the washing steps are slow because greater volumes are needed for the wash steps. 
For the assay, the washing steps take about six minutes, which is considerable given the 
assay completion time is 20 minutes. The dual function of the pump to dispense smaller 
volumes accurately and larger volumes quickly have to be balanced and perhaps it 
could be improved upon by having two pumps operating for each function. This would 
increase the size of the device though, and portability is a characteristic that would need 
to be retained for this device, for road-side testing in a police car. Another factor that is 
hindering the washing steps is the saliva matrix. High background values were obtained 
in the control well for the assays using saliva samples. These background values were 
not seen during the development of the assay using PBS samples. Proteins and 
components in saliva are contributing to the stickiness of the saliva and residues of the
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THC-HRP conjugate are not being fully washed through the tubing. To eliminate this 
effect, the saliva samples were diluted 1:1 with PBS before application to the well. The 
result from the control well was used to normalise the results from the reaction wells 
and so the physical effects of the saliva matrix could be eliminated. Sectrion 6.1.2.1 
discussed the reports in the literature concerning the instability of THC samples and the 
resulting errors that are seen in quantitative THC analytical assays. It is important to 
remember this inherent instability of THC. However, given that the ultimate aim for the 
device is road-side testing, the saliva samples will be collected and applied to the device 
immediately and so the assay should not be hindered by that problem. The issue will be 
important however, if a sample of the saliva is retained and stored for repeat laboratory- 
based testing. At this point, the possibility of a variant result from the original 
screening is highly likely. The only information that will be obtained from the Envitec 
device will be a positive or negative result based on the 200ng/ml cut-off level of 
detection. So, it will be samples that border on this limit that will need careful analysis 
and interpretation of the results in the context of the instability of THC in stored 
biological samples.
The ELISA for the detection of THC in saliva samples had a range of detection of 96.7 
to 25,000ng/ml. The inter-day coefficients of variation ranged from 0.33% to 8.53%, 
which are acceptable. The percentage recovery ranged from 72.95% to 185.57% and, 
these values are outside an acceptable level for a reliable quantitative assay for the 
detection of THC. The most likely reason for the out of range recovery values are the 
instability of the THC in the samples.
The ELISA for the detection of morphine in saliva samples had a range of detection of 
24.4 to 12,500ng/ml. The inter-day coefficients of variation ranged from 0.54% to 
14.05%, which are acceptable. The percentage recovery ranged from 80.72% to 117%, 
these values are acceptable for a reliable quantitative assay for the detection of 
morphine.
The model BIA assay for the detection of morphine was successfully developed using 
HBS as the matrix. The range of detection of the assay was 1.52 to 3125 ng/ml, the 
coefficients of variation ranged from 1.27 to 10.37% for the intra-day assay and 2.88 to 
16.24% for the inter-day assay. The percentage recovery, as a measure of accuracy of 
the assay ranged from 84.31 to 148.96%. However, when the assay was applied to 
saliva samples, the accuracy and reproducibility were reduced. For the range of 
detection of 12.2 to 781.3 ng/ml, the coefficients of variation for the inter-day assay in
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saliva samples were 17.71 to 37.74%. This is above the 20% level, which is usually 
considered the cut-off level for a reliable assay. The percentage recovery of the assay 
ranged from 57.74 to 119.54%. Attempts were made to optimise the saliva BIAcore 
assays by looking at diluting the samples, alteration of ionic strength of the saliva by 
changing the ionic strength of the diluent HBS, and investigation of use of alternative 
sensor chip surface. It was clearly shown in Section 6.2.5.1 that the saliva is interfering 
with the degree of competition of the assay, most probably caused by the ‘stickiness’ of 
the saliva due to proteins and other components. The change in ionic strength of the 
saliva samples did not contribute to optimising the assay. It appeared that the 
underlying problem with the assay was the ‘stickiness’ and non-specific binding of the 
saliva components to the sensor surface. The addition of dextran and thyroglobulin to 
the saliva samples did not eliminate this, and so the final variable to be changed was the 
sensor chip surface. This was accomplished by using a Pioneer FI chip, as it has a 
shorter dextran matrix than the CM5 chip, and so it was expected that there would be 
less non specific binding. However, the use of this chip was unsuccessful as no 
competition was observed. The reason for this was probably that not enough morphine- 
protein conjugate was immobilised on this shorter dextran surface and so there was no 
competition between the morphine immobilised and the morphine free in solution.
The BIAcore assay for the detection of THC was established by conjugating the THC- 
BtG with biotin and subsequently immobilising it through prior immobilisation of 
streptavidin on the sensor surface. Using these conditions, a competitive assay was 
established with a range of detection of 12.2 to 3125 ng/ml. The coefficients of 
variation for the intra-assay ranged from 3.32% to 11.23%, and 4.21% to 21.67% for 
the inter-assay variation. The degree of recovery for the inter-assay ranged from 57.1 to 
135.8%. The main problem with the assay was the regeneration of the surface. Only 30 
cycles of binding and regeneration with 60mM NaOH are possible, after that there is a 
greater than 22% degradation of the surface.
The final part of this chapter described the results obtained from the multi-drug abuser 
saliva samples. An important finding regarding the stability of THC in saliva in storage 
conditions could be seen in these experiments, from the concentrations measured in the 
initial ELISA test to the results seen on the Envitec test. Repeated freeze-thaw cycles of 
the real saliva samples of multi-drug users resulted in a significant decrease of the THC 
concentration. This supports other publications that have been reviewed in Section
6.1.2.1 concerning the instability of THC in biological fluids during storage.
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The saliva samples from the multi-drug users were analysed for morphine using the 
ELISA and BIAcore assay. As previously mentioned, the BlAcore assay was not very 
successful due to the high coefficients of variation, 17.71 to 37.74%, and percentage 
recoveries ranging from 47.78 to 158.31%. With these in mind the samples were 
applied to the BIAcore assay. For the seven samples that were analysed, the degree of 
correlation between the two assays ranged from 33.38 to 168.58%. This was 
disappointing but can be explained by the high variability of the BIAcore, implying that 
this assay should really only be used as a screening assay. The other issues that came to 
light during this study was firstly the small volumes of saliva that could be provided by 
the users and secondly the very high concentrations of morphine that are found in these 
samples. The concentrations of morphine ranged from 99.9 to 39469.4 ng/ml. These 
results were independently confirmed using a different morphine assay by a lab 
colleague (Brennan, unpublished data, 2001).
Overall, successful screening methods were developed for the detection of THC, by 
applying the anti-THC polyclonal antibodies onto the Envitec device, and for the 
detection of morphine by applying the anti-morphine polyclonal antibodies in the 
BIAcore assay. The Envitec is suitable for road-side testing due to its rapid, portable 
nature. The important point is that it is only suitable as a screening test. The BIAcore 
assay for morphine is also suitable as a laboratory-based screening technique. The 
ELIS As developed for the detection of THC and morphine are of a sufficient standard 
to be used as qualitative tests for the detection of these drugs in neat samples of saliva.
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Chapter 7 
Conclusions
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7.7 Overall Conclusions
The aims of this project were the production of anti-drug polyclonal and monoclonal 
antibodies and the development of novel specific assays for the detection of drugs of 
abuse in saliva. These aims were achieved through:
• The production of polyclonal antibodies against THC, cocaine and morphine and the 
application of these antibodies in ELISA tests for the detection of these drugs in 
saliva samples.
• The production of highly specific anti-amphetamine and anti-methamphetamine 
monoclonal antibodies that recognised amphetamine and its commonly abused 
‘designer’ derivatives.
• The characterisation of these monoclonal antibodies and the development of ELISA 
and novel BIAcore assays for the detection of amphetamine and derivatives in saliva 
samples.
• The application of the anti-THC polyclonal antibody on the novel Envitec device for 
the rapid screening of THC in saliva samples.
• The testing of real clinical saliva samples on the assays developed.
The preliminary work involved production of morphine and cocaine protein conjugates 
for the immunisation procedures. These drug-protein conjugates were used for the 
production of polyclonal antibodies to morphine and cocaine. THC-BSA was also used 
for the production of anti-THC polyclonal antibodies. The purified antibodies were 
then successfully applied to an ELISA format for the detection of morphine, cocaine 
and THC in saliva samples. In all cases the assays developed gave good, reproducible 
results with a level of detection correlating to that agreed upon by the SMT project 
team. As discussed in Chapter 1, the international agencies and scientific community 
have not clearly established the concentrations of these drugs in saliva samples for the 
purposes of determining positive samples.
Anti-amphetamine and anti-methamphetamine monoclonal antibodies were produced. 
The production of these specific antibodies presented a serious challenge in that there 
are many different ‘designer’ amphetamine drugs, such as MDA, MDMA, MDEA,
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MBDB that need to be recognised for a amphetamine test to be useful. On the other 
hand, there are closely related molecules such as ephedrine, found in common flu 
formulations, that must not be recognised by these antibodies in such an assay as they 
would led to false positives. In order to generate such antibodies it was necessary to 
produce monoclonal antibodies against amphetamine and against methamphetamine. 
The specific antibodies were isolated using extensive screening procedures during the 
cloning out stage of the hybridoma development. The antibodies were applied to an 
ELISA for the detection of amphetamine, methamphetamine, and the other common 
designer derivatives, MDA, MDMA, MDEA, MBDB, in saliva samples.
Affinity constant measurements of the two monoclonal antibodies were determined 
using two different techniques, the classic ELISA-based Friguet method and the 
solution-phase BIAcore assay. The equilibrium dissociation constants obtained using 
the well-based system were of comparable magnitude to those determined using 
BIAcore, showing the appropriateness of both assays. The anti-amphetamine 
monoclonal antibody showed affinity for amphetamine and MDA of the same order of 
magnitude ( K d  =1.0 xlO'9 and 2.0 xlO'9) . This can be explained by the immunogen 
used. It was an amphetamine-BSA conjugated through the para phenyl position of the 
amphetamine. This is the point of differentiation between amphetamine and MDA, the 
MDA having a methylendioxy group at the 3,4 position. The anti-methamphetamine 
antibody had equilibrium affinity constants also of similar magnitude for 
methamphetamine, MDMA and MBDB ( K d  = 5.0 xlO'9, 6.0 xlO'9, and 4.0 xlO'9). The 
interactions of the antibodies with substituted derivatives followed an expected pattern, 
the more the structure differed from the parent amphetamine or methamphetamine 
molecule, the less reactive the antibody was towards it. It can also be concluded from 
the cross reactivity and affinity studies, that the anti-amphetamine and anti- 
methamphetamine monoclonal antibodies are reacting at the substituted carbon chain 
side of the molecules.
A prototype of the Envitec device was used, and a rapid test for THC using the anti- 
THC polyclonal antibody was developed. This test fulfilled a number of prerequisites 
for a 'road-side' test, that could be used by law-enforcement agencies for screening 
saliva samples. The test was rapid being approximately 20 minutes in total from time of 
application of saliva sample to result. It was specific for THC with a cut-off level of
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detection of 200ng/ml and was easy to use. The only preparatory step involved in using 
the saliva samples was a 1:1 dilution in PBS. The ease of collection of saliva, coupled 
with this simple preparation step is significantly advantageous compared to the current 
situation of using urine or blood samples as a preliminary screening step.
A pilot clinical study, involving collection of saliva samples from drug users, was 
conducted to investigate the application of the antibodies produced for the detection of 
drugs of abuse. A number of different assays were used for the analysis of THC, and 
morphine. BIAcore assays were also investigated for the detection of morphine in saliva 
samples. Real saliva sample samples were collected from drug users and analysed in 
the different formats. The results obtained from the ELISA show surprisingly high 
levels of morphine and THC in these samples. The BIAcore assay using the anti­
morphine assay was not suitable for saliva samples. This was in contrast to the two 
other BIAcore assays developed using the anti-amphetamine and anti- 
methamphetamine monoclonal antibodies, which were found to be suitable for analysis 
of saliva samples. Overall, saliva provided a suitable matrix in all assays developed 
with the exception of the BIAcore assay using the anti-morphine polyclonal antibody. 
The only preparatory step used for the other BIAcore assays was one freeze-thaw cycle 
followed by a centrifugation step.
The current interest in rapid screening tests for drugs of abuse has placed 
immunology-based tests in centre stage. The success of such tests is reliant on the 
quality of the antibodies that are used, as illustrated in the results described in this 
thesis. The developments in the field of biosensors provide a synergistic advancement 
in this area of rapid testing. The Envitec automated device assay and the BIAcore 
assays described in this thesis are examples of the successful co-application of good 
antibodies and technology.
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Appendix A
Study on the analysis of saliva for drugs of abuse 
Subject Information Sheet and Informed Consent Form
Collection of Saliva
You are being asked to take part in a study that will test your saliva for drugs of abuse. At 
your routine clinic visit, when you give a urine sample, you will also be asked to give a 
saliva sample. To collect the saliva you will chew on a piece of material like cotton wool 
given to you by a nurse. These are special saliva collecting devices and there are no known 
risks associated with using them. After a couple of minutes of chewing when the material 
has absorbed the saliva, it will be placed in a container and the saliva taken for testing.
Confidentiality
Labelling the saliva sample with your initials and a number ensures your confidentiality. 
Your name will not appear on the sample container. The results will be compared to those 
of the urine test. Your name will not appear on any associated paperwork or publications.
AGREEMENT TO CONSENT
The research project has been fully explained to me. I have had the opportunity to ask 
questions concerning any and all aspects of the project and any procedures involved. I am 
aware that participation is voluntary and that I may withdraw my consent at any time. I am 
aware that my decision not to participate or to withdraw will not restrict my access to health 
care services normally available to me. Confidentiality of records concerning my 
involvement in this project will be maintained in an appropriate manner. When required the 
records of this research will be reviewed by the sponsors of the research.
I, the undersigned, hereby consent to participate as a subject in the above described project 
conducted at the National Drug Treatment Centre. I have received a copy of this consent
Appendix A 1
form for my records. I understand that if I have any questions concerning this research, I 
can contact the doctor at the clinic.
After reading the entire consent form, if you have no further questions about giving 
consent, please sign where indicated.
Client’s Name (Block capitals)
Client’s Signature Date (to be dated by the patient)
Investigator name (Block capitals)
Investigator’s signature Date (to be dated by the investigator)
If applicable:
Signature of Parent or Guardian
Date:
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